



eta 2009^{lisbon}



34th Annual **European** Meeting **Thyroid** of the **Association**

Programme

Aula Magna
University of Lisbon
5th – 9th September 2009
Lisbon Portugal
eta09.com





When the thyroid secretly steals life.

Taking the offensive against hypothyroidism. With Euthyrox.

- multiple dosage strengths for precise dose titration
- galenic formulation with reliable unit conformity
- first levothyroxine preparation with a European and FDA approval

Other registered tradenames: Eutirox, Supratirox, Lévothyrox



Euthyrox®

Offensive against hypothyroidism.

Active substance: Levothyroxine sodium. Prescription only medicine. Composition: Each tablet (round with cross score) of Euthyrox 25/50/75/88/100/112/125/137/150/175/200 µg contains 25/50/75/88/100/112/125/137/150/175/200 µg of levothyroxine sodium. Other ingredients: Corn starch, croscarmellose sodium, gelatin, lactose monohydrate, magnesium stearate. **Indications:** Euthyrox 25 - 200 µg: Euthyroid goitre, prophylaxis of relapse goitre after goitre resection, hypothyroidism, suppression therapy in thyroid cancer. Additional indication for Euthyrox 25 - 100 µg: Concomitant therapy in antithyroid drug therapy of hyperthyroidism after having achieved a euthyroid function. Additional indication for Euthyrox 100/150/200 µg: Thyroid suppression test. **Contraindications:** Intolerance to the active substance or any of the excipients. Untreated adrenocortical insufficiency, untreated pituitary insufficiency, untreated hyperthyroidism. Do not initiate therapy in acute myocardial infarction, acute myocarditis, acute pancreatitis. **Adverse reactions:** Adverse reactions are not to be expected under adequate therapy. In (individual) intolerance of the chosen dosage or overdosage (particularly if the dose is increased too quickly at the start of treatment): tachycardia, palpitations, cardiac arrhythmias, angina pectoris, headache, muscle weakness and cramps, sensation of heat, fever, vomiting, menstrual disorders, pseudotumor cerebri, tremor, restlessness, insomnia, hyperhidrosis, weight loss, and diarrhoea. In such cases reduce the daily dosage or interrupt treatment for several days. Allergic reactions may occur in the case of hypersensitivity. **Other notes:** Treatment with thyroid hormones should be continued consistently during pregnancy in particular. The thyroid hormone quantity secreted into breast milk during lactation is not sufficient to cause development of hyperthyroidism or suppression of TSH secretion in the infant. During pregnancy contraindicated as concomitant treatment to antithyroid drug therapy. Exclude or treat coronary insufficiency, angina pectoris, arteriosclerosis, hypertension, pituitary or adrenocortical insufficiency, and thyroid autonomy before initiating therapy with thyroid hormones. Prevent drug-induced hyperthyroidism in coronary insufficiency, heart failure, and achycardiac arrhythmias. Clarify cause of secondary hypothyroidism before initiating replacement therapy. In compensated adrenocortical insufficiency start adequate replacement therapy where necessary. When hypothyroid, postmenopausal women at increased risk of developing osteoporosis are treated, their thyroid function should be checked more frequently in order to prevent supraphysiologic levothyroxine blood levels. Do not use in: patients with galactose intolerance, lactase deficiency or glucose-galactose-malabsorption. **Presentation and pack sizes:** depending on the local registration state. For more detailed information please refer to the data sheet or package leaflet. Issued: August 2007. Merck KGaA, D-64271 Darmstadt, Germany.

Welcome



IT IS THE first time that a ETA Conference takes place in Portugal and the Portuguese Endocrine Society and all Portuguese thyroidologists are proud to host our Association and are doing their best to ensure the success of the Meeting and make your stay in Lisbon unforgettable.

Lisbon, the capital of Portugal for many centuries is a wonderful and charming City, on the large estuary of the Tagus river and port of departure for the discoveries from XIV to XVI centuries. However, the interest of Lisbon is not only the richness of its monuments and museums, testimony of a very wealthy period, but also its very special light, the charm of its old streets, its

cultural life and the excellence of its food and wine. Close surroundings include marvellous beaches and a countryside full of historical interest.

The Congress venue - Rectorship Building of the University of Lisbon - is centrally located and easily reached in a few minutes from hotels.

The social programme is really appealing and optional tours to Lisbon and surroundings are also available (www.eta09.com).

Lisbon ETA Conference will be an excellent scientific meeting with unforgettable social events in a warm and friendly Portuguese ambience.

On behalf of the LOC we are very much looking forward to welcoming you.

João Jácome de Castro
Chairman of the LOC



Content

Organizing Committees	5
Registration Information	6
Pre-Conference Events	
Saturday	8
Scientific Programme	
Sunday	18
Monday	26
Tuesday	32
Wednesday	40
Poster Sessions	
Sunday	44
Monday	64
Tuesday	76
General Information	88
Social Programme	90
Optional Tours	92
Floor Plan	94
Poster Session Floor Plan	95
Exhibition Area	96
Acknowledgements	97
Programme-at-a-glance	Back Cover



Organizing Committees

ETA Executive Committee

Peter Laurberg Denmark (President)
Luigi Bartalena Italy (Secretary)
George J. Kahaly Germany (Treasurer)
Leonidas Duntas Greece
Murat F. Erdogan Turkey
Barbara Jarzab Poland
Robin Peeters The Netherlands
Kris Poppe Belgium
Martin Schlumberger France
Graham Williams UK
Mariastella Zannini Italy

Local Organizing Committee

Honorary Chairmen

Edward Limbert
Manuel Sobrinho-Simões

Chairman

João Jácome de Castro

Vice Chairman

Francisco Carrilho

Members

Elisabete Rodrigues
Fátima Borges
Fernando Rodrigues
Helena Vilar
Lucília Salgado
Maria João Oliveira
Paula Soares
Valeriano Leite

Conference Secretariat – Organization



PCO

Rua Mariana Vilar,
Bloco 1 – Esc. 1A – 1600-537 Lisboa
Tel. +351 21712 10 10
Fax. +351 21 715 90 66
eta09@ideiasaoquadrado.com



EndoScience
Endokrinologie Service GmbH

Mozartstr. 23 - 93128 Regensburg, Germany
Tel. +49 (0) 9402-94811-11
Fax +49 (0) 9402-94811-19
euro-thyroid-assoc@endoscience.de

Registration Information

Main Conference fees

Membership status	before 30 June 09	1 July–22 August 09	On-site
Ordinary / Senior	165 €	230 €	270 €
Corresponding	250 €	290 €	350 €
Junior	110 €	180 €	210 €
Student/fellow	210 €	260 €	310 €
NON-members	420 €	470 €	500 €
Accompanying person	130 €	130 €	130 €

Day Tickets (only available on-site)

Saturday ETA/CRN + Roche Symposium	70 €
Sunday, Monday, Tuesday	100 € per day
Wednesday	70 €

Pre-Conference fees

ETA/CRN	free*
ICCIDD	40 €
Ultrasonography Course (max. 40 pax)	(fully booked)

*participants must be registered for the main conference

Social Programme

5 Sept. Welcome Cocktail	free
7 Sept. Oceanário	45 € (on availability)
8 Sept. Gala Dinner (max. 200 pax)	75 € (on availability)





Main Conference Registration Entitlements

Delegate registration includes:

- Participation in the scientific programme
- Final Programme
- Abstract Book
- Congress bag
- Coffee breaks and lunches
- Welcome Reception

Accompanying person registration includes:

- Welcome Reception
- Tour
- Gala Dinner

Pre-Conference Registration Entitlements

ETA/CRN

- Admission to the Scientific Sessions of ETA/CRN, congress material, lunch and coffee breaks

ICCIDD

- Admission to the Scientific Sessions of ICCIDD, congress material, lunch and coffee breaks

Practical Diagnostic Thyroid and Parathyroid Ultrasonography Course

- Admission to the Scientific Sessions of Course, congress material, lunch and coffee breaks

On site Registration / Secretariat Desk

The Conference Secretariat will be located on the ground floor (FLOOR 0)

The Secretariat will operate during the following hours:

Friday	September 4	No registration, access for exhibitors only Stand Set-up 09.00-17.00
Saturday	September 5	07.30-19.00
Sunday	September 6	07.00-19.00
Monday	September 7	07.00-16.00
Tuesday	September 8	07.00-19.00
Wednesday	September 9	07.00-12.00

Pre-Conference Events

Saturday
5 September

At-a-glance

Room A - Salão Nobre

08.30 –16.00

9th ETA-CRN Meeting
Meeting of the
European Thyroid Association
Cancer Research Network

Room B - Salão das Conferências

08.30 –16.00

Practical Diagnostic Thyroid
and Parathyroid Ultrasonography
Course

Room C - Sala dos Doutoramentos

08.30 –16.00

ICCIDD West Central Europe
Regional Meeting

Room A - Salão Nobre

16.30-17.45

Satellite Symposium
New Automated Assay for
Thyrotropin Receptor Autoantibodies



19.00

Transfer from the
congress venue to
the Welcome Cocktail

20.00

Welcome Cocktail

Centro Cultural de Belém see page 90 for details



**9th ETA-CRN Meeting
European Thyroid Association
Cancer Research Network**

(sponsored by Genzyme, Brahms and Merck)

Room A - Salão Nobre

09.00-15.30

President: Ulla Feldt-Rasmussen, National University Hospital, Copenhagen, Denmark

Secretary: Barbara Jarzab, Maria Skłodowska-Curie Memorial Cancer Center
and Institute of Oncology, Gliwice Branch, Poland

Treasurer: Georg Brabant, The University of Manchester, UK

Other Members: Leonidas Duntas, Greece / Clara Alvarez, Spain /
Francesca Carlomagno, Italy / Lars Bastholt, Denmark / Martin Schlumberger, France

**MEDULLARY THYROID CANCER MANAGEMENT GUIDELINES
OF THE AMERICAN THYROID ASSOCIATION: EUROPEAN COMMENTS**

8.20-8.50

Registration and coffee

8.50-9.00

Welcome and Opening

President ETA-CRN, Ulla Feldt-Rasmussen / Secretary ETA-CRN, Barbara Jarzab

Chairmen: Ulla Feldt-Rasmussen, Barbara Jarzab, Martin Schlumberger

9.00-9.45

**Presentation of Medullary Thyroid Cancer Management Guidelines
of the American Thyroid Association**

Richard T. Kloos (Columbus, Ohio)

9.45-14.45

Discussion on European comments to ATA MTC management guidelines

(each speaker presents his stand and comments to the respective ATA guidelines
in 10 minutes and the next 5 minutes are for discussion)



Saturday

Saturday
5 September

9th ETA-CRN Meeting
European Thyroid Association
Cancer Research Network

Room A - Salão Nobre

PART 1:

ISSUES RELATED TO DIAGNOSIS, TREATMENT AND MONITORING OF CLINICALLY DETECTABLE MTC

1 9.45-10.00

Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC

Rossella Elisei (Pisa, Italy)

2 10.00-10.15

Serum calcitonin estimation in medullary thyroid cancer patients: basal or stimulated levels?

Chantal Daumerie (Brussels, Belgium)

3 10.15-10.30

Preoperative evaluation and staging of MTC diagnosed / supposed by FNA or serum CT – role of imaging modalities (CT/MR/PET) and serum CT level

Bruno Niederle (Vienna, Austria)

10.30-10.45

Coffee break

4 10.45-11.00

Extent of surgery in clinically evident but operable MTC – when is central and/or lateral lymphadenectomy indicated

Sophie Leboulleux (Paris, France)

5 11.00-11.15

Postoperative follow up in patients showing no evident residual disease - cut-offs for imaging/ intervention

Michele Minuto (Pisa, Italy)

6 11.15-11.30

Treatment of advanced medullary thyroid cancer

Lars Bastholt (Odense, Denmark)

7 11.30-11.45

Functional PET imaging and Peptide Receptor Radioisotope Therapy in MTC

Marcus Luster (Ulm, Germany)

8 11.45-12.00

Clinical comments related to MTC diagnosis and management

Leonidas Duntas (Athens, Greece)

9 12.00-12.15

General discussion

12.15-13.00

LUNCH BREAK





PART 2:

ISSUES RELATED TO EARLY DIAGNOSIS AND MANAGEMENT OF HEREDITARY MTC AND MEN2

10 13.00-13.15

What is the optimal range of RET mutations to be tested?

Laura Fugazzola (Milan, Italy)

11 13.15-13.30

Genotype – phenotype correlations in RET mutation carriers and the ATA risk-based classification of RET mutations

Friedhelm Raue (Heidelberg, Germany)

12 13.30-13.45

Timing and criteria for prophylactic thyroidectomy in asymptomatic RET carriers – the role of calcitonin serum level

Barbara Jarzab (Gliwice, Poland)

13 13.45-14.00

Extent and timing of thyroidectomy in RET mutation carriers

Bruno Niederle (Vienna, Austria)

14 14.00-14.15

Hyperparathyroidism in MEN2A

Maria Alevizaki (Athens, Greece)

15 14.15-14.30

Diagnosis and treatment of pheochromocytoma in MEN2A

Hartmut Neumann (Freiburg, Germany)

16 14.30-14.50

ATA MTC guidelines and their comparison with the European practice: pro and contra

Furio Pacini (Siena, Italy) and Francois Borson-Chazot (Lyon, France)

17 14.50-15.30

General comments, discussion and time lines for final manuscript

Saturday
5 September



ICCIDD
West Central Europe
Regional Meeting

Room C - Sala dos Doutoramentos

08.30-16.00

08.30-09.00

Registration

09.00-09.10

Welcome address

Edward Limbert, Hon. Chairman, ETA LOC,
(Lisbon, Portugal)

Aldo Pinchera (Pisa, Italy)

SESSION I

SCIENTIFIC SYMPOSIUM

Chairmen:

Gerald Burrow (Mystic, USA), Aldo Pinchera (Pisa, Italy)

09.10-09.25

Iodine Status in North America

Elizabeth Pearce (USA)

09.25-09.30

Discussion

09.30-09.45

Iodine Intake in Portuguese Pregnant Women

Edward Limbert (Portugal)

09.45-09.50

Discussion

09.50-10.05

**Neuro-intellectual Disorders in Children
from Iodine Deficient Mothers with
Transient Gestational Hypothyroxinemia**

Francesco Vermiglio (Italy)

10.05-10.10

Discussion

10.10-10.25

**Gestational Hypothyroxinemia and the
Beneficial Effects of Early Dietary Iodine
Fortification**

Daniel Glinoe (Belgium)

10.25-10.30

Discussion

10.30-10.50

Coffee Break



SESSION II

CURRENT IODINE PROPHYLAXIS ISSUES

Chairman:

Michael Zimmermann (Switzerland),
Francesco Trimarchi (Italy)

10.50-11.05

Optimising Iodine Nutrition: Possible Alternative Methods to USI

Massimo Tonacchera (Italy)

11.05-11.10

Discussion

11.10-11.25

Planning and Evaluating Studies of Iodine Nutrition

Stig Andersen (Denmark)

11.25-11.30

Discussion

11.30-11.45

Monitoring the IDD Status in Croatia

Zvonko Kusic (Croatia)

11.45-11.50

Discussion

SESSION III

A) UPDATE, IODINE PROPHYLAXIS STATUS IN WEST CENTRAL EUROPE

Chairman:

Aldo Pinchera

West Central Europe Regional Coordinator

12.00-13.00

Presentation of new country data by the ICCIDD national representatives

13.00-14.00

Lunch

B) UPDATE, IODINE PROPHYLAXIS STATUS IN WEST CENTRAL EUROPE

14.00-14.10

ETA Address

Peter Laurberg, President

14.10-16.00

Continuation of country presentations

Discussion and conclusions



Saturday

Saturday
5 September

Practical Diagnostic Thyroid and Parathyroid Ultrasonography Course

Room B - Salão das Conferências

09.00-16.00

08.30-09.00

Registration and distribution of course materials

09.00-09.30

Neck anatomy, basics of ultrasonography and how to perform neck ultrasonography

Chairperson: Murat Faik Erdoğan, Turkey

- Illustrated topographic anatomy of thyroid gland, neck lymph nodes, and other structures of the neck
- Methods of performing US on the neck
- Normal gray scale and Doppler sonography of neck structures
- Measurement of antero-posterior, transverse, and longitudinal diameters
- Calculation of thyroid and nodule volume (mL) in epidemiology and clinics
- General aspects on thyroid echostructure (homogeneity, echogenicity), detection of thyroid lesions (presence of calcifications, cystic lesions)
- Case illustrations (10 minutes)

09.30-10.15

Ultrasonography in thyroid nodule, FNAB and ultrasonography guidance

Chairperson: Teresa Rago, Italy

- Sonographic definition of thyroid nodule, echographic pattern
- Different gray scale and doppler parameters of thyroid nodules
- Clinical and sonographic parameters to identify nodules at risk of malignancy
- Sensitivity and specificity of different sonographic findings for malignancy. (echogenicity, halo sign, calcification, diameters, doppler pattern, elastography)
- When do we need ultrasonography guidance for FNAB
- Different practical methods for USG guided biopsy
- Case illustrations (10-15 minutes)

10.15-10.30

Questions and Answers

10.30-11.00

Coffee break



11.00-11.30

Gray scale and Doppler sonography in thyroiditis

Chairperson: Paolo Vitti, Italy

- Conventional US and Doppler US findings of different thyroid disorders: (Hashimoto's thyroiditis, Graves' disease, subacute thyroiditis... etc)
- Case illustrations (5-10 minutes)

11.30-12.15

Ultrasound guided intervention in nodular thyroid disorders (percutaneous ethanol injections, laser treatment, etc)

Chairperson: Enrico Papini, Italy

- Indications for therapy, different techniques of PEI
- Single or multiple injections, possible side effects, short-term, and long term results
- Principles of percutaneous laser therapy, apparatus, type of needle, laser source, and technique used
- Selection criteria for thyroid lesions, indications for therapy and possible side effects, short-term, and long term results
- Case illustrations (10 minutes)

12.15-12.30

Questions and Answers

12.30-13.30

Lunch

13.30-14.00

Parathyroid lesions

Chairperson: Murat Faik Erdoğan, Turkey

- Illustrated topographic anatomy of parathyroid glands and the variations
- Methods of performing parathyroid US on the neck
- Gray scale and Doppler US findings of parathyroid disorders
- Ethanol ablation and other minimal invasive procedures of parathyroid lesions

14.00-16.00

Practice on real patients with the lecturers and self practice groups A, B, C, D, E

Saturday
5 September

Room A - Salão Nobre

16.30-17.45

Satellite Symposium

(sponsored by Roche Diagnostics)

**New Automated Assay for
Thyrotropin Receptor Autoantibodies**

Chairperson: Matthias Schott, Düsseldorf, Germany

Co-Chairperson: George J. Kahaly, Mainz, Germany

16.30 – 16.40 Welcome

16.40 – 17.05 First Automated Assay for Thyrotropin Receptor Autoantibodies

Dieter Gassner, Roche Diagnostics, Penzberg, Germany

17.05 – 17.30 Results of the MultiCenter Evaluation of the Automated Thyrotropin Receptor Autoantibodies Measurement

Matthias Schott, Düsseldorf, Germany

17.30 – 17.45 Questions and Closing



Saturday



Sunday
6 September

Main Auditorium

08:00-10:00

Oral Session 1: Topic Highlights

Chairpersons: Peter Laurberg, Aalborg, Denmark / João Jácome de Castro, Lisbon, Portugal

08.00-08.20

OP01 PRELIMINARY RESULTS OF A PHASE 1 STUDY OF XL184, A MET, VEGFR2 AND RET KINASE INHIBITOR (TKI), ADMINISTERED ORALLY TO PATIENTS WITH MEDULLARY THYROID CANCER (MTC)

Kurzrock R¹, Sherman S², Pfister D³, Cohen RB⁴, Ball D⁵, Hong D¹, Ng C⁶, Frye J⁷, Janisch L⁸, Ratain MJ⁸, Salgia R⁸

¹MD Anderson Cancer Center, Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, Division of Cancer Medicine, Houston, United States, ²MD Anderson Cancer Center, Department of Endocrine Neoplasia, Division of Internal Medicine, Houston, United States, ³Memorial Sloan Kettering Cancer Center, New York, United States, ⁴Fox Chase Cancer Center, Philadelphia, United States, ⁵Johns Hopkins University, Baltimore, United States, ⁶MD Anderson Cancer Center, Department of Radiology, Houston, United States, ⁷Exelixis, South San Francisco, United States, ⁸University of Chicago, Department of Medicine, Section of Hematology/Oncology, Chicago, United States

08.20-08.40

OP02 THE THYROID HORMONE RECEPTOR ALPHA LOCUS AND BONE: A ROLE FOR THE CIRCADIAN CLOCK GENE REV-ERB-ALPHA

Medici M¹, Van Meurs JB¹, Verbiest M¹, Van der Deure WM¹, Uitterlinden AG¹, Visser TJ¹, Peeters RP¹

¹Erasmus Medical Center, Endocrinology, Rotterdam, Netherlands

08.40-09.00

OP03 MICRORNA CLASSIFICATION OF THYROID FOLLICULAR NEOPLASIA

Rossing M^{1,2}, Henao R³, Winther O³, Klausen M², Godballe C⁴, Kroghdahl A⁵, Glud M², Nielsen FC², Bennedbaek FN¹

¹Herlev Hospital, Department of Endocrinology and Metabolism, Herlev, Denmark, ²Rigshospitalet, University of Copenhagen, Department of Clinical Biochemistry, Copenhagen, Denmark, ³Bioinformatics Centre, University of Copenhagen, Copenhagen, Denmark, ⁴Odense University Hospital, Head & Neck Surgery, Odense, Denmark, ⁵Odense University Hospital, Department of Pathology, Odense, Denmark

09.00-09.20

OP04 CHARACTERISATION AND PLASTICITY OF ADULT STEM/PROGENITOR CELLS IN THE HUMAN THYROID

Fierabracci A¹, Puglisi MA¹, Giuliani L¹, Mattarocci S², Gallinella-Muzi M³

¹Children's Hospital Bambino Gesù, Autoimmunity and Organ Regeneration Laboratory, Rome, Italy, ²CNR, Istituto di Neurobiologia e Medicina Molecolare, Rome, Italy, ³Tor Vergata University, Department of Surgery, Rome, Italy

09.20-09.40

OP05 THYROID ASSOCIATED OPHTHALMOPATHY AFTER TREATMENT FOR GRAVES' HYPERTHYROIDISM WITH ANTI-THYROID DRUGS OR IODINE-131

Träsk F¹, Tallstedt L¹, Abraham-Nordling M¹, Andersson T², Berg G³, Calissendorff J¹, Hallengren B³, Hedner P⁴, Lantz M³, Nyström E³, Ponjavic V⁴, Taube A⁵, Törning O¹, Wallin G¹, Åsman P³, Lundell G¹, TT 96

¹Karolinska Institute, Stockholm, Sweden, ²Sahlgrenska University Hospital, Gothenburg, Sweden, ³Malmö University Hospital, Malmö, Sweden, ⁴Lund University Hospital, Lund, Sweden, ⁵Department of Information Science, Uppsala, Sweden



09.40-10.00

OP06 A TWO-STEP CANDIDATE-GENE ASSOCIATION STUDY IDENTIFIES *FOXE1* AS A LOW PENETRANCE GENE ASSOCIATED TO THYROID CANCER AND REVEALS THE UNDERLYING MECHANISM

Landa I¹, Ruiz-Llorente S², Montero-Conde C², Inglada-Pérez L¹, Schiavi F³, Pita G⁴, Milne R⁴, Maravall J⁵, Ramos I⁶, Andía V⁷, Rodríguez-Poyo P⁷, Jara-Albarrán A⁷, Álvarez-Escolá C⁸, Meoro A⁹, Del Peso C⁹, Arribas L¹⁰, Díaz-Pérez J-Á¹¹, Iglesias P¹², Caballero J¹³, Serrano J¹⁴, Picó A¹⁴, Pomares F¹⁵, Giménez G¹⁶, López-Mondéjar P¹⁷, Castello R¹⁸, Pelizzo M-R¹⁹, Mauricio D⁵, Opocher G^{3,19}, Cascón A¹, Rodríguez-Antona C^{1,20}, González-Neira A⁴, Santisteban P², Robledo M^{1,20}

¹Spanish National Cancer Research Centre (CNIO), Hereditary Endocrine Cancer Group, Madrid, Spain, ²Instituto de Investigaciones Biomedicas ,Alberto Sols' CSIC-UAM, Molecular Endocrinology Department, Madrid, Spain, ³Veneto Institute of Oncology IRCCS, Padova, Italy, ⁴Spanish National Cancer Research Centre (CNIO), Madrid, Spain, ⁵Hospital Universitario Arnau de Vilanova, Lleida, Spain, ⁶Hospital de Requena, Valencia, Spain, ⁷Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸Hospital Universitario La Paz, Madrid, Spain, ⁹Hospital Universitario Reina Sofía, Murcia, Spain, ¹⁰Hospital Marina Alta, Denia, Spain, ¹¹Hospital Universitario San Carlos, Madrid, Spain, ¹²Hospital General de Segovia, Segovia, Spain, ¹³Hospital Reina Sofía, Córdoba, Spain, ¹⁴Hospital General Universitario de Alicante, Alicante, Spain, ¹⁵Hospital Universitario San Juan de Alicante, Alicante, Spain, ¹⁶Hospital de Sabadell-Parc Taulí, Sabadell, Spain, ¹⁷Hospital General Universitario de Elche, Elche, Spain, ¹⁸University of Verona, Verona, Italy, ¹⁹University of Padova, Padova, Italy, ²⁰ISCIII Center for Biomedical Research on Rare Diseases (CIBERER), Madrid, Spain

Main Auditorium

10.00-10.10 The Lissitzky Career Award

The 2009 award is sponsored exclusively by **Diagnostic Hybrids, Ohio, USA**

10.15-10.30

Coffee Break

Main Auditorium

10.30-12.00

Symposium 1 (Educational): Hybrid imaging in thyroid tumors

Chairpersons: Murat Erdogan, Ankara, Turkey / Laurence Leenhardt, Paris, France

10.30-11.00 SPECT-CT IN DIFFERENTIATED THYROID CARCINOMA

Markus Luster (Ulm, Germany)

11.00-11.30 FDG-PET IN INCIDENTAL THYROID NODULES AND NODULES WITH INDETERMINATE CYTOLOGY

Thera Links (Groningen, The Netherlands)

11.30-12.00 PET IN THE FOLLOW-UP OF DIFFERENTIATED THYROID CARCINOMA

Sophie Leboulleux (Paris, France)

Sunday
6 September

Room A - Salão Nobre

10.30-12.00

Symposium 2 (Basic): Molecular basis of thyroid hormone action in disease

Chairpersons: Josef Köhrle, Berlin, Germany / Monica Dentice, Naples, Italy

10.30-11.00 UPRREGULATION OF D3 IN MALIGNANCY

Domenico Salvatore (Naples, Italy)

11.00-11.30 D3 INDUCTION IN HYPOXIA AND HEART FAILURE

Warner M. Simonides (Amsterdam, The Netherlands)

11.30-12.00 MUTATIONS AND ALTERNATIVE SPLICING OF DEIODINASE AND THYROID HORMONE RECEPTOR GENES IN RENAL CANCER

Agnieszka Piekietko-Witkowska (Warsaw, Poland)

Poster Exhibition Area

see plan on page 95

12.00-13.00

Lunch and Poster discussions on site: Poster sessions P01 – P11

Posters P001 – P065

see page 44

13.00-14.00

Poster discussions on site: Poster sessions P12 – P21

Posters P066 – P131

see page 53

Main Auditorium

14.00-14.45 *The ETA GENZYME Prize Lecture*

***The thyroid and pregnancy:
historical and scientific vignette on the Brussels' studies***

Daniel Glinioer, Brussels, Belgium

14.45-15.00

Coffee Break

15.00-15.45

Meet-the-Expert

- 1 **Room B - Salão das Conferências**
MicroRNAs in the thyroid
Alfredo Fusco (Naples, Italy)
- 2 **Room C - Sala dos Doutoramentos**
Thyroid and obesity
Maria Jesus Obregon (Madrid, Spain)
- 3 **Room A - Salão Nobre**
Thyroid hormones and mood disorders
Eric Fliers (Amsterdam, The Netherlands)
- 4 **Main Auditorium**
**Rare ultrasonographic findings:
improve your visual skill**
Murat Erdogan (Ankara, Turkey)
Teresa Rago (Pisa, Italy)
Paolo Vitti (Pisa, Italy)

Sunday

Main Auditorium

16.00-18.00

Oral Session 2: Clinical Thyroidology

Chairperson: Kris Poppe, Brussels, Belgium / Fatima Borges, Lisbon, Portugal

16.00-16.15

OP07 MILD IODINE DEFICIENCY: A PERSISTENT PUBLIC HEALTH PROBLEM IN BELGIUM

Moreno-Reyes R¹, Carpentier YA¹, Macours P¹, Gulbis B¹, Corvilain B¹, Glinoe D², Goldman S¹

¹Erasmus Hospital, Université Libre de Bruxelles, Bruxelles, Belgium, ²Saint Pierre Hospital, Université Libre de Bruxelles, Bruxelles, Belgium

16.15-16.30

OP08 ASSESSMENT OF SUSTAINABILITY OF THE OBLIGATORY IODINE PROPHYLAXIS IN POLAND

Trofimiuk M¹, Szybiński Z¹, Lewiński A², Buziak-Bereza M¹, Zygmunt A², Gołkowski F¹, Sowiński J³, Dorant B⁴, Bandurska-Stankiewicz E⁵, Naskalski J⁶, Rostworowski W⁶, Hubalewska-Dydejczyk A¹

¹Medical College, Jagiellonian University, Chair and Department of Endocrinology, Kraków, Poland, ²Medical University, Department of Endocrinology and Metabolic Diseases, Lodz, Poland, ³Medical University, Chair and Department of Endocrinology, Metabolism, and Internal Diseases, Poznań, Poland, ⁴Medical Academy, Chair and Department of Pediatrics, Hematology, Oncology and Endocrinology, Gdańsk, Poland, ⁵General District Hospital, Endocrinology, Diabetology and Internal Diseases Ward, Olsztyn, Poland, ⁶Medical College, Jagiellonian University, Department of Clinical Biochemistry, Kraków, Poland

Sunday
6 September

16.30-16.45

OP09 IMPACT OF MATERNAL THYROID HORMONE AND IODINE ON PROGENY'S PSYCHOMOTOR DEVELOPMENT: WHICH HORMONES, WHEN AND WHICH CONSEQUENCES

Costeira MJ¹, Oliveira P², Ares S³, Saenz-Rico B⁴, Escobar GM³, Palha JA⁵

¹Centro Hospitalar Alto Ave, EPE, Neonatology Department, Guimarães, Portugal, ²University of Minho, Department of Production & Systems Engineering, Braga, Portugal, ³Instituto de Investigaciones Biomédicas Alberto Sols, Centro Mixto Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain, ⁴Universidade Complutense de Madrid, Madrid, Spain, ⁵School of Health Sciences, University of Minho, Life and Health Sciences Research Institute (ICVS), Braga, Portugal

16.45-17.00

OP10 PREVALENCE OF HYPOTHYROIDISM IN ADULT SURVIVORS OF CHILDHOOD MALIGNANCY

Brabant G¹, Toogood A², Shalet S¹, Hawkins M³

¹The Christie, Endocrinology, Manchester, United Kingdom, ²University Hospital Birmingham, Endocrinology, Birmingham, United Kingdom, ³University of Birmingham, Public Health and Epidemiology, Birmingham, United Kingdom

17.00-17.15

OP11 ANNUAL PATTERN OF SERUM TSH IN A RETROSPECTIVE CROSS-SECTIONAL AND LONGITUDINAL ANALYSIS OF OVER 20,000 RECORDS IN THYROXINE TREATED AND NON-TREATED SUBJECTS. EVIDENCE FOR SEASON-DEPENDENT REQUIREMENT FOR THYROXINE IN HYPOTHYROIDS

Gullo D¹, Latina A¹, Frasca F¹, Belfiore A²

¹Garibaldi-Nesima Hospital, Department of Endocrinology, Catania, Italy, ²University Magna Graecia, Department of Clinical and Experimental Medicine, Endocrine Unit, Catanzaro, Italy

17.15-17.30

OP12 REPLACEMENT THERAPY IN HYPOTHYROIDISM: COMPARISON OF „HIGH-NORMAL“ AND „LOW-NORMAL“ TSH LEVEL

Fadeyev V¹, Morgunova T², Manuilova Y²

¹Federal Endocrinological Research Centre of Russian Federation, Moscow, Russian Federation, ²Moscow Medical Academy, Endocrinology, Moscow, Russian Federation

17.30-17.45

OP13 DOSE-DEPENDENT ACUTE EFFECTS OF RECOMBINANT HUMAN TSH (RHTSH) ON THYROID SIZE AND FUNCTION. COMPARISON OF 0.1, 0.3 AND 0.9 MG OF RHTSH

Fast S¹, Nielsen VE¹, Bonnema SJ¹, Hegedüs L¹

¹Odense University Hospital, Endocrinology and Metabolism, Odense, Denmark

17.45-18.00

OP14 IS REGULATION OF ENERGY EXPENDITURE BY THE NOVEL BILE ACID (BA) - THYROID HORMONE LINK ALSO RELEVANT FOR HUMANS?

Valentini L¹, Ockenga J¹, Tiedge U², Schuetz T¹, Gläser S¹, Omar A¹, Kasim E¹, Kroencke T³, Lochs H¹, Köhrle J⁴, Brabant G⁵

¹Charité Universitätsmedizin, Gastroenterology, Hepatology & Endocrinology, Berlin, Germany, ²University of Groningen Medical Center, Center for Liver, Digestive and Metabolic Diseases, Groningen, Netherlands, ³Charité Universitätsmedizin, Dept of Radiology, Berlin, Germany, ⁴Charité Universitätsmedizin, Institute for Experimental Endocrinology and Endocrinological Research Center EnForCé, Berlin, Germany, ⁵The Christie, University of Manchester, Endocrinology, Manchester, United Kingdom



Room A - Salão Nobre

16.00-18.00

Oral Session 3: Young Investigators

Chairpersons: Theo Visser, Rotterdam, The Netherlands / Daniel Glinoe, Brussels, Belgium

16.00-16.15

OP15 UNEXPECTEDLY WIDE RANGE OF TRANSCRIPTION ACTIVITY MEDIATED BY THYROID-HORMONE RESPONSE ELEMENTS IN THE MOUSE HEART *IN VIVO*

Pol CJ¹, Zuidwijk MJ¹, Muller A¹, Visser TJ², Simonides WS¹

¹VU University Medical Center, Laboratory for Physiology, Institute for Cardiovascular Research, Amsterdam, Netherlands,

²Erasmus University Medical Center, Department of Internal Medicine, Rotterdam, Netherlands

16.15-16.30

OP16 IDENTIFICATION OF ROS-GENERATING NADPH OXIDASE NOX4 IN THYROID: ROLE IN DNA-DAMAGE RESPONSES INDUCED BY ONCOGENIC H-RAS

Weyemi U^{1,2}, Boufraquech M^{1,2}, Caillou B³, Talbot M³, Ameziane El Hassani R^{3,4}, Lacroix L³, Lagente-Chevallier O¹, Bidart J-M^{2,3}, Virion A^{1,2}, Schlumberger M^{2,3}, Dupuy C^{1,2}

¹CNRS FRE2939, Institut Gustave Roussy, Villejuif, France, ²Université Paris-Sud 11, Orsay, France, ³Institut Gustave Roussy, Villejuif, France, ⁴UBRM, Centre National de l'Energie, des Sciences et des Techniques Nucléaires, Rabat, Morocco

16.30-16.45

OP17 IDENTIFICATION OF SUMOYLATION SITES ON CCDC6, THE PRODUCT OF FIRST AND MOST FREQUENTLY OBSERVED RET-FUSED GENE, UNCOVER A MODE OF REGULATING CCDC6 FUNCTION

Merolla F¹, Leone V¹, Luise C¹, Vecchio G¹, Grieco M², Fusco A¹, Celetti A³

¹Naples, Federico II, Cellular and Molecular Biology and Pathology, Naples, Italy, ²Second University Naples, Caserta, Italy,

³Institute of Endocrinology and Oncology, CNR, Naples, Italy

16.45-17.00

OP18 SHORT OLIGODEOXYNUCLEOTIDES (DGOLIGOS) TARGETING OF THE THRB GENE 5'-UTR MARKEDLY INCREASE THE EFFICIENCY OF TRBETA PROTEIN TRANSLATION - A THERAPEUTIC POTENTIAL OF SENSE/ANTISENSE BASED DGOLIGOS AS GIBB'S FREE ENERGY MODULATORS OF 5'-UTR STEM-LOOP STRUCTURE

Master A¹, Wojcicka A¹, Poplawski P¹, Piekielko-Witkowska A¹, Boguslawska J¹, Brozda I¹, Williams GR², Nauman A¹

¹Medical Center of Postgraduate Education, Department of Biochemistry and Molecular Biology, Warsaw, Poland,

²Imperial College London, Molecular Endocrinology Group, MRC Clinical Sciences Centre, Hammersmith Hospital, London, United Kingdom

17.00-17.15

OP19 DIFFERENCES IN HYPOTHALAMUS-PITUITARY-THYROID (HPT) AXIS SETPOINT REGULATION BETWEEN GPB5 (THYROSTIMULIN) KNOCK OUT (GPB5^{-/-}) AND WILD TYPE (WT) MICE

van Zeijl CJJ¹, Fliers E¹, Surovtseva OV¹, Wiersinga WM¹, Boelen A¹

¹Academic Medical Center, University of Amsterdam, Department of Endocrinology & Metabolism, Amsterdam, Netherlands

Sunday

Sunday
6 September

17.15-17.30

OP20 ENDOSCOPIC DECOMPRESSION SURGERY IN 150 CONSECUTIVE PATIENTS WITH SEVERE GRAVES' ORBITOPATHY

Ponto KA¹, Mann WJ², Pitz S³, Hommel G⁴, Kahaly GJ¹

¹Gutenberg University Medical Center, Department of Medicine I, Mainz, Germany, ²Gutenberg University Medical Center, Department of ENT, Mainz, Germany, ³Gutenberg University Medical Center, Department of Ophthalmology, Mainz, Germany, ⁴Gutenberg University Medical Center, Department of Medical Statistics, Mainz, Germany

17.30-17.45

OP21 PREGNANCY IS A NEGATIVE OUTCOME PREDICTOR IN DIFFERENTIATED THYROID CANCER

Perrino M¹, Vannucchi G¹, Dazzi D¹, Colombo C¹, Rossi S², Beck-Peccoz P¹, Fugazzola L¹

¹Fondazione Policlinico IRCCS, Department of Medical Sciences, University of Milan and Endocrine Unit, Milan, Italy, ²Pathology Unit, Ospedale S. Paolo, Department of Medicine, Surgery and Dentistry, University of Milan, Milan, Italy

17.45-18.00

OP22 TREND OF SERUM TG MEASURED WITH ULTRASENSITIVE ASSAY IN THE FOLLOW-UP OF DIFFERENTIATED THYROID CARCINOMA (DTC) PATIENTS WITH NO EVIDENCE OF DISEASE

Tala HP¹, Castagna MG¹, Cipri C¹, Fioravanti C¹, Sestini F¹, Belardini V¹, Bonicolini L¹, Pacini F¹

¹University of Siena, Section of Endocrinology & Metabolism, Siena, Italy

Main Auditorium

18.00-18.30

Thyroid Nodule Guidelines

Chairpersons: Laszlo Hegedus, Odense, Denmark / Enrico Papini, Albano, Italy / Paolo Vitti, Pisa, Italy

Presentation of ETA/AACE/AME Thyroid Nodule Guidelines

Ralf Paschke, Leipzig, Germany



Sunday

Main Auditorium

18.45-20.30

Satellite Symposium

(sponsored by MERCK SERONO)

Absorption and Interchangeability of Levothyroxine

Chairperson: George J. Kahaly, Mainz, Germany

18.45-19.00 **Welcome Address and Introduction**

George J. Kahaly (Mainz, Germany)

19.00-19.30 **ABSORPTION OF LEVOTHYROXINE**

Salvatore Benvenaga (Messina, Italy)

19.30-20.00 **CLINICAL PITFALL CASES** (thyroid cancer, childhood, pregnancy)

Barbara Jarzab (Gliwice, Poland)

20.00-20.30 **INTERCHANGEABILITY OF LEVOTHYROXINE MEDICATIONS**

Kenneth Burman (Washington, DC, USA)

20.30 – 21.30

Get together and buffet
offered by MERCK SERONO

Monday
7 September

Room A - Salão Nobre

08.00-10.00

Oral Session 4: Thyroid Cancer (Basic)

Chairpersons: Giancarlo Vecchio, Naples, Italy / Paula Soares, Porto, Portugal

08.00-08.15

OP23 ANALYSIS OF ALTERNATIVE MECHANISMS OF RET GENE ACTIVATION IN FAMILIAL AND SPORADIC MEDULLARY THYROID CARCINOMA

Ciampi R¹, Romei C¹, Vivaldi A¹, Cosci B¹, Tacito A¹, Renzini G¹, Bottici V¹, Basolo F², Pinchera A¹, Elisei R¹

¹Università di Pisa, Endocrinologia e Metabolismo, Pisa, Italy, ²Università di Pisa, Chirurgia, Pisa, Italy

08.15-08.30

OP24 SULINDAC-SULFIDE ACTIVATES FOXO3A VIA INHIBITION OF THE PI3K/AKT AXIS AND INDUCES APOPTOSIS IN THYROID CARCINOMA CELLS

Weidinger C¹, Krause K¹, Fuhrer D¹

¹University of Leipzig, Leipzig, Germany

08.30-08.45

OP25 ACTIVATION OF TYRO3/AXL TYROSINE KINASE RECEPTORS IN THYROID CANCER

Avilla E¹, Guarino V¹, Visciano C¹, Liotti F¹, Svelto M¹, Franco R², Melillo RM¹

¹University of Naples Federico II, DBPCM/IEOS, Naples, Italy, ²National Cancer Institute, G. Pascale Foundation, Department of Clinical Immunology, Naples, Italy

08.45-09.00

OP26 TRANSCRIPTOME OF MICRODISSECTED PAPILLARY THYROID CANCER CELL

Oczko-Wojciechowska M¹, Rusin A², Kowalska M¹, Kowal M¹, Tyszkiewicz T¹, Chekan M¹, Czarniecka A³, Gubala E¹, Jarzab B¹

¹MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Nuclear Medicine and Endocrine Oncology, Gliwice, Poland, ²MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Department of Tumor Biology, Gliwice, Poland, ³MSC Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Oncologic Surgery Clinic, Gliwice, Poland

09.00-09.15

OP27 TGFβ MEDIATES BRAF-INDUCED EPITHELIAL TO MESENCHYMAL TRANSITION AND INVASION IN THYROID CANCER

Riesco-Eizaguirre G^{1,2}, De la Vieja A^{1,3}, Rodriguez I¹, Nistal M⁴, Santisteban P¹

¹Instituto de Investigaciones Biomedicas (CSIC-UAM), Madrid, Spain, ²Hospital Universitario La Paz, Servicio de Endocrinología, Madrid, Spain, ³Instituto de Salud Carlos III, Area de Biología Celular y Desarrollo, Madrid, Spain, ⁴Hospital Universitario La Paz, Servicio de Anatomía Patológica, Madrid, Spain

09.15-09.30

OP28 THE ANALYSIS OF SILENCING MECHANISM OF THE TUMOUR SUPPRESSOR GENES - P16(INK4A), CDH1 AND RASSF1A - IN THYROID NEOPLASMS

Czarnecka K¹, Brzezińska E^{1,2}, Pastuszak-Lewandoska D^{1,2}, Dedecjus M^{1,2}, Brzeziński J^{1,2}, Lewiński A^{1,2}

¹Medical University of Lodz, Chair of Endocrinology and Metabolic Diseases, Lodz, Poland, ²Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland



09.30-09.45

OP29 AURORA B INHIBITOR AZD1152 INDUCES MITOTIC CATASTROPHE IN ANAPLASTIC THYROID CARCINOMA CELLS AND ENHANCES THE CELL KILLING ACTIVITY OF THE ONCOLYTIC ADENOVIRUS DL922-947

Portella G¹, Libertini S¹, Abagnale A¹, Barbato S¹, Passaro C¹, Botta G¹, Rispoli E¹

¹University of Naples Federico II, Dipartimento di Biologia e Patologia Cellulare e Molecolare, Naples, Italy

09.45-10.00

OP30 EXPRESSION OF CLAUDIN-1, -3, -4, -5, -7 DURING HUMAN THYROID DEVELOPMENT: AN IMMUNOHISTOCHEMICAL STUDY

Ambrosetti MC¹, Colato C², Dardano A³, Monzani F³, Filetti S⁴, Menestrina F², Chilosi M², Ferdeghini M¹

¹University of Verona, Department of Morphological and Biomedical Sciences, Verona, Italy, ²University of Verona, Department of Pathology, Verona, Italy, ³University of Pisa, Department of Internal Medicine, Pisa, Italy, ⁴University of Roma 'La Sapienza', Department of Clinical Sciences, Roma, Italy

Main Auditorium

08.00-10.00

Oral Session 5: Thyroid Autoimmunity

Chairpersons: George J. Kahaly, Mainz, Germany / Francisco Carrilho, Coimbra, Portugal

08.00-08.15

OP31 MICROCHIMERISM IS ASSOCIATED WITH THYROID AUTOIMMUNITY. EVIDENCE FROM A TWIN STUDY

Brix TH¹, Hansen PS², Kyvik KO², Hegedüs L¹

¹Odense University Hospital, Endocrinology and Metabolism, Odense, Denmark, ²University of Southern Denmark, Danish Twin Registry, Odense, Denmark

08.15-08.30

OP32 TWO NEW HUMAN MONOCLONAL AUTOANTIBODIES TO THE TSH RECEPTOR WITH DIFFERENT BIOLOGICAL ACTIVITIES (STIMULATING AND BLOCKING) ISOLATED FROM A SINGLE BLOOD SAMPLE

Sanders J¹, Evans M¹, Tagami T², Roberts E¹, Hu X¹, Kabelis K¹, Richards T¹, Sanders P¹, Wilmot J¹, Young S¹, Furmaniak J¹, Rees Smith B¹

¹FIRS Laboratories, RSR Ltd, Cardiff, United Kingdom, ²National Hospital Organization, Kyoto Medical Center, Kyoto, Japan

08.30-08.45

OP33 INTERACTION OF THYROID STIMULATING AND BLOCKING AUTOANTIBODIES WITH AMINO ACIDS 22-260 OF THE TSH RECEPTOR

Young S¹, Collyer A¹, Sanders J¹, Sanders P¹, Baker S¹, Sullivan A¹, Powell M¹, Furmaniak J¹, Rees Smith B¹

¹FIRS Laboratories, RSR Ltd, Cardiff, United Kingdom

08.45-09.00

OP34 PPAR-ALPHA AGONISTS MODULATE TH1 AND TH2 CHEMOKINES IN THYROCYTES, FIBROBLASTS AND PREADIPOCYTES FROM PATIENTS WITH GRAVES' OPHTHALMOPATHY

Ferrari SM¹, Antonelli A¹, Fallahi P¹, Ghiri E¹, Ferrannini E¹

¹University of Pisa, Department of Internal Medicine, Pisa, Italy

Monday

Monday

7 September

09.00-09.15

OP35 CIRCULATING SELENOPROTEIN P CONCENTRATIONS ARE DECREASED IN PATIENTS WITH GRAVES' DISEASE AND CORRELATE INVERSELY TO SEVERITY OF ORBITOPATHY

Dehina N¹, Eckstein A², Minich W¹, Behrends T¹, Morgenthaler NG¹, Köhrle J¹, Schomburg L¹

¹Charité Universitätsmedizin Berlin, Institute for Experimental Endocrinology, Berlin, Germany,

²Essen University Hospital, Department of Ophthalmology, Essen, Germany

09.15-09.30

OP36 AUTOANTIBODIES TO THE INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR IN PATIENTS WITH GRAVES' ORBITOPATHY

Minich W¹, Eckstein A², Dehina N¹, Schomburg L¹

¹Charité Universitätsmedizin Berlin, Institute for Experimental Endocrinology, Berlin, Germany,

²Essen University Hospital, Department of Ophthalmology, Essen, Germany

09.30-09.45

OP37 THE INTRACELLULAR CD4+ EFFECTOR PATHWAY IN PATIENTS WITH CHRONIC LYMPHOCYTIC THYROIDITIS AND VITILIGO

Centanni M¹, Del Duca SC¹, Virili C¹, Amendolara G¹, Gargano L¹, Lo Coco E², Lenti L², Santaguida MG¹

¹'Sapienza' University of Rome, Polo Pontino, Latina, Experimental Medicine, Rome, Italy,

²'Sapienza' University of Rome, Experimental Medicine, Rome, Italy

09.45-10.00

OP38 PARATHYROID HORMONE-RELATED PEPTIDE IS DOWN-REGULATED AND APOLIPOPROTEIN L DOMAIN-CONTAINING 1 IS UP-REGULATED BOTH IN ACTIVE AND CHRONIC PHASE OF GRAVES' OPHTHALMOPATHY

Planck T¹, Parikh H², Brorson H³, Mårtensson T³, Åsman P⁴, Groop L¹, Hallengren B¹, Lantz M¹

¹Malmö University Hospital, Department of Endocrinology, Malmö, Sweden, ²Malmö University Hospital, Department of Clinical Sciences, Malmö, Sweden, ³Malmö University Hospital, Department of Plastic Surgery, Malmö, Sweden,

⁴Malmö University Hospital, Department of Ophthalmology, Malmö, Sweden

10.00-10.30

Coffee Break



Main Auditorium

10.30-12.00

Symposium 3 (Clinical): Implications of long-term TSH suppression

Chairpersons: Graham Williams, London, UK / Stig Andersen, Aalborg, Denmark

10.30-11.00 **RISKS TO THE CARDIOVASCULAR SYSTEM AND MORTALITY**

Bernadette Biondi (Naples, Italy)

11.00-11.30 **RISKS TO THE SKELETON**

Duncan Bassett (London, UK)

11.30-12.00 **TSH SUPPRESSION AND QUALITY OF LIFE**

Jan Smit (Leiden, The Netherlands)

Room A - Salão Nobre

10.30-12.00

Symposium 4 (Basic): Cell Biology of the Thyroid

Chairpersons: Lucio Nitsch, Naples, Italy / Ana Aranda, Madrid, Spain

10.30-11.00 **THE CONTROL OF THYROID CELL PROLIFERATION**

Pierre Roger (Brussels, Belgium)

11.00-11.30 **RADIATION AND THYROID CELL BIOLOGY**

Corinne Dupuy (Paris, France)

11.30-12.00 **MECHANISMS OF STUNNING**

Mikael Nilsson (Göteborg, Sweden)

Monday

Monday

7 September

Poster Exhibition Area

see plan on page 95

12.00 -13.00

Lunch and Poster discussions on site: Poster sessions P22 – P33

Posters P132 – P202

see page 64

Main Auditorium

13.00-14.30

Satellite Lunch Symposium (sponsored by GENZYME)

***Clinical Management of Thyroid Carcinoma:
State of the Art***

Overview:

An interactive meeting using key pad technology, where the expert faculty will discuss and gain audience feedback on the real life management of clinical cases

Introduction:

Treatment and follow up of thyroid cancer patients in the era of guidelines: a clinical case

Chairman: Martin Schlumberger, Paris, France

Initial treatment

Furio Pacini, Siena, Italy

Follow up

Markus Luster, Ulm, Germany

Treatment of recurrent and persistent disease

Jan Smit, Leiden, The Netherlands



Main Auditorium

14.30-15.15 *The ETA MERCK SERONO Prize Lecture*

Ins and outs of cellular thyroid hormone transport

Theo J. Visser, Rotterdam, The Netherlands

15.15-15.30

Coffee Break

15.30-16.15

Meet-the-Expert

5 Room A - Salão Nobre

The TSH receptor

Sabine Costagliola, Brussels, Belgium

Main Auditorium

15.30-16.15

Interactive Case Discussion: Treatment of thyroid nodules

Chairperson: Jacques Orgiazzi, Lyon, France

Discussants: Martin Grussendorf, Stuttgart, Germany

Laszlo Hegedus, Odense, Denmark

(Audience response system by courtesy of
Folke Söderström, Sweden)



16.30

Departure for Excursion

Transfers from the congress venue

Oceanário de Lisboa see page 91 for details

Monday

Tuesday
8 September

Room A - Salão Nobre

08.00-10.00

Oral Session 6: Cell Biology

Chairpersons: Mariastella Zannini, Naples, Italy / Marian Ludgate, Cardiff, UK

08.00-08.15

OP39 IDENTIFICATION OF A NEW CLUSTER OF TRANSMEMBRANE RESIDUES THAT ARE ESSENTIAL FOR SWITCHING THE THYROTROPIN RECEPTOR TO THE ACTIVE STATE

Haas A-K¹, Kleinau G¹, Neumann S², Worth CL¹, Schüle R¹, Krause G¹

¹Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany, ²National Institutes of Health, NIDDK, Bethesda, MD, United States

08.15-08.30

OP40 THYROID STIMULATING HORMONE (TSH) IS A NOVEL, LOCALLY PRODUCED REGULATOR OF HUMAN EPIDERMAL BIOLOGY THAT UNDERLIES CLASSICAL HYPOTHALAMUS-PITUITARY-THYROID AXIS CONTROLS

Bodó E^{1,2}, Kany B², Gáspár E², Knüver J², Kromminga A³, van Beek N², Poeggeler B², Wenzel BE⁴, Paus R^{2,5}

¹Agricultural and Molecular Research Institute, College of Nyíregyháza, Nyíregyháza, Hungary, ²University of Lübeck, Department of Dermatology, Lübeck, Germany, ³IPM Biotech, Hamburg, Germany, ⁴Medical University Lübeck, Dept. Internal Med. I, Lübeck, Germany, ⁵University of Manchester, School of Translational Medicine, Manchester, United Kingdom

08.30-08.45

OP41 THYROID STIMULATING HORMONE AS A NOVEL GROWTH FACTOR FOR T CELL DEVELOPMENT IN THE THYMUS

van der Weerd K^{1,2}, van Hagen PM², Heuvelmans SJWM², Visser TJ¹, van Dongen JM², van der Lelij AJ¹, Staal FTJ²

¹Erasmus MC, Internal Medicine, Rotterdam, Netherlands, ²Erasmus MC, Immunology, Rotterdam, Netherlands

08.45-09.00

OP42 DELIMITATION AND FUNCTIONAL CHARACTERIZATION OF THE BIDIRECTIONAL THOX-DUOXA PROMOTER REGIONS

Christophe D¹, Christophe-Hobertus C¹

¹Université Libre de Bruxelles, IBMM-IRIBHM, Gosselies, Belgium

09.00-09.15

OP43 REGULATION OF THE THYROID DUAL OXIDASE ACTIVITY BY ESTROGEN, THYROTROPIN AND IODINE

Cardoso LDC¹, Ferreira ACF¹, Freitas ML¹, Ginabreda MGP¹, Pantaleão TU¹, Leal ALC¹, Silva GS¹, Silva L¹, Costa VMC¹, Carvalho DPD¹

¹Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

09.15-09.30

OP44 FUNCTIONAL RNA EDITING OF THE DUOX2 GENE

Moreno JC¹, Ventura PS¹, Klootwijk W¹, Visser TJ¹

¹Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands



09.30-09.45

OP45 ELUCIDATING THE ROLE OF TSH-CAMP-PKA SIGNALLING FOR THYROIDAL GENE EXPRESSION IN A NON-MAMMALIAN VERTEBRATE MODEL, XENOPUS LAEVIS

Opitz R^{1,2}, Lorenz C², Trubiroha A², Kloas W²

¹Université Libre de Bruxelles, Institute of Interdisciplinary Research in Molecular Human Biology (IRIBHM), Brussels, Belgium, ²Leibniz-Institute of Freshwater Ecology and Inland Fisheries Berlin, Berlin, Germany

09.45-10.00

OP46 THE ROLE OF MIR-146B ON TGF-BETA SIGNALING PATHWAY IN THYROID FOLLICULAR CELLS

Geraldo MV¹, Kimura ET¹

¹University of Sao Paulo, Department of Cell & Developmental Biology, Institute of Biomedical Science, Sao Paulo, Brazil

Main Auditorium

08.00-10.00

Oral Session 7: Hyperthyroidism

Chairpersons: Luigi Bartalena, Varese, Italy / Fernando Rodrigues, Coimbra, Portugal

08.00-08.15

OP47 EPIDEMIOLOGY OF SUBTYPES OF HYPERTHYROIDISM IN DENMARK - A POPULATION-BASED STUDY

Carlé A¹, Pedersen IB¹, Knudsen N², Perrild H², Ovesen L³, Rasmussen LB⁴, Jørgensen T⁵, Laurberg P¹, The Danish Investigation of Iodine Intake and Thyroid Diseases (DanThyr)

¹Aalborg Hospital, Aarhus University Hospital, Denmark, Department of Endocrinology & Internal Medicine, Aalborg, Denmark, ²Bispebjerg Hospital, Copenhagen, Denmark, Endocrine Unit, Medical Clinic I, Copenhagen NV, Denmark, ³Copenhagen, Denmark, National Heart Foundation, Copenhagen K, Denmark, ⁴Danish Institute for Food and Veterinary Research, Copenhagen, Department of Nutrition, Søborg, Denmark, ⁵Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark

08.15-08.30

OP48 VARIATION IN PHENOTYPIC APPEARANCE OF GRAVES' DISEASE: EFFECT OF GENETIC ANTICIPATION AND DURATION OF COMPLAINTS

Vos XG¹, Tijssen JGP², Wiersinga WM¹

¹Academic Medical Center, University of Amsterdam, Department of Endocrinology and Metabolism, Amsterdam, Netherlands, ²Academic Medical Center, University of Amsterdam, Department of Cardiology, Amsterdam, Netherlands

08.30-08.45

OP49 COMPARISON OF R-HUMAN-TSH AND MONOCLONAL ANTIBODY-M22 BASED ASSAYS FOR THE MEASUREMENT OF TRAB IN PATIENTS WITH THYROID DISEASE

Bülow Pedersen J¹, Handberg A², Knudsen N³, Heickendorff L², Laurberg P¹

¹Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark, ²Aarhus University Hospital, Aarhus, Denmark, ³Bispebjerg Hospital, Copenhagen, Denmark

Tuesday

Tuesday
8 September

08.45-09.00

OP50 RADIOIODINE THERAPY COMBINED WITH LITHIUM CARBONATE INCREASES CURE RATE IN PATIENTS WITH GRAVES' DISEASE

Giovannetti C¹, Fessehastion R¹, Campomori A¹, Tanda ML², Ceccarelli C¹, Vitti P¹, Bartalena L², Martino E¹, Bogazzi F¹

¹University of Pisa, Department of Endocrinology and Metabolism, Pisa, Italy, ²University of Insubria, Department of Clinical Medicine, Varese, Italy

09.00-09.15

OP51 SURGERY RATES AND USE OF RADIOIODINE FOR BENIGN THYROID DISORDERS FOLLOWING IODIZATION - A NATIONWIDE STUDY

Cerqueira C¹, Knudsen N², Ovesen L³, Jørgensen T¹

¹Glostrup University Hospital, Research Centre for Prevention and Health, Glostrup, Denmark, ²Bispebjerg Hospital, Department of Endocrinology and Gastroenterology, Copenhagen, Denmark, ³Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark

09.15-09.30

OP52 COMBINED PERCUTANEOUS LASER ABLATION AND 131-IODINE FOR THE TREATMENT OF LARGE TOXIC NODULAR GOITRE

Todino V¹, Chianelli M^{2,3}, Bizzarri G⁴, Misichi P¹, Guglielmi R², Pacella CM⁴, Papini E²

¹Regina Apostolorum Hospital, Nuclear Medicine, Albano, Italy, ²Regina Apostolorum Hospital, Endocrinology, Albano, Italy, ³University Medical Center Groningen, Nuclear Medicine, Groningen, Netherlands, ⁴Regina Apostolorum Hospital, Interventional Radiology, Albano, Italy

09.30-09.45

OP53 LONG TERM OUTCOME OF GRAVES' OPTHALMOPATHY (GO) TREATED WITH GLUCOCORTICOID (GC) FOLLOWING TOTAL THYROID ABLATION (TTA): FOLLOW-UP OF A RANDOMIZED CLINICAL TRIAL

Leo M¹, Sisti E¹, Latrofa F¹, Rocchi R¹, Altea MA¹, Profilo MA¹, Megna L², Nardi M², Pinchera A¹, Marcocci C¹, Marinò M¹

¹University Hospital of Pisa, Department of Endocrinology and Kidney, Pisa, Italy, ²University Hospital of Pisa, Department of Neuroscience, Pisa, Italy

09.45-10.00

OP54 DECREASED SERUM TSH LEVELS ARE NOT ASSOCIATED WITH MORTALITY IN THE ADULT NORTHEAST GERMAN POPULATION

Ittermann T¹, Haring R¹, Sauer S¹, Wallaschofski H¹, Dörr M¹, Nauck M¹, Völzke H¹

¹University of Greifswald, Greifswald, Germany

10.00-10.30

Coffee Break



Room A - Salão Nobre

10.30-12.00

Symposium 5 (Basic):

Genetics of thyroid disease: methodological aspects and clinical relevance

Chairpersons: Krishna Chatterjee, Cambridge, UK / Dagmar Führer, Leipzig, Germany

10.30-11.00 **METHODOLOGICAL APPROACH AND CLINICAL RELEVANCE OF GENE POLYMORPHISM**

Simon Pearce, Newcastle-upon-Tyne, UK

11.00-11.30 **GENETIC DETERMINATION OF THYROID HORMONE SETPOINT**

Robin Peeters, Rotterdam, The Netherlands

11.30-12.00 **JOINT SUSCEPTIBILITY GENES FOR AUTOIMMUNE THYROIDITIS AND TYPE 1 DIABETES**

George J. Kahaly, Mainz, Germany

Main Auditorium

10.30-12.00

Symposium 6 (Clinical):

Theodore Kocher's Centennial Symposium: thyroid surgery

Chairpersons: Wilmar M. Wiersinga, Amsterdam, The Netherlands / Francisco Castro e Sousa, Coimbra, Portugal

10.30-11.00 **REGISTRY OF SURGICAL RESULTS: ORGANIZATION AND OUTCOMES**

Christian Godballe, Odense, Denmark

11.00-11.30 **EVIDENCE-BASED APPROACH TO DIFFERENT TYPES OF CONVENTIONAL THYROID SURGERY, TO OPTIMIZE CURE AND MINIMIZE SIDE EFFECTS**

Dana Hartl, Paris, France

11.30-12.00 **MINI-INVASIVE THYROIDECTOMY**

Paolo Miccoli, Pisa, Italy

Poster Exhibition Area

see plan on page 95

12.00-13.00

Lunch and Poster discussions on site: Poster sessions P34 – P44

Posters P203 – P278

see page 76

Tuesday

Tuesday

8 September

Main Auditorium

13.00-14.30

Satellite Symposium

(sponsored by Exelixis and Bristol-Myers Squibb)

New Advances in Medullary Thyroid Cancer

Chairperson: Martin Schlumberger, Paris, France

ATA-ETA TREATMENT GUIDELINES IN MEDULLARY THYROID CARCINOMA

Richard Kloos (Columbus, OH, USA)

TARGETING MET IN MEDULLARY THYROID CARCINOMA

Livio Trusolino (Turin, Italy)

CURRENT CLINICAL TRIALS IN MEDULLARY THYROID CARCINOMA

Steven Sherman (Houston, TX, USA)

14.30-15.15

Meet-the-Expert

- 6 Room B - Salão das Conferências**
Studies design using transgenic mice
Graham Williams, London, UK
- 7 Room C - Sala dos Doutoramentos**
Resistance to thyroid hormones
Joao Anselmo, Ponta Delgada, Azores, Portugal
- 8 Main Auditorium**
Long-term side effects of low-activity radioiodine therapy
Barbara Jarzab, Gliwice, Poland
- 9 Room A - Salão Nobre**
Thyroid problems in children born to mothers with Graves' disease
Thomas Vulsma, Amsterdam, The Netherlands

15.15-15.30

Coffee Break



Room A - Salão Nobre

15.30-17.30

Oral Session 8: Models of thyroid disease

Chairpersons: Duncan Bassett, London, UK / P. Reed Larsen, Boston, USA

15.30-15.45

OP55 THE THYROID HORMONE RECEPTOR α MODULATES LPS-INDUCED CHANGES IN PERIPHERAL THYROID HORMONE METABOLISM

Kwakkel J¹, Chassande O², van Beeren HC¹, Fliers E¹, Wiersinga WM¹, Boelen A¹

¹Academic Medical Center, University of Amsterdam, Endocrinology & Metabolism, Amsterdam, Netherlands,

²INSERM U 577, Université Victor Segalen Bordeaux 2, Bordeaux, France

15.45-16.00

OP56 DIFFERENTIAL REGULATION OF ADIPOGENESIS BY THYROID HORMONE RECEPTOR ISOFORMS

Mishra A¹, Araki O¹, Cheng S-Y¹

¹National Cancer Institute, Bethesda, United States

16.00-16.15

OP57 THE ROLE OF HES1 FOR NORMAL THYROID DEVELOPMENT: A KNOCK-OUT MICE STUDY

Carre A¹, Szinnai G^{1,2}, Tron E¹, Richard B¹, Castanet M¹, Jorgensen M³, Serup P³, Polak M^{1,4}

¹University Paris-Descartes, Faculty Necker, INSERM U845, Paris, France, ²University Children's Hospital Basel, Paediatric Endocrinology, Basel, Switzerland, ³Hagedorn Research Institute, Department of Developmental Biology, Gentofte, Denmark, ⁴Necker Enfants-Malades Hospital, APHP, Pediatric Endocrine Unit, Centre des Maladies Endocriniennes Rares de la Croissance, Paris, France

16.15-16.30

OP58 CLEAVAGE OF THE TSHR IN CELLS DEFICIENT IN ADAM (A DESINTEGRIN AND METALLOPROTEASE) 17 AND ADAM 10

Belle M¹, Le Gall S², Saftig P³, Docherty A⁴, Sehara-Fujisawa A⁵, Blobel C², Misrahi M⁶

¹INSERM U 854, Hopital Bicetre, Le Kremlin Bicetre, France, ²Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, New York, United States, ³Biochemisches Institut, Christians-Albrecht Universität Kiel, Kiel, Germany, ⁴Department of Oncology, Celltech Research, Slough, United Kingdom, ⁵Department of Growth Regulation, Institute for Frontier Medical Sciences, Kyoto, Japan, ⁶INSERM U 854, Hopital Bicetre, Le Kremlin-Bicêtre, France

16.30-16.45

OP59 SYSTEMIC SODIUM IODIDE SYMPORTER GENE THERAPY IN HEPATOCELLULAR CARCINOMA USING NON-VIRAL GENE DELIVERY VECTORS

Klutze K¹, Russ V², Willhauck MJ¹, Wunderlich N¹, Gildehaus FJ³, Goke B¹, Wagner E², Ogris M², Spitzweg C¹

¹Ludwig-Maximilians-University, Dept. of Internal Medicine II, Munich, Germany, ²Ludwig-Maximilians-University, Dept. of Pharmacy, Center of Drug Research, Pharmaceutical Biology-Biotechnology, Munich, Germany,

³Ludwig-Maximilians-University, Dept. of Nuclear Medicine, Munich, Germany

16.45-17.00

OP60 CHROMOGRANIN A SERVES AS SPECIFIC TUMOR ANTIGEN RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES: POTENTIAL IMPLICATION FOR THE TREATMENT OF MEDULLARY THYROID CARCINOMA

Papewalis C¹, Wuttke M¹, Kouatchoua C¹, Jacobs B¹, Schinner S¹, Willenberg HS¹, Scherbaum WA¹, Schott M¹

¹University Hospital Düsseldorf, Düsseldorf, Germany

Tuesday

Tuesday
8 September

17.00-17.15

OP61 TEMPORAL RELATIONSHIP BETWEEN ORGAN RESPONSES TO 3,5-DIODO-L-THYRONINE IN HIGH-FAT DIET-FED RATS: ROLE OF AMPK

de Lange P¹, Senese R¹, Cioffi F¹, Lombardi A², Valli V¹, Moreno M³, Silvestri E³, de Matteis R⁴, Goglia F³, Lanni A¹

¹Second University of Napoli, Dip Scienze della Vita, Caserta, Italy, ²University of Napoli, Dip. Scienze Biologiche, Napoli, Italy, ³University of Sannio, Dip. Scienze Biologiche ed Ambientali, Benevento, Italy, ⁴University of Urbino, Istituto di Scienze Fisiologiche, Urbino, Italy

17.15-17.30

OP62 ASSESSMENT OF HEPATIC GENE EXPRESSION IN TYPE 3 DEIODINASE-DEFICIENT MICE SUBJECTED TO BACTERIAL INFECTION

Boelen A¹, de Waard E¹, Kwakkel J¹, St Germain D², Fliers E¹, Hernandez A²

¹Academic Medical Center, Endocrinology and Metabolism, Amsterdam, Netherlands, ²Dartmouth Medical School, Department of Medicine, Lebanon, United States

Main Auditorium

15.30-17.30

Oral Session 9: Thyroid Cancer (clinical)

Chairpersons: Furio Pacini, Siena, Italy / Edward Limbert, Lisbon, Portugal

15.30-15.45

OP63 FUNCTIONAL ANALYSES OF FOUR NOVEL RET GERMLINE MUTATIONS: JUXTAMEMBRANE MUTATIONS DISPLAY THE HIGHEST LEVEL OF AUTOPHOSPHORYLATION

Muzza M¹, Cordella D², Bombled J³, Bressac-de Paillerets B³, Francis Z⁴, Beck-Peccoz P¹, Schlumberger M⁴, Persani L², Fugazzola L¹

¹Endocrine Unit Fondazione Policlinico IRCCS, Dept. of Medical Sciences, University of Milan, Milan, Italy, ²Laboratory of Experimental Endocrinology, Istituto Auxologico Italiano IRCCS, Department of Medical Sciences, University of Milan, Milan, Italy, ³Institut Gustave Roussy and University Paris Sud 11, Department of Biology and Medical Diseases, Villejuif, France, ⁴Institut Gustave Roussy and University Paris Sud 11, Department of Medicine, Villejuif, France

15.45-16.00

OP64 RESCUE OF SODIUM IODIDE SYMPORTER EXPRESSION BY COMBINED TARGETING OF THE ERK AND AKT SIGNALLING PATHWAYS

Bullock M¹, Robinson BG¹, Clifton-Bligh RJ¹

¹Kolling Institute of Medical Research, Hormones and Cancer, Sydney, Australia

16.00-16.15

OP65 POTENTIAL ROLE OF CXCR4 AND SDF-1 AS INDICATORS OF AGGRESSIVENESS IN PAPILLARY THYROID CARCINOMA

Pagano L¹, Caillou B², Lacroix L², Guarino V³, Biondi B¹, Santoro M³, Melillo RM³, Schlumberger M²

¹University of Naples ,Federico II', Department of Clinical and Molecular Endocrinology and Oncology, Naples, Italy, ²Institut Gustave Roussy, Villejuif, France, ³University of Naples ,Federico II', Dipartimento di Biologia e Patologia Cellulare e Molecolare c/o Istituto di Endocrinologia ed Oncologia Sperimentale del CNR G. Salvatore, Naples, Italy

16.15-16.30

OP66 COMBINED ANALYSIS OF CLAUDIN-1 EXPRESSION AND 1513A/C POLYMORPHISM OF THE P2X7 RECEPTOR GENE: PROGNOSTIC ROLE IN PAPILLARY THYROID CANCER

Dardano A¹, Colato C², Ursino S¹, Polini A¹, Ambrosetti MC³, Brazzarola P⁴, Tognini S¹, Ferdeghini M³, Monzani F¹

¹University of Pisa, Internal Medicine, Pisa, Italy, ²University of Verona, Pathology, Verona, Italy, ³University of Verona, Morphological and Biomedical Sciences, Verona, Italy, ⁴University of Verona, Anesthesiology and Surgery, Verona, Italy

16.30-16.45

OP67 PROGNOSTIC ROLE OF PROPHYLACTIC CENTRAL NODE DISSECTION ASSOCIATED TO TOTAL THYROIDECTOMY IN PAPILLARY THYROID CANCER

Colombo C¹, Perrino M¹, Vannucchi G¹, Vicentini L², Beck-Peccoz P¹, Fugazzola L¹

¹Fondazione Policlinico IRCCS, Department of Medical Sciences, University of Milan & Endocrine Unit, Milan, Italy, ²Fondazione Policlinico IRCCS, University of Milan, Endocrine Surgery Units, Milan, Italy

16.45-17.00

OP68 THE THYROID AXIS 'SETPOINTS' ARE SIGNIFICANTLY ALTERED AFTER LONG-TERM SUPPRESSIVE LT4 THERAPY

Verburg FA¹, Hategan MC¹, Maeder U², Luster M³, Reiners C¹, Smit JWA⁴

¹University of Würzburg, Nuclear Medicine, Würzburg, Germany, ²University of Würzburg, Tumour Center, Würzburg, Germany, ³University of Ulm, Nuclear Medicine, Ulm, Germany, ⁴Leiden University Medical Center, Endocrinology, Leiden, Netherlands

17.00-17.15

OP69 POST-I-131 ABLATION SPECT-CT HAS AN ADDITIONAL DIAGNOSTIC VALUE TO POST-ABLATION PLANAR SCINTIGRAPHY AND CERVICAL ULTRASOUND

Hategan MC¹, Verburg FA¹, Schloegl S¹, Biko J¹, Luster M², Kreissl MC¹, Reiners C¹

¹University of Würzburg, Nuclear Medicine, Würzburg, Germany, ²University of Ulm, Nuclear Medicine, Ulm, Germany

17.15-17.30

OP70 EVALUATION OF THE USEFULNESS OF NAF-PET IN DIAGNOSIS OF BONE METASTASES FROM THYROID CANCER IN COMPARING WITH THAT OF CONVENTIONAL TC-99M-DIPHOSPHONATE BONE SCINTIGRAPHY

Kawabe J¹, Higashiyama S¹, Kawamura E¹, Hayashi T¹, Kurooka H¹, Onoda N², Ishikawa T², Shiomi S¹

¹Graduate School of Medicine, Osaka City University, Department of Nuclear Medicine, Osaka City, Japan, ²Graduate School of Medicine, Osaka City University, Department of Oncological Surgery, Osaka City, Japan

Main Auditorium

17.30-19.00

General Assembly



20.30

Gala Dinner

Palácio Foz see page 91 for details

Tuesday

Wednesday

9 September

Room B - Salão das Conferências

08.00-10.00

Oral Session 10: Genetics of thyroid disease

Chairpersons: Ralf Paschke, Leipzig, Germany / Valeriano Leite, Lisbon, Portugal

08.00-08.15

OP71 DUAL-OXIDASE 2 GENETIC MODIFICATIONS IN CHILDREN WITH HYPOTHYROIDISM: IDENTIFICATION AND FUNCTIONAL ANALYSIS OF NEW VARIANTS AND MUTATIONS

Bagattini B¹, De Marco G¹, Montanelli L¹, Agretti P¹, Ferreira Freitas A¹, Dimida A¹, Ferrarini E¹, Ramos H¹, Ceccarelli C¹, Brozzi F¹, Di Cosmo C¹, Pinchera A¹, Vitti P¹, Tonacchera M¹

¹Department of Endocrinology, University of Pisa, Pisa, Italy

08.15-08.30

OP72 IDENTIFICATION OF 28 NOVEL NKX2-1 MUTATIONS IN 102 PATIENTS WITH BROAD SPECTRUM OF BRAIN AND THYROID DYSFUNCTIONS

Krude H¹, Thorwarth A¹, Schnittert S¹, Biebermann H¹, Jyrch S¹, Dame C², Ropers H-H³, Grueters A¹, Ullmann R³

¹Charite University of medicine Berlin, Institute for Experimental Pediatric Endocrinology, Berlin, Germany,

²Charite University of medicine Berlin, Molecular Neonatology, Berlin, Germany, ³Max-Planck Institute for Molecular Genetics, Human Molecular Genetics, Berlin, Germany

08.30-08.45

OP73 PHENOTYPIC VARIABILITY OF PAX8 MUTATIONS IN CONGENITAL HYPOTHYROIDISM: A DIGENISM HYPOTHESIS WITH A POTENTIAL ROLE OF TSHR?

Castanet M^{1,2}, Carre A¹, Tron E¹, De Roux N³, Cabrol S⁴, Puel O⁵, Queinnec C⁶, Léger J⁷, Polak M^{1,2}

¹Université Paris Descartes, INSERM U845, Paris, France, ²Hôpital Necker Enfants Malades, AP-HP, Service d'Endocrinologie

et Diabétologie Pédiatrique, Paris, France, ³INSERM U 690, Hopital Robert Debré, Paris, France, ⁴Hopital Armand

Trousseau, AP-HP, Scc Explorations Fonctionnelles, Paris, France, ⁵Hopital Pellegrin, Scc de Pédiatrie Médicale, Bordeaux,

France, ⁶CH de Cornouailles-Hopital Laennec, Scc de Pédiatrie, Quimper, France, ⁷Hopital Robert Debré,

Scc d'Endocrinologie et Diabétologie Pédiatrique, Paris, France

08.45-09.00

OP74 ANALYSIS OF JAGGED 1 MUTATIONS IN PATIENTS WITH CONGENITAL HYPOTHYROIDISM

Calebiro D^{1,2}, de Filippis T², Marelli F^{1,2}, Porazzi P^{1,2,3}, Corbetta S^{1,4}, Tiso N³, Persani L^{1,2}

¹University of Milan, Milan, Italy, ²IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy,

³University of Padua, Padua, Italy, ⁴IRCCS Policlinico S. Donato, S. Donato Milanese, Italy

09.00-09.15

OP75 MOLECULAR CHARACTERIZATION OF GENES LOCATED AT 2Q21 IN FAMILIAL AND SPORADIC FOLLICULAR-CELL-DERIVED THYROID TUMOURS

Prazeres H^{1,2,3}, Torres J¹, Rodrigues F⁴, Figueiredo P⁵, Lacerda M⁵, Martins T², Sobrinho-Simoes M¹, Soares P¹

¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal, ²Laboratory of

Molecular Pathology of the Portuguese Institute of Oncology of Coimbra., Coimbra, Portugal, ³Medical Faculty, University

of Porto, Porto, Portugal, ⁴Endocrinology Service of the Portuguese Institute of Oncology of Coimbra, Coimbra, Portugal,

⁵Histopathology Laboratory of the Portuguese Institute of Oncology of Coimbra, Coimbra, Portugal



09.15-09.30

OP76 SCREENING FOR CHROMOSOMAL ABERRATIONS BY ARRAY CGH IN 80 PATIENTS WITH CONGENITAL HYPOTHYROIDISM DUE TO THYROID DYSGENESIS

Thorwarth A¹, Mueller P, Biebermann H¹, Ropers H-H², Grueters A¹, Ullmann R², Krude H¹

¹Charite University of medicine Berlin, Institute for Experimental Pediatric Endocrinology, Berlin, Germany,

²Max-Planck Institute for Molecular Genetics, Human Molecular Genetics, Berlin, Germany

09.30-09.45

OP77 GENETIC HETEROGENEITY IN PATIENTS WITH CONGENITAL HYPOTHYROIDISM WITH TOTAL AND/OR PARTIAL IODIDE ORGANIFICATION: HIGH FREQUENCY OF MONOALLELIC MUTATIONS AND NEW GENE SEQUENCE ALTERATIONS

Neves SC¹, Dias V², Chagas AJ², Kwon C¹, Knobel M¹, Medeiros-Neto G¹, Rubio IGS¹

¹University of São Paulo Medical School, Thyroid Unit (Lim 25) Endocrinology, São Paulo, Brazil,

²University of Minas Gerais Medical School, NUPAD, Belo Horizonte, Brazil

09.45-10.00

OP78 DIFFERENCES IN THE GENETIC PROFILE OF RISK FOR GRAVES' DISEASE IN A BRAZILIAN AND IN A DUTCH POPULATION

Ward LS¹, Vos XG², Bufalo NE¹, Leite JL¹, Santos RB³, Romaldini JHP³, Wiersinga WM²

¹Molecular Genetics of Cancer Laboratory, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil,

²Department of Endocrinology and Metabolism, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Division of Endocrinology, School of Medicine-Catholic University of Campinas, Campinas, Brazil

Room A - Salão Nobre

08.00-10.00

Oral Session 11: Thyroid hormone metabolism and action

Chairpersons: Pieter De Lange, Naples, Italy / Joao Anselmo, Ponta Delgada, Azores, Portugal

08.00-08.15

OP79 POSTNATAL EARLY OVERNUTRITION CHANGES THE LEPTIN SIGNALING PATHWAY IN THE HYPOTHALAMUS-PITUITARY-THYROID AXIS OF YOUNG AND ADULT RATS

Moura EG¹, Rodrigues AL¹, Passos MC², Conceição EP¹, Lisboa PC¹

¹State University of Rio de Janeiro, Physiology, Rio de Janeiro, Brazil, ²State University of Rio de Janeiro, Nutrition, Rio de Janeiro, Brazil

08.15-08.30

OP80 REGULATION OF GENE EXPRESSION IN THE FOETAL RAT BRAIN BY THYROID HORMONE

Morte B¹, Ausó E², Díez D³, Martín M³, Grijota-Martínez C¹, Navarro D², Morreale G⁴, Berbel P², Bernal J⁴

¹CIBERER, U708, Madrid, Spain, ²Universidad de Elche, Instituto de Neurociencias, Alicante, Spain,

³CSIC, Instituto de Investigaciones Biomédicas, Madrid, Spain, ⁴CSIC, Instituto de Investigaciones Biomédicas, CIBERER, U708, Madrid, Spain

Wednesday

Wednesday
9 September

08.30-08.45

OP81 THE REGULATION OF THE MITOCHONDRIAL ENERGY METABOLISM IN HUMAN HAIR FOLLICLES (HF) UNDERLIES THE CLASSICAL HYPOTHALAMUS-PITUITARY-THYROID (HPT) AXIS

Gáspár E¹, Bodó E^{1,2}, Poeggeler B¹, van Beek N¹, Knüver J¹, Paus R^{1,3}, Wenzel BE⁴

¹Medical University Lübeck, Dept. of Dermatology, Lübeck, Germany, ²Agricultural and Molecular Research Institute, College of Nyíregyháza, Nyíregyháza, Hungary, ³University of Manchester, School of Translational Medicine, Manchester, United Kingdom, ⁴Medical University Lübeck, Dept. Internal Med. I, Lübeck, Germany

08.45-09.00

OP82 THE *IN VITRO* CHARACTERIZATION OF SEVEN NEWLY IDENTIFIED MUTATIONS IN MCT8 FOUND IN PATIENTS WITH THE ALLAN-HERNDON-DUDLEY SYNDROME

Friesema E¹, Kersseboom S¹, Visser WE¹, Klootwijk W¹, Visser T¹

¹Erasmus MC, Rotterdam, Netherlands

09.00-09.15

OP83 LARGELY DIFFERENT GENE EXPRESSION PROFILES IN CELLS FROM MCT8 PATIENTS

Visser WE¹, Swagemakers SM², van Ijcken WF², van der Spek PJ², Visser TJ¹

¹Erasmus Medical Center, Internal Medicine, Rotterdam, Netherlands, ²Erasmus Medical Center, Bioinformatics, Rotterdam, Netherlands

09.15-09.30

OP84 EFFECTS OF AMIODARONE AND DRONEDARONE TREATMENT ON CENTRAL THYROID HORMONE METABOLISM IN RATS

Beeren van HC¹, Wiersinga W¹, Kwakkel J¹, Boelen A¹, Fliers E¹

¹Academic Medical Centre, Endocrinology, Amsterdam, Netherlands

09.30-09.45

OP85 CARDIAC METABOLISM OF 3-IODOTHYRONAMINE

Chiellini G¹, Saba A¹, Frascarelli S¹, Ghelardoni S¹, Marchini M¹, Raffaelli A², Zucchi R¹

¹University of Pisa, Pisa, Italy, ²CNR ICCOM, Pisa, Italy

09.45-10.00

OP86 MOLECULAR MECHANISM OF TRANS-REPRESSION OF MYOSIN HEAVY CHAIN β GENE BY THYROID HORMONE

Nakamura H¹, Iwaki H¹, Misawa H¹, Sasaki S¹

¹Hamamatsu University School of Medicine, Department of Internal Medicine 2, Hamamatsu, Japan

10.00-10.15

Coffee Break



Room A - Salão Nobre

10.15-11.45

Symposium 7 (Translational): Tyrosine kinase inhibitors for differentiated thyroid carcinoma: mechanisms of action and clinical applications

Chairpersons: Rossella Elisei, Pisa, Italy / Jan Smit, Leiden, The Netherlands

10.15-10.45 **ONCOGENIC ADDICTION:
MECHANISM OF ACTION AND RESISTANCE**

Francesca Carlomagno (Naples, Italy)

10.45-11.15 **TRIAL DESIGN:
LOGISTICS, CLINICAL PROBLEMS, EXTRATHYROIDAL SIDE EFFECTS**

Lars Bastholt (Odense, Denmark)

11.15-11.45 **RESULTS OF CLINICAL TRIALS**

Martin Schlumberger (Paris, France)

Room B - Salão das Conferências

10.15-11.45

Symposium 8 (Educational): Environment, chemicals and the thyroid

Chairpersons: Leonidas Duntas, Athens, Greece / Valentin Fadeyev, Moscow, Russia

10.15-10.45 **FOOD, CHEMICALS AND THE THYROID**

Michael Zimmermann (Zurich, Switzerland)

10.45-11.15 **VOLCANOS AND THYROID DISEASE**

Gabriella Pellegri (Catania, Italy)

11.15-11.45 **THE EFFECTS OF PLASTICIZERS ON THE THYROID:
EMPHASIS ON BISPHENOL A**

Lutz Schomburg (Berlin, Germany)

Room A - Salão Nobre

11.45-12.00 **Closing Ceremony**

Presentation of

YOUNG INVESTIGATORS PRIZE (Clinical / Basic) sponsored by BRAHMS

POSTER PRIZE (Clinical) sponsored by the ETA

POSTER PRIZE (Basic) sponsored by the ETA

Wednesday

Sunday
6 September

Poster Exhibition Area

12.00-13.00

Lunch and Poster discussions on site Poster Sessions P01 – P11

P01 Thyroid Cell and Molecular Biology 1

Discussion Leader: Mariastella Zannini (Naples, Italy)

P001

PROLIFERATION AND SURVIVAL MOLECULES IMPLICATED IN THE INHIBITION OF BRAF PATHWAY IN THYROID CANCER CELLS HARBOURING DIFFERENT GENETIC MUTATIONS

Preto A^{1,2}, Gonçalves J¹, Figueiredo J¹, Rebocho AP¹, Rocha AS¹, Vasconcelos MH¹, Seca H¹, Seruca R¹, Soares P^{1,3}, Sobrinho-Simões M^{1,3,4}

¹IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), Porto, Portugal, ²Univeristy of Minho, Department of Biology, Braga, Portugal, ³Medical Faculty, University of Porto, Porto, Portugal, ⁴Hospital S. João, Department of Pathology, Porto, Portugal

P002

HIGH IODIDE CONCENTRATION REGULATES NIS AND SELENOPROTEINS EXPRESSION IN THYROID CELLS

Leoni SG¹, Kimura ET², Santisteban P¹, De la Vieja A¹

¹Instituto de Investigaciones Biomedicas 'Alberto Sols' CSIC-UAM, Departamento de Fisiopatología Endocrina y del Sistema Nervioso, Madrid, Spain, ²Instituto de Ciências Biomédicas - USP, Departamento de Biologia Celular e do Desenvolvimento, São Paulo, Brazil

P003

NITRIC OXIDE SIGNALLING AS A CENTRAL PATHWAY CONTROLLING THE OXIDATIVE METABOLISM OF FOLLICULAR THYROID CARCINOMA

Le Pennec S¹, Jacques C¹, Poirier J¹, Malthiery Y^{1,2}, Savagner F^{1,2}, Mirebeau-Prunier D^{1,2}

¹INSERM, U694, Angers, France, ²CHU Angers, Biochimie Génétique, Angers, France

P004

CDH-16 GENE EXPRESSION IN THYROID CELL DIFFERENTIATION AND TRANSFORMATION

Cali G¹, Mogavero S², Pallante P², Nitsch R³, Ferraro A⁴, de Cristofaro T¹, Zannini S¹, Fusco A⁴, Nitsch L²

¹IEOS, CNR, Napoli, Italy, ²University Federico II, DBPCM, Napoli, Italy, ³IMBA, Vienna, Austria, ⁴NOGEC-CEINGE, Napoli, Italy

P005

THYROSOPHERES: AN IN VITRO MODEL FOR HUMAN THYROID CARCINOGENESIS

Frasca F¹, Vella V¹, Giani F¹, Nicolosi ML¹, Lotta S¹, Pandini G¹, Vigneri R¹

¹Endocrinology, University of Catania, Internal Medicine, PO Garibaldi Nesima, Catania, Italy

P006

OVERACTIVATION OF THE PI3K/AKT/MTOR PATHWAY IS OBSERVED IN THYROID BENIGN DISEASES

Faustino AE¹, Rocha AS^{1,2}, Pópulo H¹, Soares P^{1,3}, Sobrinho-Simões M^{1,3}

¹IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), Porto, Portugal, ²Institute of Interdisciplinary Research (IRIBHM), Free University of Brussels, School of Medicine, Brussels, Belgium, ³Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal

P007

EFFECT OF VITAMIN D RECEPTOR DISRUPTION ON THYROID MORPHOLOGY AND FUNCTION

Clinckspoor I¹, Gérard A-C², Many M-C², Van Sande J³, Bouillon R¹, Carmeliet G¹, Decallonne B¹

¹KULeuven, Leuven, Belgium, ²UCL, Brussels, Belgium, ³ULB, Brussels, Belgium



P008

SOMATOSTATIN RECEPTOR 2 EXPRESSION IN COLD THYROID NODULES

Sancak S¹, Hardt A², Singer J³, Klöppel G³, Tanay Eren F⁴, Sen LS⁵, Güllüoglu BM⁵, Sever Z⁴, Akalin NS¹, Eszlinger M², Paschke R²

¹Marmara Medical School, Section of Endocrinology and Metabolism, Istanbul, Turkey, ²University of Leipzig, 3rd Medical Department, Leipzig, Germany, ³University Clinic Schleswig-Holstein, Institute for Pathology, Kiel, Germany, ⁴Marmara Medical School, Department of Pathology, Istanbul, Turkey, ⁵Marmara Medical School, General Surgery Department, Istanbul, Turkey

P009

ELECTRIC AND MAGNETIC FIELD DO NOT MODIFY THE BIOCHEMICAL PROPERTIES OF FRTL-5 CELLS

Dimida A¹, Agretti P¹, Tonacchera M¹, Ferrarini E¹, Niccolai F¹, Grasso L¹, De Marco G¹, Martinelli M², Ricci AS³, Galimberti M³, Siervo B³, Licitra G⁴, Francia F⁴, Pinchera A¹

¹Department of Endocrinology, University of Pisa, Pisa, Italy, ²IPCF CNR, Pisa, Italy, ³Department of Physics, University of Pisa, Pisa, Italy, ⁴Environmental Protection Agency, Florence, Italy

P02 Genetics of Benign Thyroid Disease 1

Discussion Leader: Roberto Di Lauro (Naples, Italy)

P010

NON-GOITROUS AND NON-AUTOIMMUNE HYPERTHYROIDISM CAUSED BY A HETEROZYGOUS TSHR MUTATION

Winkler F¹, Kleinau G², Rediger A¹, Tarnow P¹, Grohmann L¹, Gaetjens P¹, Krause G², Grütters A¹, Krude H¹, Biebermann H¹

¹Charité Universitätsmedizin, Institute for Experimental Pediatric Endocrinology, Berlin, Germany, ²Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany, ³Gemeinschaftspraxis Kinderheilkunde und Jugendmedizin, Pädiatrische Endokrinologie und Diabetologie, Bremen, Germany

P011

HIGH SUSCEPTIBILITY HAPLOTYPES OF THE TSHR GENE IN GRAVES-BASEDOW DISEASE

Lucas AM¹, Colobran R², Armengol MP², Ruiz M³, Martínez-Cáceres E², Juan M³, Pujol-Borrell R²

¹Germans Trias i Pujol, Hospital. Universitat Autònoma., Endocrinology and Nutrition, Badalona, Spain, ²BST/LIRAD. Universitat Autònoma., Badalona, Spain, ³BST/LIRAD, Badalona, Spain

P012

NOVEL MCT8 GENE MUTATION FOUND IN A BOY WITH ALLAN-HERNDON-DUDLEY SYNDROME (AHDS), UNEXPECTEDLY LOW TRH-STIMULATED SERUM TSH AND SEVERE NEUROLOGICAL FEATURES

Mariotti S¹, Boccone L², Dessì V³, Meloni A², Loudianos G²

¹University of Cagliari, Dept. Medical Sciences 'M. Aresu' - Endocrinology, Monserrato - Cagliari, Italy, ²Ospedale Regionale per le Microcitemie, Cagliari, Italy, ³University of Cagliari, Dept. Biomedical Sciences and Biotechnologies, Cagliari, Italy

P013

STUDY ON THE POLYMORPHISMS OF GLUCOCORTICOID RECEPTOR (GR): IMPACT ON THE RESPONSE TO STEROID TREATMENT AND SIDE EFFECTS IN PATIENTS WITH GRAVES' ORBITOPATHY (GO)

Covelli D¹, Vannucchi G¹, Campi I¹, Cirello V¹, Muzza M¹, Dazzi D¹, Currò N², Simonetta S², Fugazzola L¹, Beck-Peccoz P¹, Salvi M¹

¹Fondazione Ospedale Maggiore IRCCS, Department of Medical Sciences, Endocrine Unit, Milan, Italy, ²Fondazione Ospedale Maggiore IRCCS, Ophthalmology, Milan, Italy

P014

THE BCL1 GLUCOCORTICOID RECEPTOR GENE POLYMORPHISM AND TREATMENT IN SEVERE GRAVES' OPHTHALMOPATHY (GO)

Alevizaki M^{1,2}, Mantzou E¹, Saltiki K^{1,2}, Terzidis K², Wiersinga W³

¹Athens University School of Medicine, Department of Endocrinology and Metabolism "Evgenidion" Hospital, Athens, Greece, ²Athens University School of Medicine, Dept Medical Therapeutics, Alexandra Hospital, Athens, Greece, ³Academic Medical Centre, Amsterdam, Dept of Endocrinology and Orbital Center, Amsterdam, Netherlands

Sunday
6 September

P015

CTLA-4 -318 POLYMORPHISMS ROLE IN GRAVES' OPTHALMOPATHY

Bufo NE¹, Santos RB², Guilhem MS¹, Silva ACN¹, Leite JL¹, Romaldini JH², Ward LS¹

¹Molecular Genetics of Cancer Laboratory, Faculty of Medical Sciences, State University of Campinas, Campinas, Brazil,

²Division of Endocrinology, School of Medicine-Catholic University of Campinas, Campinas, Brazil

P03 Genetics of Benign Thyroid Disease 2

Discussion Leader: Mikael Nilsson (Göteborg, Sweden)

P016

STUDY OF A POLYMORPHISMS IN THE PROMOTER REGION OF THE SEPS1 GENE AND RISK OF HASHIMOTO THYROIDITIS

Ribeiro dos Santos L^{1,2}, Neves C^{3,4}, Lima J¹, Canedo P¹, Soares P^{1,4}

¹IPATIMUP (Institute of Molecular Pathology and Immunology of the University of Porto), Porto, Portugal,

²Medical Faculty of Coimbra /University of Açores, Department of Biology, Ponta Delgada, Portugal,

³Service of Endocrinology, Hospital S. João, EPE, Porto, Portugal, ⁴Medical Faculty, University of Porto, Porto, Portugal

P017

CHARACTERIZATION OF A NOVEL LOSS OF FUNCTION MUTATION OF PAX8 ASSOCIATED WITH CONGENITAL HYPOTHYROIDISM

Di Palma T¹, Ferrara M², Macchia P², Ris-Stalpers C³, Zannini MS¹, de Vroede M⁴

¹Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS-CNR), Naples, Italy, ²Molecular and Clinical Endocrinology and

Oncology University of Naples Federico II, Naples, Italy, ³Laboratory of Pediatric Endocrinology, AMC, Amsterdam, Netherlands,

⁴Division of Pediatric Endocrinology, University Medical Center Utrecht, Utrecht, Netherlands

P018

POLYMORPHISM C1858T PTPN22 GENE ASSOCIATION WITH SUSCEPTIBILITY TO AUTOIMMUNE THYROID DISEASE IN NOVOSIBIRSK POPULATION

Nikitin Y¹, Ryamar O¹, Maksimov V¹, Mustafina S¹, Simonova G¹, Sherbakova L¹, Voevoda M¹

¹Institute of Internal Medicine SB RAMS, Novosibirsk, Russian Federation

P019

LACK OF GENOTYPE / PHENOTYPE CORRELATIONS FOR SOMATIC TSH-RECEPTOR MUTATIONS IN HOT THYROID NODULES

Lueblinghoff J¹, Mueller S¹, Jaeschke H¹, Eszlinger M¹, Berger H², Bircan R³, Gozu H⁴, Sancak S⁴, Paschke R¹

¹University of Leipzig, III Medical Department, Leipzig, Germany, ²University of Leipzig, IMISE, Leipzig, Germany,

³Marmara University Medical School, Department of Medical Biology, Istanbul, Turkey, ⁴Dr. Lufit Kirdal Kartal Education and Research Hospital, Section of Endocrinology and Metabolism, Istanbul, Turkey

P020

X CHROMOSOME INACTIVATION PATTERN AND INTERINDIVIDUAL VARIATIONS IN THYROID VOLUME. A STUDY OF EUTHYROID DANISH FEMALE TWINS

Hansen PS¹, Brix TH², Bennedbaek FN², Bonnema SJ², Kyvik KO¹, Hegedüs L²

¹University of Southern Denmark, The Danish Twin Registry, Odense, Denmark, ²Odense University Hospital, Endocrinology and Metabolism, Odense, Denmark

P021

EVIDENCE FOR A MORE PRONOUNCED EFFECT OF GENETIC PREDISPOSITION THAN ENVIRONMENTAL FACTORS ON GOITROGENESIS BY A CASE CONTROL STUDY

Wicht J¹, Singer J¹, Paschke R¹

¹University of Leipzig, III Medical Department, Leipzig, Germany



P04 Molecular Biology of Thyroid Cancer 1

Discussion Leader: Giancarlo Vecchio (Naples, Italy)

P022

THE CHEMOKINE CXCL10 DYSREGULATION IN PAPILLARY THYROID CANCER

Fallahi P¹, Antonelli A¹, Ferrari SM¹, Frascerra S¹, Lupi C², Minuto M³, Berti P³, Basolo F², Miccoli P³

¹University of Pisa, Department of Internal Medicine, Pisa, Italy, ²University of Pisa, Pathology Unit, Pisa, Italy,

³University of Pisa, Department of Surgery, Pisa, Italy

P023

GENE EXPRESSION PROFILING ASSOCIATED WITH THE PROGRESSION TO POORLY DIFFERENTIATED THYROID CARCINOMAS

Pita JM¹, Cavaco BM¹, Leite V^{1,2,3}

¹Instituto Português de Oncologia de Lisboa Francisco Gentil, Centro de Investigação de Patobiologia Molecular, Lisbon, Portugal,

²Instituto Português de Oncologia de Lisboa Francisco Gentil, Serviço de Endocrinologia, Lisbon, Portugal, ³Universidade Nova de Lisboa, Faculdade de Ciências Médicas, Lisbon, Portugal

P024

BRAF IN PRIMARY AND RECURRENT PAPILLARY THYROID CANCERS: RELATIONSHIP WITH THE 131-IODINE (131-I) AND 2-[¹⁸F]-FLUORO-2-DEOXI-D-GLUCOSE (18-FDG) UPTAKE CAPABILITY

Watutantrige Fernando S¹, Barollo S², Pavan N³, Pelizzo MR³, Pennelli G², Mantero F¹, Nacamulli D¹, Casara D⁴, Girelli ME¹, Mian C¹

¹University of Padua, Department of Medical and Surgical Sciences, Endocrinology Unit, Padua, Italy, ²Oncology Veneto Institute (I.O.V.-IRCCS), Padua, Italy, ³University of Padua, Department of Medical and Surgical Sciences, Special Surgery Unit, Padua, Italy,

⁴University of Padua, Department of Radiotherapy, Nuclear Medicine Unit, Padua, Italy

P025

DAP3: A CANDIDATE FACTOR FOR CONTROLLING CELL GROWTH AND MITOCHONDRIAL HOMEOSTASIS IN THYROID TUMORS

Jacques C¹, Fontaine JF², Franc B³, Mirebeau-Prunier D^{1,4}, Le Pennec S¹, Malthiery Y^{1,4}, Savagner F^{1,4}

¹INSERM, U694, Angers, France, ²Max-Delbrück-Centrum für Molekulare Medizin, Computational Biology and Data Mining Group, Berlin, Germany, ³Hôpital Ambroise Paré (APHP), Service d'Anatomie Pathologique, Boulogne, France,

⁴CHU Angers, Biochimie Génétique, Angers, France

P026

BRAF MUTATION AND FUSION ONCOGENES (RET/PTC-1, RET/PTC-3, AKAP9/BRAF AND PAX8/PPAR γ) EXPRESSION IN THYROID NODULAR DISEASE IN CHILDREN: ANALYSIS OF 119 ASPIRATES FROM BIOPSY

Niedziela M¹, Maceluch J¹

¹Poznan University of Medical Sciences, Department of Pediatric Endocrinology and Diabetology, Poznan, Poland

P027

MOLECULAR ONCOLOGY STUDY ON ADULT-ONSET PAPILLARY THYROID CANCER AMONG ATOMIC-BOMB SURVIVORS

Hamatani K¹, Takahashi K¹, Taga M¹, Ito R¹, Hayashi Y², Nakachi K¹

¹Radiation Effects Research Foundation, Radiobiology/Molecular Epidemiology, Hiroshima, Japan,

²Geriatric Health Service Faculty Hidamari, Hiroshima, Japan

Sunday
6 September

P05 Molecular Biology of Thyroid Cancer 2

Discussion Leader: Georg Brabant (Manchester, UK)

P028

H-RAS 81T→C POLYMORPHISM IN ANEUPLOIDIZATION OF THYROID TUMORS

Castro P^{1,2}, Celestino R¹, Cameselle-Teijeiro J³, Soares P^{1,2}, Sobrinho-Simões M^{1,2}

¹IPATIMUP, Porto, Portugal, ²Medical Faculty, University of Porto, Pathology, Porto, Portugal, ³University of Santiago de Compostela, Pathology, Santiago de Compostela, Spain

P029

A NEW PCR/DIGESTION METHOD FOR THE SCREENING OF V600E BRAF MUTATION IN THYROID TISSUE AND CYTOLOGICAL SAMPLES

D'Andrea B¹, Varriale G¹, Paduano M², Lucarelli E¹, Sinisi AA³

¹Dia-chem Tecnologie Biomediche-Biologia Molecolare, Napoli, Italy, ²Università Federico II, Dipartimento di Biologia e Patologia Cellulare e Molecolare 'L. Califano', Napoli, Italy, ³Seconda Università di Napoli, Clinical and Experimental Medicine and Surgery, Napoli, Italy

P030

ROUTINE BRAF MUTATION ANALYSIS IN THYROID CANCER PATIENTS ; PATIENT ACCEPTABILITY AND RELATIONSHIP OF CLINICOPATHOLOGIC FEATURES - PRELIMINARY STUDY

Bae JS¹, Chae BJ¹, Park WC¹, Jung CK², Lim DJ³, Jung SR⁴, Kim JS¹, Kim SN¹

¹The Catholic University of Korea, Surgery, Seoul, Republic of Korea, ²The Catholic University of Korea, Pathology, Seoul, Republic of Korea, ³The Catholic University of Korea, Endocrinology, Seoul, Republic of Korea, ⁴The Catholic University of Korea, Radiology, Seoul, Republic of Korea

P031

IMMUNOHISTOCHEMICAL STUDY OF THE SODIUM/IODIDE SYMPORTER EXPRESSION IN POST-CHERNOBYL UKRAINIAN BENIGN AND MALIGNANT THYROID TUMORS

Voskoboynik L¹, Romei C², Vivaldi A², Cosci B², Ciampi R², Pinchera A², Elisei R², Bogdanova T¹, Tronko M¹

¹Institute of Endocrinology and Metabolism AM, Kiev, Ukraine, ²Department of Endocrinology, University of Pisa, Pisa, Italy

P032

STATUS OF GNAQ (GUANINE NUCLEOTIDE-BINDING PROTEIN-Q) GENE IN THYROID TUMOURS

Vinagre J¹, Pópulo H^{1,2}, Seca H¹, Celestino R^{1,2,3}, Sobrinho-Simões M^{1,4,5}, Soares P^{1,4}

¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal, ²Medical Faculty, University of Porto, Porto, Portugal, ³Institute of Biomedical Sciences of University of Porto, Porto, Portugal, ⁴Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal, ⁵Hospital de São João, Porto, Portugal

P06 Thyroid Autoimmunity 1

Discussion Leader: Chantal Daumerie (Brussels, Belgium)

P033

CLINICAL VALUE OF M22 BASED ASSAYS FOR TSH-RECEPTOR ANTIBODY (TRAB) IN THE FOLLOW-UP OF ANTITHYROID DRUG TREATED GRAVES' DISEASE: COMPARISON WITH THE SECOND GENERATION HUMAN TRAB ASSAY

Massart C¹, Sapin R², d'Herbomez M³

¹Unité d'Hormonologie, INSERM 0203, Centre d'Investigation Clinique CHU, Rennes, France, ²Laboratoire d'Explorations par les Isotopes, ULP/CNRS UMR 7191, Strasbourg, France, ³Laboratoire de Médecine Nucléaire, Lille, France



P034

THE PREVALENCE OF THYROID CANCER IN PATIENTS WITH NODULAR HASHIMOTO'S THYROIDITIS

Anıl C¹, Göksel S², Başçıl Tütüncü N¹, Nar A¹, Gürsoy A¹

¹Başkent University Faculty of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey, ²Başkent University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey

P035

A ROLE FOR AUTOANTIBODIES IN ENHANCEMENT OF PRO-INFLAMMATORY CYTOKINE RESPONSES TO THYROID PEROXIDASE

Nielsen CH¹, Brix TH², Leslie RGQ³, Hegedüs L²

¹Copenhagen University Hospital Rigshospitalet, Institute for Inflammation Research, Copenhagen, Denmark, ²Odense University Hospital, Department of Endocrinology, Odense, Denmark, ³University of Southern Denmark, Institute for Medical Biology, Odense, Denmark

P036

DISTRIBUTION OF SUBPOPULATIONS AND FENOTYPES OF DENDRITIC CELLS IN PATIENTS WITH CHRONIC THYROIDITIS AND PATIENTS MONITORED BECAUSE OF DIFFERENTIATED THYROID CANCER

Dedecjus M^{1,2}, Stasiolek M¹, Brzezinski J^{1,2}, Selmaj K¹, Lewinski A^{1,2}

¹Medical University of Lodz, Chair of Endocrinology and Metabolic Diseases, Lodz, Poland, ²Polish Mother's Memorial Hospital - Research Institute, Lodz, Poland

P037

RISK FACTORS FOR THE DEVELOPMENT OF SUBCLINICAL HYPOTHYROIDISM IN PATIENTS WITH AUTOIMMUNE THYROIDITIS (AT) AND NORMAL THYROID FUNCTION AT THE DIAGNOSIS

Checchi S¹, Montanaro A¹, Ciuli C¹, Brusco L¹, Theodoropoulou A¹, Fioravanti C¹, Sestini F¹, Pasqui L¹, Pacini F¹

¹Section of Endocrinology, University of Siena, Department of Internal Medicine, Endocrinology & Metabolism and Biochemistry, Siena, Italy

P038

THYROPEROXIDASE GENE EXPRESSION IN BREAST CANCER CELLS: A CONTRIBUTE TO EXPLAIN THE RELATIONSHIP BETWEEN BREAST CANCER AND THYROID AUTOIMMUNITY

Rosellini V¹, Fiore E¹, Giustarini E¹, Muller I¹, Funel N², Campani D², Pinchera A¹, Giani C¹

¹University of Pisa, Endocrinology, Pisa, Italy, ²University of Pisa, Pathology, Pisa, Italy

P039

IMMUNOHISTOCHEMICAL DETECTION OF C CELL HYPERPLASIA AND CEA TISSUE EXPRESSION IN AUTOIMMUNE DISORDERS OF THE THYROID GLAND

Valaris K¹, Litsiou H², Kavantzaz N³, Balafouta S²

¹University of Athens Medical School, Pathology, Athens, Greece, ²University of Athens, Pathology, Athens, Greece, ³University of Athens Medical School, Attikon Hospital, Pathology, Athens, Greece

P07 Thyroid Autoimmunity 2

Discussion Leader: Stefano Mariotti (Cagliari, Italy)

P040

DOES PARATRACHEAL LYMPH NODE HAVE CLINICAL VALUE IN PATIENTS WITH AUTOIMMUNE THYROIDITIS?

Akbaba G¹, Berker D¹, Isik S¹, Aydin Y², Tutuncu Y¹, Ozuguz U¹, Guler S¹

¹Ankara Numune Research and Training Hospital, Endocrinology and Metabolism Clinic, Ankara, Turkey, ²Duzce University Faculty of Medicine, Endocrinology and Metabolism, Duzce, Turkey

Sunday
6 September

P041

INDICES OF THYROID AUTOIMMUNITY AND CORTISOL LEVELS: ASSOCIATIONS WITH AGE IN AN ELDERLY AMBULATORY POPULATION

Terzidis K¹, Panoutsopoulos A¹, Tourli P¹, Mantzou E², Papageorgiou G¹, Saltiki K^{1,2}, Mara C¹, Alevizaki M^{1,2}

¹Athens University School of Medicine, Endocrine Unit, Dept Medical Therapeutics, Alexandra Hospital, Athens, Greece, ²Athens University School of Medicine, Department of Endocrinology and Metabolism "Evgenidion" Hospital, Athens, Greece

P042

GROWTH HORMONE DEFICIENCY IN PATIENTS WITH AUTOIMMUNE HYPOTHYROIDISM, ESTABLISHED WITH GHRH/GHRP-6 TEST

Eskes SA¹, Endert E¹, Fliers E¹, Wiersinga WM¹

¹Academic Medical Center Amsterdam, Endocrinology and Metabolism, Amsterdam, Netherlands

P043

AVIDITY OF THYROGLOBULIN ANTIBODY IN SERA FROM PATIENTS WITH HASHIMOTO'S THYROIDITIS WITH DIFFERENT THYROID FUNCTIONAL STATUS

Zhang Y¹, Gao Y¹, Li M-R¹, Xie L-D¹, Lu G-Z¹, Gao Y-M¹, Guo X-H¹

¹Peking University First Hospital, Department of Endocrinology, Beijing, China

P044

EFFECT OF SELENIUM ON THYROID PEROXIDASE ANTIBODY ASSAY

Parham K¹, Lazarus J²

¹University Hospital of Wales, Medical Biochemistry, Cardiff, United Kingdom, ²Cardiff University, Centre for Endocrine and Diabetes Sciences, Cardiff, United Kingdom

P045

MEASUREMENT OF INTERLEUKIN - 12 IN SERA OF PATIENTS WITH HASHIMOTO'S THYROIDITIS

Geranova J¹, Manolova P²

¹Trakia University, Endocrinology, Stara Zagora, Bulgaria, ²University Hospital of Stara Zagora, Laboratory of Clinical Immunology, Stara Zagora, Bulgaria

P08 Thyroid Function, Obesity and Heart 1

Discussion Leader: Francesco Trimarchi (Messina, Italy)

P046

STIMULATION OF LEPTIN SECRETION AFTER RECOMBINANT HUMAN TSH ADMINISTRATION IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA

Galli G¹, Pinchera A¹, Molinaro E¹, Maffei M², Mammoli C¹, Pelosini C¹, Fierabracci P¹, Tamberi A¹, Pacini F³, Vitti P¹, Elisei R¹, Santini F¹

¹University of Pisa, Endocrinology and Kidney, Pisa, Italy, ²Dulbecco Telethon Institute, Pisa, Italy, ³University of Siena, Department of Internal Medicine, Endocrinology and Metabolism, and Biochemistry, Siena, Italy

P047

INTERACTIONS BETWEEN AGE AND CARDIOVASCULAR PARAMETERS IN PATIENTS WITH AUTOIMMUNE THYROIDITIS AND SUBCLINICAL HYPOTHYROIDISM

Strongin LG¹, Nekrasova TA¹, Ledentsova OV², Kasakova LV¹, Lukushkina AY¹

¹Nizhny Novgorod State Medical Academy, Endocrinology Department, Nizhny Novgorod, Russian Federation, ²Nizhny Novgorod Regional Diagnostic Center, Endocrinology Department, Nizhny Novgorod, Russian Federation



P048

INCREASED TSH AND DECREASED MITOCHONDRIAL FUNCTION IN OBESE ADOLESCENT COMPARED TO LEAN CONTROL PERSONS

Wilms L¹, Larsen J², Kvetny J³

¹The Mitochondrial Research Unit, Naestved, Denmark, ²Naestved Sygehus, Department of Clinical Pathology, Naestved, Denmark, ³The Mitochondrial Research Unit, Naestved Sygehus & Faculty of Health Sciences, University of Copenhagen, Internal Medicine, Naestved, Denmark

P049

IMPAIRED L-T4 ABSORPTION IN SEVERE OBESITY

Gkotsina M¹, Michalaki M¹, Markantes G¹, Faltaka A¹, Mamali E¹, Kalfarentzos F², Markou KB¹

¹Department of Internal Medicine; Division of Endocrinology; University of Patras Medical School, Patras, Greece, ²Department of Surgery; University of Patras Medical School, Patras, Greece

P050

WHETHER ROUTINE MEASUREMENT OF TSH IN ALL ADOLESCENTS WITH OBESITY IS NECESSARY?

Kiyaev AV¹, Saveliev LI^{2,3}, Pollyak OY¹, Gerasimova LY³, Tsvirenko SV^{2,3}

¹Regional Children's Hospital, Pediatric Endocrinology, Ekaterinburg, Russian Federation, ²Ural State Medical Academy, Laboratory Diagnostic, Ekaterinburg, Russian Federation, ³Regional Children's Hospital, Laboratory Diagnostic, Ekaterinburg, Russian Federation

P09 Thyroid Function, Obesity and Heart 2

Discussion Leader: Jean-Louis Wemeau (Lille, France)

P051

EFFECT OF LEVOTHYROXINE REPLACEMENT ON INTIMA-MEDIA THICKNESS, ENDOTHELIAL FUNCTION AND CARDIOVASCULAR RISK FACTORS IN SUBCLINICAL HYPOTHYROIDISM

Cabral M¹, Teixeira P¹, Salles E¹, Leite S², Montenegro C³, Soares D⁴, Jodelia H⁴, Vaisman M¹

¹Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ²Centro de Estudos e Pesquisas da Mulher, Rio de Janeiro, Brazil, ³Ultra-sonografia Botafogo, Rio de Janeiro, Brazil, ⁴Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil

P052

FREQUENCY OF HYPOTHYROIDISM IN MALES AND FEMALES WITH AND WITHOUT METABOLIC SYNDROME

Borissova A-M¹, Kovatcheva R¹, Shinkov AD¹, Atanassova I¹, Aslanova N¹, Vlahov J¹, Dakovska L¹, Vukov M²

¹University Hospital of Endocrinology, Clinic of Thyroid and Metabolic Bone Diseases, Sofia, Bulgaria, ²National Centre for Medical Information, Medical University, Sofia, Bulgaria

P053

TSH AND FREE THYROXINE IN AN OBESE POPULATION BEFORE AND AFTER SURGICAL WEIGHT LOSS

Vieira A¹, Rodrigues D¹, Ruas L¹, Oliveira P¹, Santos J¹, Martinho M², Carrilho F¹, Carvalho M¹

¹Coimbra's University Hospital, EPE, Endocrinology, Diabetes and Metabolism, Coimbra, Portugal, ²Portuguese Institute of Oncology, Endocrinology, Coimbra, Portugal

P054

THYROID FUNCTION IS INTRINSICALLY LINKED TO SERUM LIPIDS AND INSULIN RESISTANCE IN PATIENTS WITH AUTOIMMUNE THYROIDITIS

Neves C¹, Alves M¹, Pereira LM¹, Carvalho E¹, Pimentel I¹, Ramalho R², Guimarães C², Ramos JP², Carvalho D¹, Delgado L², Medina JL¹

¹Endocrinology Service, S. João Hospital, Faculty of Medicine, University of Porto, Porto, Portugal, ²Immunology Service, S. João Hospital, Faculty of Medicine, University of Porto, Porto, Portugal

Sunday
6 September

P055

THYROID HORMONES AND STROKE

Martins CS¹, Vilas Boas A¹

¹Hospital de São João, Porto, Portugal

P10 Thyroid Cancer Surgery 1

Discussion Leader: Christian Godballe (Odense, Denmark)

P056

US-GUIDED AND DYE-ASSISTED TARGETED SURGERY FOR NODAL RECURRENCES FROM THYROID CARCINOMA

Giugliano G¹, De Fiori E², Costa S¹, Gibelli B¹, Chiesa F¹

¹Istituto Europeo di Oncologia, Head and Neck Surgery, Milan, Italy, ²Istituto Europeo di Oncologia, Radiology, Milan, Italy

P057

PRELIMINARY RESULTS OF INTRAOPERATIVE PHOTODYNAMIC VISUALIZATION OF PARATHYROID GLANDS WITH PER OS USE OF 5-AMINOLEVULINIC ACID

Sleptsov I¹, Bubnov A¹, Chernikov R¹, Fedotov Y¹, Semenov A¹, Chinchuk I¹, Uspenskaya A¹, Karelina J¹, Makarin V¹

¹North-Western Regional Medical Center of Roszdrav, Endocrine Surgery, St. Petersburg, Russian Federation

P058

PROPHYLACTIC CENTRAL NECK DISSECTION FOR PAPILLARY THYROID CANCER WITH INTRAOPERATIVE PHOTODYNAMIC VISUALISATION OF PARATHYROID GLANDS

Sleptsov I¹, Bubnov A¹, Chernikov R¹, Fedotov Y¹, Karelina J¹, Chinchuk I¹, Semenov A¹, Uspenskaya A¹, Makarin V¹

¹North-Western Regional Medical Center of Roszdrav, Endocrine Surgery, St. Petersburg, Russian Federation

P059

CONTRALATERAL CENTRAL LYMPH NODE METASTASES IN PAPILLARY THYROID CARCINOMA WITH UNILATERAL LYMPH NODE METASTASIS IN THE LATERAL NECK

Koo BS¹, Lim YC²

¹Chungnam National University Hospital, Department of Otolaryngology, Head and Neck Surgery, Daejeon, Korea, Republic of,

²Konkuk University, School of Medicine, Department of Otorhinolaryngology - Head & Neck Surgery, Seoul, Republic of Korea

P060

FREQUENCY & PATTERN OF CERVICAL LYMPH NODE SKIP METASTASIS IN PAPILLARY THYROID CARCINOMA

Lim YS¹, Lee BJ¹, Lee JC¹, Sin SC¹, Wang SG¹

¹Pusan National University School of Medicine, Otorhinolaryngology-Head & Neck Surgery, Pusan, Republic of Korea

P11 Thyroid Cancer Surgery 2

Discussion Leader: Sophie Leboulleux (Paris, France)

P061

OCCULT LYMPH NODE METASTASES IN NECK LEVEL V IN PAPILLARY THYROID CARCINOMA

Lim YC¹, Koo BS²

¹Konkuk University, School of Medicine, Department of Otorhinolaryngology - Head & Neck Surgery, Seoul, Republic of Korea,

²Chungnam National University Hospital, Department of Otolaryngology, Head and Neck Surgery, Daejeon, Republic of Korea



P062

METASTASIS OF RIGHT UPPER PARA-ESOPHAGEAL LYMPH NODES IN CENTRAL COMPARTMENT LYMPH NODE DISSECTION OF PAPILLARY THYROID CANCER

Lee B-J¹, Wang S-G¹, Lee J-C¹, Lim YS¹, Lee Y-S¹, Kim Y-K², Kim I-J²

¹Pusan National University School of Medicine, Otorhinolaryngology-Head and Neck Surgery, Busan, Republic of Korea ²Pusan National University School of Medicine, Internal Medicine, Busan, Republic of Korea

P063

THYROID PAPILLARY CARCINOMA - HOW TO TREAT?

Ribas SP¹, Koch P¹, Soares V¹

¹Hospital São Marcos, Cirurgia, Braga, Portugal

P064

CENTRAL LYMPH NODE METASTASES IN UNILATERAL PAPILLARY THYROID MICROCARCINOMA

Lim YC¹, Koo BS²

¹Konkuk University, School of Medicine, Department of Otorhinolaryngology - Head & Neck Surgery, Seoul, Republic of Korea,

²Chungnam National University Hospital, Department of Otolaryngology, Head and Neck Surgery, Daejeon, Republic of Korea

P065

SURGICAL TREATMENT OF THYROID CARCINOMA USING MINIMALLY INVASIVE OPEN APPROACH AND HARMONIC SCALPEL

Nenkov RN¹, Radev RS¹

¹Medical University of Varna, Thoracic Surgery, Varna, Bulgaria

Poster Exhibition Area

see plan on page 95

13.00-14.00

Poster Discussions on Site

Poster Sessions P12 – P21

P12 Thyroid Cell and Molecular Biology 2

Discussion Leader: Jacques Dumont (Brussels, Belgium)

P066

DUOX1 AND DUOX2 ACTIVITIES ARE DIFFERENTIALLY REGULATED BY THE TWO MAIN THYROID SIGNALING PATHWAYS

Rigutto S¹, Hoste C¹, Grasberger H², Milenkovic M¹, Communi D¹, Corvilain B^{1,3}, Dumont JE¹, Miot F¹, De Deken X¹

¹Université Libre de Bruxelles, IRIBHM, Brussels, Belgium, ²University of Chicago, Department of Medicine, Chicago, United States,

³Hôpital Erasme, Université Libre de Bruxelles, Department of Endocrinology, Brussels, Belgium

P067

THYROTROPIN RECEPTOR (TSHR) ACTIVATION INCREASES HYALURONAN (HA) PRODUCTION IN PREADIPOCYTE-FIBROBLASTS; EXPLANATION FOR HA ACCUMULATION IN THYROID DYSFUNCTION?

Zhang L¹, Bowen T¹, Paddon C¹, Grennan-Jones F¹, Steadman R¹, Ludgate M¹

¹School of Medicine, Cardiff University, Cardiff, United Kingdom

Sunday
6 September

P068

IN ADDITION TO HYDROPHILIC ALSO HYDROPHOBIC RESIDUES OF THE TSHR HINGE REGION ARE INVOLVED IN RECEPTOR SIGNALING AND HORMONE BINDING

Mueller S¹, Kleinau G², Jaeschke H¹, Krause G², Paschke R¹

¹University of Leipzig, III. Medical Department, Leipzig, Germany, ²Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany

P069

COMPARATIVE FUNCTIONAL ANALYSIS OF GAIN-OF-FUNCTION TSH RECEPTOR MUTATIONS BY PROTEOMICS

Krause K¹, Ludgate M², Krohn K¹, Fuhrer D¹

¹University of Leipzig, Leipzig, Germany, ²University of Cardiff, Cardiff, United Kingdom

P070

EFFECT OF TRIIODOTHYRONINE ON ADIPONECTIN EXPRESSION AND SECRETION AND LEPTIN SECRETION FROM WHITE ADIPOSE TISSUE EXPLANTS OF EUTHYROID RATS

Cabanelas A¹, Cordeiro A¹, Almeida NAS¹, Paula GSM¹, Coelho VM², Ortiga-Carvalho TM¹, Pazos-Moura CC¹

¹Federal University of Rio de Janeiro, IBCCF, Rio de Janeiro, Brazil, ²Federal University of Rio de Janeiro, ICB, Rio de Janeiro, Brazil

P071

MOLECULAR DISSECTION OF THE INTERACTIONS BETWEEN TSH RECEPTOR AND THYROSTIMULIN, AN HORMONE WITH THYROTROPIC ACTIVITY

Zoenen M¹, Caltabiano G², Nagasaki H³, Campillo M², Pardo L², Vassart G¹, Costagliola S¹

¹IRIBHM, ULB, Brussels, Belgium, ²Facultat de Medicina, Universitat Autònoma de Barcelona, Laboratori de Medicina Computacional, Unitat de Bioestadística, Barcelona, Spain, ³Nagoya University, School of Medicine, Department of Metabolic Medicine, Nagoya City, Japan

P072

THE THYROTROPIN RECEPTOR AND MOLECULAR INTERACTION WITH DIFFERENT G-PROTEIN SUBTYPES

Kleinau G¹, Jäschke H², Worth CL¹, Müller S², Paschke R², Krause G¹

¹Leibniz-Institut für Molekulare Pharmakologie, Berlin, Germany, ²University of Leipzig, III. Medical Department, Leipzig, Germany

P073

IODIDE TRANSPORTER MODULATION IN THE PLACENTA

Burns RA¹, Smith DF¹, O'Herlihy C^{1,2}, Smyth PP¹

¹University College Dublin, Health Sciences Centre, Dublin, Ireland, ²National Maternity Hospital, UCD Department of Obstetrics & Gynaecology, Dublin, Ireland

P074

THYROID DISORDERS - ASSESSMENTS OF TRACE ELEMENTS, CLINICAL, AND LABORATORY PARAMETERS

Przybylik-Mazurek E¹, Zagrodzki P^{2,3}, Hubalewska-Dydejczyk A¹, Kuźniarz S¹

¹Jagiellonian University in Kraków, Collegium Medicum, Endocrinology, Kraków, Poland, ²Jagiellonian University in Kraków, Collegium Medicum, Department of Food Chemistry and Nutrition, Kraków, Poland, ³Henryk Niewodniczański Institute of Nuclear Physics, Kraków, Poland



P13 Genetics of Thyroid Cancer

Discussion Leader: Dillwyn Williams (Cambridge, UK)

P075

WDR3 GENE IS ASSOCIATED WITH THYROID CANCER RISK AND IT SHOWS AN ABERRANT EXPRESSION IN HUMAN THYROID CANCER CELLS

Gimenez EM¹, Akdi A¹, Pastor S¹, Castell J², Biarnés F³, Marcos R¹, Velázquez A¹

¹Universidad Autónoma de Barcelona, Genética y Microbiología, Bellaterra, Spain, ²Servicio de Medicina Nuclear, Hospital Vall d'Hebron, Barcelona, Spain, ³Unidad de Endocrinología, Hospital Josep Trueta, Girona, Spain

P076

GERMLINE SDHD VARIANTS MODULATE THE DEVELOPMENT OF MEDULLARY THYROID CARCINOMA

Lima J^{1,2}, Prazeres HJ^{1,3}, Soares R¹, Máximo V^{1,2}, Soares P^{1,2}, Rodrigues F³, Sobrinho-Simões M^{1,2,4}

¹IPATIMUP, Porto, Portugal, ²Medical Faculty, University of Porto, Porto, Portugal, ³Portuguese Institute of Oncology, Coimbra, Portugal, ⁴Department of Pathology, Hospital S. João, Porto, Portugal

P077

RET GLY⁵³³CYS INDUCES PROLIFERATION, INVASION AND GENETIC INSTABILITY IN A RAT THYROID CELL LINE

Oliveira MNL¹, Tamanaha R¹, Hemerly JP¹, Latini FRM¹, Cerutti JM¹

¹Federal University of São Paulo, Department of Morphology and Genetics, São Paulo, Brazil

P078

HETEROGENEOUS PATTERN OF COPY NUMBER VARIATIONS IN COLD THYROID NODULES DETECTED BY HIGH-DENSITY SNP ARRAYS

Eszlinger M¹, Krohn K^{1,2}, Paschke R¹

¹Universität Leipzig, Medizinische Klinik & Poliklinik III, Leipzig, Germany, ²Universität Leipzig, IZKF Leipzig, Leipzig, Germany

P079

P27(KIP1) POLYMORPHISMS IN MEDULLARY THYROID CARCINOMA: A NEW PROGNOSTIC FACTOR

Circelli L^{1,2}, Faggiano A³, Colantuoni V^{1,2}, Renzullo A⁴, Coppola VR⁴, Accardo G⁴, Colao A³, Bellastella A⁴, Pasquali D⁴

¹Università degli Studi del Sannio - Benevento, Dipartimento di Scienze Biologiche ed Ambientali, Benevento, Italy, ²CEINGE, Napoli, Italy, ³Facoltà di Medicina e Chirurgia, Università "Federico II", Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Napoli, Italy, ⁴Seconda Università di Napoli, Dip Internistica Clinica e Sperimentale, Sezione di Endocrinologia, Napoli, Italy

P080

MOLECULAR GENETIC ANALYSIS OF MEDULLARY AND PAPILLARY THYROID CARCINOMAS: UNUSUAL CASES

Vaclavikova E¹, Sykrova V¹, Dvorakova S¹, Dvorakova K², Holub V², Novak Z², Vlcek P³, Bendlova B¹

¹Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic,

²Institute of Endocrinology, Department of Clinical Endocrinology, Prague, Czech Republic,

³2nd Faculty of Medicine, Charles University and Teaching Hospital Motol, Department of Nuclear Medicine and Endocrinology, Prague, Czech Republic

P081

SNP RS2145418 A CONSERVED REGION OF 1P12 IS ASSOCIATED WITH SUSCEPTIBILITY TO THYROID DISEASES

Akdi A¹, Kallel R², Giménez EM¹, Pastor S^{1,3}, Marcos R^{1,3}, Schmid KW⁴, Hadj Kacem H², Velázquez A^{1,3}

¹Universitat Autònoma de Barcelona, Bellaterra, Spain, ²Centre de Biotechnologie de Sfax, Sfax, Tunisia,

³CIBER Epidemiología y Salud Pública, ISCIII, Spain, ⁴Institute of Pathologie, University of Essen Medical School, Essen, Germany

Sunday
6 September

P082

ASSOCIATION OF A432A *RET* POLYMORPHISM WITH *RET/PTC* IN PATIENTS WITH PAPILLARY THYROID CARCINOMA

Sykorova V¹, Vaclavikova E¹, Dvorakova S¹, Kodetova D², Kodet R², Astl J³, Vesely D³, Betka J³, Hoch J⁴, Smutny S⁴, Vlcek P⁵, Bendlova B¹

¹Institute of Endocrinology, Department of Molecular Endocrinology, Prague, Czech Republic, ²2nd Faculty of Medicine and Faculty Hospital Motol, Department of Pathology and Molecular Medicine, Prague, Czech Republic, ³1st Faculty of Medicine, Charles University, Department of Otorhinolaryngology and Head and Neck Surgery, Prague, Czech Republic, ⁴2nd Faculty of Medicine, Charles University and Teaching Hospital Motol, Department of Surgery, Prague, Czech Republic, ⁵Faculty Hospital Motol, Department of Nuclear Medicine and Endocrinology, Prague, Czech Republic

P083

PHENOTYPIC CHARACTERIZATION OF A *RET* PROTO-ONCOGENE MUTATION WITH DISTINCT DISTRIBUTION IN THE CENTRAL REGION OF PORTUGAL IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A

Martinho M¹, Martins TD¹, Azevedo T¹, Prazeres H², Martins TC², Cruz C³, Neves A³, Bugalho MJ⁴, Lemos M⁵, Carrilho F⁶, Carneiro M⁶, Campos B¹, Rodrigues F¹

¹Portuguese Institute of Oncology of Coimbra, Endocrinology, Coimbra, Portugal, ²Portuguese Institute of Oncology of Coimbra, Molecular Pathology Laboratory, Coimbra, Portugal, ³Portuguese Institute of Oncology of Coimbra, Head and Neck Surgery Department, Coimbra, Portugal, ⁴Portuguese Institute of Oncology of Lisbon, Lisbon, Portugal, ⁵Health Sciences Research Centre, Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal, ⁶Coimbra University Hospital, Coimbra, Portugal

P14 Molecular Biology of Thyroid Cancer 3

Discussion Leader: Barbara Jarzab (Gliwice, Poland)

P084

ROLE OF WNT4 IN THYROID CANCER

De Menna M^{1,2}, Mancini D², Ferraro A¹, Di Lauro R^{2,3}, De Vita G²

¹SEMM, CEINGE Biotechnologie Avanzate, Naples, Italy, ²Università di Napoli Federico II, Biologia e Patologia Cellulare e Molecolare, Naples, Italy, ³Stazione Zoologica Anton Dohrn, Naples, Italy

P085

IMMUNOHISTOCHEMICAL EXPRESSION OF CLAUDIN-1, 7 AND GALECTIN-3 IN PAPILLARY THYROID CARCINOMA: CORRELATION TO DIFFERENT HISTOLOGICAL PATTERNS AND AGGRESSIVE CLINICAL BEHAVIOUR

Colato C¹, Ambrosetti MC², Brazzarola P³, Dardano A⁴, Davì MV⁵, Francia G⁵, Giannini R⁶, Basolo F⁶, Monzani F⁴, Menestrina F¹, Chilosì M¹, Ferdeghini M²

¹University of Verona, Department of Pathology, Verona, Italy, ²University of Verona, Department of Morphological and Biomedical Sciences, Verona, Italy, ³University of Verona, Department of Anesthesiological and Surgical Sciences, Verona, Italy, ⁴University of Pisa, Department of Internal Medicine, Pisa, Italy, ⁵University of Verona, Department of Biomedical and Surgical Sciences, Verona, Italy, ⁶University of Pisa, Department of Surgery, Pisa, Italy

P086

EXPRESSION OF THE PROTEINS (POT1 AND TRF-1) OF THE SHELTERIN COMPLEX IN FAMILIAL PAPILLARY THYROID CANCER PATIENTS WITH SHORT TELOMERES

Cantara S¹, Capezzone M¹, Marchisotta S¹, Busonero G¹, Capuano S¹, Pacini F¹

¹University of Siena, Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, Siena, Italy



P087

DIFFERENTIAL EXPRESSION OF THE HGF/C-MET LIGAND/RECEPTOR SIGNALING AND THREE DOWNSTREAM MOLECULES (STAT3, PI3K, RHO) IN BENIGN AND MALIGNANT THYROID NODULES

Trovato M¹, Ruggeri RM², Vitarelli E¹, Barresi G¹, Benvenga S², Trimarchi F²

¹University of Messina, Dep of Pathology, Messina, Italy, ²University of Messina, Dep Clin-Exp of Medicine and Pharmacology, Unit of Endocrinology, Messina, Italy

P088

MUC-1 EXPRESSION DOES NOT PREDICT DIFFERENTIATED THYROID CARCINOMA PATIENTS' OUTCOME

Silva JR¹, Morari EC¹, Guillen ACT¹, Gerhard R², Soares FA³, Vassallo J⁴, Ward LS¹

¹Laboratory of Cancer Molecular Genetics, Faculty of Medical Sciences (FCM), State University of Campinas, Campinas, Brazil, ²Department of Radiology, Oncology, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil, ³Department of Pathology, Hospital AC Camargo - Antonio Prudente Foundation, Sao Paulo, Brazil, ⁴Laboratory Investigative and Molecular Pathology, CIPED, Faculty of Medical Sciences (FCM), State University of Campinas, Campinas, Brazil

P089

DETERMINANTS OF SODIUM/IODIDE SYMPORTER EXPRESSION IN FOLLICULAR THYROID CARCINOMA CELLS (FTC133)

Krohn K^{1,2}, Lorenz S^{1,2}

¹University of Leipzig, IZKF Leipzig, Leipzig, Germany, ²III. Medical Department, Research Laboratory Endocrinology, Leipzig, Germany

P15 Molecular Biology of Thyroid Cancer 4

Discussion Leader: Gilbert Vassart (Brussels, Belgium)

P090

INHIBITION OF ARGINASE II MEDIATES APOPTOSIS IN FOLLICULAR THYROID CARCINOMA CELL LINE

Sousa MSA¹, Latini FRM², Monteiro HP³, Cerutti JM²

¹Federal University of São Paulo, Medicine, São Paulo, Brazil, ²Federal University of São Paulo, Morphology, São Paulo, Brazil, ³Federal University of São Paulo, Biochemistry, São Paulo, Brazil

P091

DIFFERENTIAL EXPRESSION OF SURVIVIN IN THYROID CANCER

Pannone G¹, Bufo P¹, Santoro A¹, Zamparese R¹, Renzullo A², Coppola VR², Accardo G², Bellastella A², Pasquali D²

¹Università di Foggia, Dipartimento di Scienze Chirurgiche Sezione di Anatomia Patologica, Foggia, Italy, ²Seconda Università di Napoli, Dip Internistica Clinica e Sperimentale, Sezione di Endocrinologia, Napoli, Italy

P092

DIFFERENTIATED EXPRESSION OF VEGF AND DLL-4 IN BENIGN AND MALIGNANT THYROID TISSUES

Geers C¹, Colin IM², Gérard A-C²

¹Universitair Ziekenhuis Brussel, Pathology, Brussels, Belgium, ²Université Catholique de Louvain, Unit of Experimental Morphology, Brussels, Belgium

P093

HYPERMETHYLATION OF P16/CDKN2, RIZ1, AND FHIT IN THYROID PAPILLARY CANCER

Sun D-I¹, Kim M-S², Cho K-J³

¹The Catholic University of Korea, Otolaryngology-Head and Neck Surgery, Seoul, Republic of Korea, ²The Catholic University of Korea, Seoul, Republic of Korea, ³The Catholic University of Korea, Uijeongbu, Republic of Korea

Sunday
6 September

P094

INTEGRIN ($\alpha 6 \beta 4$) REGULATION OF ANAPLASTIC THYROID CARCINOMA PROGRESSION *IN VITRO* AND *IN VIVO*

Noh TW¹, Kim JM¹, Kim HP², Chung J², Lee EJ¹

¹Yonsei University College of Medicine, Endocrinology, Seoul, Republic of Korea, ²Louisiana State University Health Sciences Center, Biochemistry and Molecular Biology, Shreveport, United States

P095

TAZ/WWTR1 IS A NEW MARKER FOR PAPILLARY THYROID CARCINOMA

de Cristofaro T¹, Ferraro A², Corrado A³, Franco R³, Fusco A¹, Zannini S¹

¹Istituto di Endocrinologia ed Oncologia Sperimentale (IEOS-CNR), Napoli, Italy, ²NOGEC (Naples Oncogenomic Center)-CEINGE, Biotechnologie Avanzate, Napoli, Italy, ³Pathology Unit, Istituto dei Tumori 'Fondazione G. Pascale', Napoli, Italy

P096

DIPEPTIDYL PEPTIDASE IV AS MARKER IN THE SCREENING FOR DIFFERENTIATING AGENTS IN TRANSFORMED THYROCYTES

Froehlich E¹, Maier E², Wahl R¹

¹University of Tuebingen, Internal Medicine IV (Dept. of Endocrinology, Metabolism, Nephrology and Clinical Chemistry), Tuebingen, Germany, ²Institute of Anatomy, Tuebingen, Germany

P16 Graves' Disease and Graves' Orbitopathy 1

Discussion Leader: Anja Eckstein (Essen, Germany)

P097

EFFECTS OF ENALAPRIL IN ORBITAL FIBROBLASTS FROM PATIENTS WITH GRAVES' OPHTHALMOPATHY

Altea MA¹, Botta R¹, Lisi S¹, Sellari-Franceschini S², Rocchi R¹, Casini G², Nardi M², Sisti E¹, Leo M¹, Profilo MA¹, Marcocci C¹, Pinchera A¹, Marinò M¹

¹University Hospital of Pisa, Department of Endocrinology and Kidney, Pisa, Italy, ²University Hospital of Pisa, Department of Neurosciences, Pisa, Italy

P098

PATIENTS WITH GRAVES' DISEASE EXPERIENCE IMPAIRMENT IN MAJOR AREAS OF QUALITY OF LIFE, REGARDLESS OF THYROID DYSFUNCTION. A MULTIVARIATE ANALYSIS INCLUDING PATIENTS WITH NON-TOXIC GOITRE AS CONTROLS

Cramon P¹, Watt T¹, Hegedüs L², Bonnema SJ², Groenvold M³, Bjorner JB⁴, Rasmussen AK¹, Feldt-Rasmussen U¹

¹Copenhagen University Hospital Rigshospitalet, Dpt. of Medical Endocrinology, Copenhagen, Denmark, ²Odense University Hospital, Medical Endocrinology and Metabolism, Odense, Denmark, ³University of Copenhagen, Health Service Research, Copenhagen, Denmark, ⁴National Research Centre for the Working Environment, Copenhagen, Denmark

P099

HIGH DOSES INTRAVENOUS STEROIDS IN THE TREATMENT OF PATIENTS WITH GRAVES' ORBITOPATHY AND ACUTE OPTIC NEUROPATHY: OUTCOME RELATED TO STEROID DOSE AND DISEASE DURATION

Vannucchi G¹, Covelli D¹, Campi I¹, Dazzi D¹, Currò N², Simonetta S², Beck-Peccoz P¹, Salvi M¹

¹Fondazione Policlinico IRCCS Milan, Department of Medical Sciences, Endocrine Unit, Milan, Italy, ²Fondazione Policlinico IRCCS Milan, Ophthalmology, Milan, Italy

P100

SUSTAINED REMISSION OF GRAVES' HYPERTHYROIDISM DURING LONG-TERM LOW DOSE ANTI-THYROID -DRUG (ATD) THERAPY OF PATIENTS WITH SEVERE GRAVES' ORBITOPATHY (GO)

Laurberg P¹, Berman DC²

¹Aalborg Hospital, Aarhus University Hospital, Dept Endocrinology, Aalborg, Denmark, ²Aalborg Hospital, Aarhus University Hospital, Dept Ophthalmology, Aalborg, Denmark



P101

CENTRAL SEROUS CHORIORETINOPATHY AS SIDE EFFECT OF INTRAVENOUS PULSED METHYLPREDNISOLONE FOR DYSTHYROID OPTIC NEUROPATHY

Ramos HE¹, Graf H¹

¹Federal University of Paraná, SEMPR - Serviço de Endocrinologia e Metabologia, Hospital de Clínicas, Curitiba, Brazil

P102

ORBITAL MULTISPIRAL COMPUTED TOMOGRAPHY (MSCT) FOR EVALUATION OF THE ACTIVITY AND THE SEVERITY OF GRAVE'S ORBITOPATHY (GO)

Sviridenko N¹, Remizov O¹, Belovalova I¹, Tabeeva K¹, Sheremeta M¹, Likhvantseva V², Bukhman A¹

¹Endocrinological Research Centre, Russian Ministry of Health and Social Development, Clinical Endocrinology Institute, Moscow, Russian Federation, ²Central Clinical Hospital of the Russian Academy of Sciences, Ophthalmology Department, Moscow, Russian Federation

P103

THE PREVALENCE OF PULMONARY HYPERTENSION IN GRAVES' DISEASE

Suk JH¹, Cho K-I¹, Kim MK¹, Kim TI¹

¹Maryknoll Hospital, Department of Internal Medicine, Busan, Democratic People's Republic of Korea

P17 Graves' Disease and Graves' Orbitopathy 2

Discussion Leader: Janusz Nauman (Warsaw, Poland)

P104

USE OF ¹³¹I IN PATIENTS WITH GRAVES' DISEASE: EARLY CLINICAL EVALUATION

Montanelli L¹, Brozzi F¹, Filizola RG², Mazzi B¹, Bianchi F¹, Santini P¹, Lippi F¹, Vitti P¹, Pinchera A¹, Tonacchera M¹, Ceccarelli C¹

¹University of Pisa, Endocrinology and Metabolism, Pisa, Italy, ²Universidade Federal da Paraíba, João Pessoa, Departamento de Medicina Interna, Paraíba, Brazil

P105

STANDARD TREATMENT WITH A SINGLE FIXED DOSE OF 10 MCI RADIOACTIVE IODINE THERAPY IN GRAVES' DISEASE

Mota F¹, Matos C¹, Marques O¹, Pereira M¹, Pereira CG¹, Coelho L¹, Oliveira JM²

¹Hospital Sao Marcos, Endocrinologia, Braga, Portugal, ²Centro de Imagem Molecular, Braga, Portugal

P10

IATROGENIC HYPOTHYROIDISM AND EXACERBATION OF ORBITOPATHY DURING THE TREATMENT OF GRAVES' HYPERTHYROIDISM

Okamura K¹, Bandai S¹, Fujikawa M¹, Sato K¹, Iida M¹

¹Kyushu University, 2nd Dept of Internal Medicine, Faculty of Medicine, Fukuoka, Japan

P107

THE EFFECT OF EARLY THYROIDECTOMY ON THE COURSE OF GRAVES' ORBITOPATHY (GO)

Thanos M¹, Johnson KM¹, Walz MK², Mann K³, Esser J¹, Eckstein A¹

¹University of Essen, Department of Ophthalmology, Essen, Germany, ²Huyssenstift, Department of Surgery, Essen, Germany, ³University of Essen, Department of Medicine, Division of Endocrinology, Essen, Germany

P108

GRAVES DISEASE TREATMENT - RETROSPECTIVE STUDY IN 162 PATIENTS

Oliveira MJ¹, Mendes P¹, Oliveira JM², Campos Costa D², Valente V³, Santos F³, T Gomes J³, Marques AP¹

¹Hospital Pedro Hispano, Endocrinology, Matosinhos, Portugal, ²HPP MM, Nuclear Medicine, Porto, Portugal,

³Hospital Pedro Hispano, Surgery, Matosinhos, Portugal

Sunday
6 September

P109

GRAVES' DISEASE IN A DISTRICT THYROID CLINIC: OUR OWN EXPERIENCE

Matos ACC¹, Mota F¹, Pereira M¹, Marques O¹, Pereira CG¹, Coelho L¹, Oliveira JM², Frias A¹

¹Hospital of S. Marcos, Endocrinology Department, Braga, Portugal, ²CIMO-Centro de Imagem Molecular, Braga, Portugal

P110

CLINICAL EFFICIENCY OF GRAVE'S DISEASE RADIOIODINE TREATMENT

Chikh I¹, Komerdu I¹, Nechaeva O¹, Dreval A¹, Shestakova T¹

¹Moscow Regional Research Clinical Institute, Moscow, Russian Federation

P18 Thyroid and Pregnancy 1

Discussion Leader: Daniel Glinoe (Brussels, Belgium)

P111

THYROID HOMEOSTASIS AND URINE IODINE, THIOCYANATE AND PERCHLORATE IN PREGNANT WOMEN RESIDING IN ATHENS, GREECE

Alexiou M¹, Koukkou E¹, Ilias I¹, Nikopoulou S¹, Markou K², Georgopoulos N², Vagenakis A², Pearce E³, Braverman L³, He X³

¹Endocrine Department Elena Venizelou Hospital, Athens, Greece, ²University of Patras Medical School, Patras, Greece, ³Boston University School of Medicine, Boston MA, United States

P112

IODINE INTAKE IN PORTUGUESE PREGNANT WOMEN. RESULTS OF A COUNTRYWIDE STUDY

Limbert ES¹, Prazeres S², São Pedro M², Miranda A³, Ribeiro M³, Jacome de Castro J⁴, Carrilho F⁵, Reguengo H⁶, Borges F⁷

¹Portuguese Cancer Institute, Endocrinology, Lisbon, Portugal, ²Portuguese Cancer Institute, Laboratory of Endocrinology, Lisbon, Portugal, ³Portuguese Cancer Institute, Epidemiology, Lisbon, Portugal, ⁴Military Hospital, Endocrinology, Lisbon, Portugal, ⁵University Hospital, Endocrinology, Coimbra, Portugal, ⁶Hospital Santo António, Clinical Pathology, Porto, Portugal, ⁷Hospital Santo António, Endocrinology, Porto, Portugal

P113

IS THE IMPACT OF CONTROLLED OVARIAN HYPERSTIMULATION (COH) ON THYROID FUNCTION DIFFERENT IN WOMEN WITH - AND WITHOUT THE HYPERSTIMULATION SYNDROME?

Poppe KG¹, D'haeseleer M¹, Glinoe D², Tournaye H³, Schiettecatte J³, Devroey P³, Haentjens P¹, Velkeniers B¹

¹UZ Brussel VUB, Endo, Brussels, Belgium, ²Hopital Universitaire St-Pierre, ULB, Endo, Brussels, Belgium, ³UZ Brussel VUB, Reproductive Medicine, Brussels, Belgium

P114

THYROID FUNCTION IN THE THIRD TRIMESTER OF PREGNANCY AND AFTER DELIVERY IN AN IODINE-SUFFICIENT REPUBLIC OF SLOVENIA

Gaberscek S¹, Fister P², Zatelet K¹, Krhin B¹, Pirnat E¹, Gersak K³, Hojker S¹

¹University Medical Centre Ljubljana, Department of Nuclear Medicine, Ljubljana, Slovenia, ²University Medical Centre Ljubljana, University Children's Hospital, Ljubljana, Slovenia, ³University Medical Centre Ljubljana, Department of Obstetrics and Gynaecology, Ljubljana, Slovenia

P115

INCREASED LEVOTHYROXINE DOSAGE DURING PREGNANCY IN WOMEN WITH CENTRAL HYPOTHYROIDISM

Villaret L¹, Caron P², Chabre O¹

¹CHU Grenoble, Endocrinology, La Tronche, France, ²CHU Toulouse, Endocrinology, Toulouse, France



P116

SOME ASPECTS OF THYROID SCREENING IN PREGNANCY

Springer D¹, Límanová Z², Jiskra J², Zima T¹

¹Charles University, General Teaching Hospital, Department of Clinical Biochemistry and Laboratory Medicine of the First Faculty of Medicine, Prague, Czech Republic, ²Charles University, General Teaching Hospital, 3rd Medical Department - Clinical Department of Endocrinology and Metabolism, Prague, Czech Republic

P19 Thyroid and Pregnancy 2

Discussion Leader: John Lazarus (Cardiff, UK)

P117

GENERAL SCREENING FOR THYROID DYSFUNCTION IN PREGNANCY IS NECESSARY UNDER CONDITIONS OF CZECH REPUBLIC

Jiskra J¹, Springer D², Antořová M¹, Potluková E¹, Telička Z¹, Límanová Z¹

¹Charles University, General Teaching Hospital, 3rd Medical Department - Clinical Department of Endocrinology and Metabolism, Prague, Czech Republic, ²Charles University, General Teaching Hospital, Department of Clinical Biochemistry and Laboratory Medicine, Prague, Czech Republic

P118

HISTORY OF PREECLAMPSIA IS NOT ASSOCIATED WITH AN INCREASED RISK OF THYROID DYSFUNCTION

Links T¹, Dekker R², Jochemsen B³, Santema J², Roozendaal C⁴, Pampus M⁵, van Doormaal J⁶

¹University Medical Center Groningen, Endocrinology, Groningen, Netherlands, ²Medical Center Leeuwarden, Obstetrics and Gynaecology, Leeuwarden, Netherlands, ³University Medical Center Groningen, Obstetrics and Gynaecology, Groningen, Netherlands, ⁴University Medical Center Groningen, Laboratory Center, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶University Medical Center Groningen, Internal Medicine, Groningen, Netherlands

P119

ASSESSMENT OF THE THYROID HORMONE'S PROFILE DURING PREGNANCY

Kostecka-Matyja M¹, Hubalewska-Dydejczyk A¹, Buziak-Bereza M¹, Trofimiuk M¹, Gil J¹, Basta A², Kaim P²

¹Jagiellonian University Cracov, 1. Chair and Department of Endocrinology, Kraków, Poland, ²Jagiellonian University Cracov, Chair and Department of Gynecology and Obstetrics, Kraków, Poland

P120

FINE NEEDLE ASPIRATION AND PREGNANCY: WHEN SHOULD IT BE PERFORMED?

Paiva S¹, Ribeiro C¹, Ruas L¹, Sobral E², Carrilho F¹, Santos J¹, Moura P², Carvalheiro M¹

¹University Hospital, Endocrinology, Coimbra, Portugal, ²University Hospital, Obstetric, Coimbra, Portugal

P121

EVALUATION OF THYROID FUNCTION AND ANTROPOMETRIC PARAMETERS IN NEWBORNS FROM MOTHERS AFFECTED BY THYROID DISEASES

Russo L¹, Gianetti E², Ciampi M², Santini F², Gazzarrini D³, Pierini S³, Gelato G⁴, Donato T⁴, Celandroni A⁴, Vitti P¹, Pinchera A¹, Tonacchera M¹

¹University of Pisa, Endocrinology and Metabolism, Pisa, Italy, ²University of Pisa, Pisa, Italy, ³U.O. Pediatria - Ospedale F. Lotti, Pontedera, Italy, ⁴Ospedale F. Lotti, Pontedera, Italy

Sunday
6 September

P20 Surgery of Benign Goiter 1

Discussion Leader: Michael Weissel (Vienna, Austria)

P122

CAN PARATHORMONE PREDICT CALCIUM VARIATIONS AFTER TOTAL THYROIDECTOMY?

Koch P¹, Soares V¹, Ribas S¹

¹Hospital São Marcos, Cirurgia, Braga, Portugal

P123

PROSPECTIVE RANDOMIZED STUDY OF THYROID SURGERY USING THE HARMONIC SCALPEL

Tsamis D¹, Alevizos L¹, Michalopoulos NV¹, Memos N¹, Kantsos H¹, Terzis A¹, Markogiannakis H¹, Kekis PB¹, Kiriakou G², Malaktari S², Manouras A¹

¹Athens Medical School, University of Athens, Hippokrateion Hospital, Department of Endocrine Surgery, 1st Department of Propaeutic Surgery, Athens, Greece, ²Hippokrateion Hospital, Department of Endocrinology, Athens, Greece

P124

APPLICATION OF 2-OCTYLCYANOACRYLATE TISSUE ADHESIVE IN TOTAL THYROIDECTOMIES WITH A MODIFIED TECHNIQUE COMPARED TO SUBCUTICULAR SUTURING: A PROSPECTIVE RANDOMIZED STUDY

Michalopoulos NV¹, Tsamis D¹, Alevizos L¹, Kontogianni P¹, Natoudi M¹, Kleidi E¹, Linardoutsos D¹, Flessas I¹, Peitsidou K¹, Markogiannakis H¹, Manouras A¹

¹Athens Medical School, University of Athens, Hippokrateion Hospital, Department of Endocrine Surgery, 1st Department of Propaeutic Surgery, Athens, Greece

P125

MINIMALLY INVASIVE VIDEO-ASSISTED THYROIDECTOMY (MIVAT) - PRELIMINAR EXPERIENCE

Capela Costa J¹, Costa S¹, Osório F¹, Sá Couto P¹, Matos Lima L¹, Pimenta A¹

¹Hospital de São João, Cirurgia Geral - Unidade de Cirurgia Endócrina e Mama, Porto, Portugal

P126

PREOPERATIVE VITAMIN D LEVELS AND POSTOPERATIVE HYPOCALCEMIA IN TOTAL THYROIDECTOMY

Vanlerberghe L¹, Vauterin T¹, Dick C¹, Langlois M², Van den Bruel AA³

¹AZ Sint Jan Brugge, Otorhinolaryngology, Head and Neck Surgery, Brugge, Belgium, ²AZ Sint Jan Brugge, Clinical Chemistry, Brugge, Belgium, ³AZ Sint Jan Brugge, Internal Medicine/ Endocrinology, Brugge, Belgium

P21 Surgery of Benign Goiter 2

Discussion Leader: Paolo Beck-Peccoz (Milan, Italy)

P127

GRANISETRON VS TROPISERON IN THE PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING AFTER TOTAL THYROIDECTOMY

Papadima A¹, Tsamis D², Alevizos L², Michalopoulos NV², Lagoudianakis EE², Antonakis PT², Markogiannakis H², Makri I¹, Kiriakou G³, Malaktari S³, Gouliami M¹, Manouras A²

¹Hippokrateion Hospital, Department of Anesthesiology, Athens, Greece, ²Athens Medical School, University of Athens, Hippokrateion Hospital, Department of Endocrine Surgery, 1st Department of Propaeutic Surgery, Athens, Greece,

³Hippokrateion Hospital, Department of Endocrinology, Athens, Greece

P128

VIDEO ASSISTED NECK SURGERY FOR THYROID TUMORS

Nakajo A¹, Arima H¹, Nakano S², Shirao K¹, Kaneko T³, Natsugoe S¹

¹Kagoshima University, Surgical Oncology, Kagoshima, Japan, ²Nakano Clinic, Kagoshima, Japan, ³Kaneko Clinic, Kagoshima, Japan



P129

SURGICAL TREATMENT OF GRAVES' DISEASE; A THREE YEAR RETROSPECTIVE ANALYSIS

Soares CA^{1,2}, Capela J¹, Matos Lima L¹, Pimenta A^{1,2}

¹Hospital de São João, Serviço de Cirurgia Geral, Porto, Portugal, ²Faculdade de Medicina da Universidade do Porto, Porto, Portugal

P130

THYROID SURGERY AUDIT IN AN ENDOCRINE AND BREAST SURGERY UNIT

Valente F¹, Pimenta T¹, Sá Vinhas L¹, Matos-Lima L¹, Pimenta A¹

¹H. S. João, Surgery, Porto, Portugal

P131

THYROID SURGERY IN A REGIONAL HOSPITAL - IS IT WORTHWHILE?

Silva E¹, Amaral L¹, Martins P¹, Mendes J¹, Medeiros A¹, Melo AS¹

¹Hospital Divino Espírito Santo, Ponta Delgada, Portugal

Monday
7 September

Poster Exhibition Area

see plan on page 95

12.00-13.00

Lunch and Poster Discussions on site *Poster Sessions P22 – P33*

P22 Thyroid hormone metabolism and action 1

Discussion Leader: Domenico Salvatore (Naples, Italy)

P132

A NOVEL PATHWAY FOR MODULATION OF HEPATIC GLUCOSE PRODUCTION BY THYROID HORMONE INVOLVING THE HYPOTHALAMIC PARAVENTRICULAR NUCLEUS AND THE SYMPATHETIC NERVOUS SYSTEM

Klieverik LP¹, Riel AV¹, Janssen SF¹, Foppen E², Bisschop PH¹, Serlie MJ¹, Boelen A¹, Ackermans MT³, Sauerwein HP¹, Kalsbeek A^{1,2}, Fliers E¹

¹Academic Medical Center, University of Amsterdam, Department of Endocrinology and Metabolism, Amsterdam, Netherlands,

²Netherlands Institute for Neuroscience, Amsterdam, Netherlands, ³Academic Medical Center, University of Amsterdam, Department of Clinical Chemistry, Laboratory of Endocrinology, Amsterdam, Netherlands

P133

SHORT AND LONG-TERM EFFECTS OF MATERNAL NICOTINE EXPOSURE DURING LACTATION ON BODY ADIPOSITY AND THYROID FUNCTION OF RAT OFFSPRING

Passos MC¹, Oliveira E², Santos-Silva AP², Pinheiro CR², Lisboa PC², Moura EG²

¹State University of Rio de Janeiro, Nutrition, Rio de Janeiro, Brazil, ²State University of Rio de Janeiro, Physiology, Rio de Janeiro, Brazil

P134

TRIiodOTHYRONINE (T3) CHANGES SULPHATIDE METABOLISM IN RAT PANCREATIC BETA-CELLS AND MIGHT EXPLAIN THE T3-INDUCED REDUCTION IN INCIDENCE OF DIABETES MELLITUS IN BB RATS

Hartoft-Nielsen M-LC^{1,2}, Roeske-Nielsen A², Blomqvist M³, Rasmussen ÅK¹, Feldt-Rasmussen U¹, Månsson J-E³, Buschard K²

¹University Hospital of Copenhagen, Rigshospitalet, Endocrinology PE-2131, Copenhagen, Denmark,

²University Hospital of Copenhagen, Rigshospitalet, Bartholin Institutet, Copenhagen, Denmark,

³Sahlgrenska University Hospital, Institute of Clinical Neuroscience, Experimental Neuroscience Section, Göteborg, Sweden

P135

3,5-DIiodOTHYRONINE STIMULATES FATTY ACID METABOLISM IN SKELETAL MUSCLE OF HYPOTHYROID RATS

Lombardi A¹, Busiello R¹, Napolitano L¹, Moreno M², de Lange P³, Senese R³, Cioffi F³, Lanni A³, Goglia F²

¹University of Napoli, Dip. Scienze Biologiche, Napoli, Italy, ²University of Sannio, Dip. Scienze Biologiche ed Ambientali, Benevento, Italy, ³Second University of Napoli, Dip Scienze della Vita, Caserta, Italy

P136

3,5-DIiodO-L-THYRONINE PREVENTS HIGH FAT DIET-INDUCED INSULIN RESISTANCE BY REDUCING TRIGLYCERIDES ACCUMULATION

Moreno M¹, de Matteis R², Lionetti L³, Mollica M³, de Lange P⁴, Lombardi A³, Glinni D¹, Lanni A⁴, Goglia F¹

¹University of Sannio, Dip. Scienze Biologiche ed Ambientali, Benevento, Italy, ²University of Urbino, Istituto di Scienze Fisiologiche, Urbino, Italy, ³University of Napoli, Dip. Scienze Biologiche, Napoli, Italy, ⁴Second University of Napoli, Dip Scienze della Vita, Caserta, Italy



P137

AGE-DEPENDENT REGULATION OF GLUTATHIONE S-TRANSFERASE IN THYROID HORMONES-RESISTENT MICE

Faustino LC¹, Pires RM¹, Lima AC¹, Ortiga-Carvalho T¹

¹Universidade Federal do Rio de Janeiro, Instituto de Biofísica Carlos Chagas Filho, Rio de Janeiro, Brazil

P23 Thyroid hormone metabolism and action 2

Discussion Leader: Robin Peeters (Rotterdam, The Netherlands)

P138

OPTIMIZING TYPE 2 DEIODINASE ASSAYS IN MOUSE MUSCLE

Marsili A¹, Mulcahey M², Huang S², Shrivastava A¹, Harney J¹, Larsen PR¹

¹Brigham and Women's Hospital, Harvard Medical School, Endocrinology, Thyroid Section, Boston, United States,

²Children's Hospital, Endocrinology, Boston, United States

P139

TOWARDS THE IDENTIFICATION OF IODOTHYRONINE DECARBOXYLASES

Hoefig CS¹, Schlärman P¹, Piehl S¹, Bertoldi M², Scanlan TS³, Schweizer U¹, Köhrle J¹

¹Charité Universitätsmedizin, Institute for Experimental Endocrinology, Berlin, Germany, ²Università degli Studi di Verona, Dipartimento Scienze Morfologico-Biomediche, Verona, Italy, ³Oregon Health & Science University, Department of Physiology & Pharmacology, Portland, United States

P140

REGULATION OF THE THERMOGENIC FUNCTION BY THE NUCLEAR T3 RECEPTOR ISOFORMS, TR β 1 AND TR α 1, IN BROWN ADIPOCYTES

Martinez de Mena R^{1,2}, Obregon M-J^{1,2}

¹Instituto de Investigaciones Biomedicas (CSIC), Fisiopatología Endocrina y del Sistema Nervioso, Madrid, Spain,

²CIBER Fisiopatología Obesidad y Nutrición (ISCIII), Madrid, Spain

P141

T2 AND T3 EFFECTS IN INS-1E CELLS AND HUMAN ISLETS

Antonelli A¹, Santini E¹, Fallahi P¹, Ferrari SM¹, Ghiri E¹, Barsotti E¹, Marchetti P², Goglia F³, Ferrannini E¹

¹University of Pisa, Department of Internal Medicine, Pisa, Italy, ²University of Pisa, Diabetic Unit, Pisa, Italy, ³University of Sannio, Department of Physiology, Benevento, Italy

P142

EFFECT OF 3-IODOTHYRONAMINE ON MYOCARDIAL CALCIUM HOMEOSTASIS

Ghelardoni S¹, Chiellini G¹, Suffredini S², Brogioni S², Frascarelli S¹, Ronca-Testoni S¹, Cerbai E², Zucchi R¹

¹University of Pisa, Pisa, Italy, ²University of Florence, Florence, Italy

P143

LATEST INFORMATION ABOUT THE NEWLY FOUND TR β ISOFORM TR β Δ

Sun B¹, Liu Y^{1,2}, Huo L¹, Xiong W¹, Liang D¹, Zuo A¹, Guo G¹, Zhang J¹

¹Tianjin Medical University, Institute of Endocrinology/Metabolic Disease Hospital, Tianjin, China, ²Tianjin Medical University, Dental Hospital, Tianjin, China

Monday
7 September

P24 Thyroid Cancer 1

Discussion Leader: Andrzej Lewinski (Lodz, Poland)

P144

THYROGLOBULIN MEASUREMENT IN A SENSITIVE IMMUNOASSAY HAS COMPARABLE SENSITIVITY TO HYPOTHYROIDISM STIMULATED THYROGLOBULIN IN THE FOLLOW-UP OF LOW-RISK DIFFERENTIATED THYROID CANCER PATIENTS BUT NOT IN HIGH-RISK PATIENTS

Nakabashi CCD¹, Crispim F¹, Yamazaki CA¹, Camacho CP¹, Andreoni DM¹, Ikejiri ES¹, Mamone MDCOC¹, Kasamatsu TS¹, Matsumura LK¹, Furlanetto RP¹, Hidal JT¹, Biscolla RPM¹, Maciel RMB¹

¹Federal University of São Paulo, Medicine/Endocrinology, Sao Paulo, Brazil

P145

EMPIRICAL HIGH DOSE RADIOACTIVE IODINE THERAPY AND POST-TREATMENT WHOLE SCAN ARE NOT HELPFUL IN THE FOLLOW UP OF THE PATIENTS WITH ELEVATED SERUM THYROGLOBULIN AND NEGATIVE NECK ULTRASONOGRAPHY AND FDG-PET

Kim WG¹, Kim EY¹, Kim TY¹, Kim WB¹, Ryu J-S², Gong G³, Yoon JH⁴, Hong SJ⁴, Suk JH⁵, Shong YK¹

¹Asan Medical Center, University of Ulsan College of Medicine, Endocrinology & Metabolism, Seoul, Republic of Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Nuclear Medicine, Seoul, Republic of Korea, ³Asan Medical Center, University of Ulsan College of Medicine, Pathology, Seoul, Republic of Korea, ⁴Asan Medical Center, University of Ulsan College of Medicine, Surgery, Seoul, Republic of Korea, ⁵Maryknoll Hospital, Internal Medicine, Pusan, Republic of Korea

P146

RADIOSENSIBILITY IN THYROID CANCER PATIENTS

García Quispes WA¹, Pastor S^{1,2}, Castell J³, Biarnes J⁴, Velázquez A^{1,2}, Marcos R^{1,2}

¹Universitat Autònoma de Barcelona, Departament de Genètica i de Microbiologia, Bellaterra, Spain,

²CIBER Epidemiología y Salud Pública, ISCIII, Spain, ³Servei de Medicina Nuclear, Hospital Vall d'Hebron, Barcelona, Spain,

⁴Unitat de Endocrinologia, Hospital Josep Trueta, Girona, Spain

P147

PREDICTORS OF RADIOIODINE-REFRACTORY METASTATIC DISEASE IN PAPILLARY THYROID CARCINOMA

Barquiel B¹, Lecumberri B¹, Álvarez-Escolá C¹, Pallardo LF¹, Nistal M², Santisteban P³, Riesco-Eizaguirre G⁴

¹Hospital Universitario La Paz, Servicio de Endocrinología, Madrid, Spain, ²Hospital Universitario La Paz, Servicio de Anatomía Patológica, Madrid, Spain, ³Instituto de Investigaciones Biomedicas 'Alberto Sols' CSIC-UAM, Madrid, Spain, ⁴Instituto de Investigaciones Biomedicas 'Alberto Sols' CSIC-UAM; Hospital Universitario La Paz, Servicio de Endocrinología, Madrid, Spain

P148

OFF-LABEL USE OF SORAFENIB IN PATIENTS WITH METASTATIC THYROID CANCER UNRESPONSIVE TO CONVENTIONAL THERAPIES: A SPONTANEOUS STUDY

Passannanti PE¹, Bottici V¹, Molinaro E¹, Agate L¹, Biagini A¹, Viola D¹, Dal Canto L², Mazzeo S², Battaglia V², Pinchera A¹, Elisei R¹

¹University Hospital of Pisa, Department of Endocrinology and Kidney, Pisa, Italy, ²University Hospital of Pisa, Department of Oncology-Division of Diagnostic and Farmaceutic Unit, Pisa, Italy

P149

RECOMBINANT TSH BEFORE RADIOIODINE ABLATION GIVES BETTER SUCCESS RATES AS WELL AS LOWER WHOLE BODY AND BLOOD DOSE AS COMPARED TO THYROID HORMONE WITHDRAWAL

Dandekar P¹, Barbachano Y², Harrington K¹, Chittenden S³, Pratt B³, Flux G³, Nutting C¹, Newbold K¹

¹The Royal Marsden NHS Foundation Trust, Head and Neck - Thyroid Unit, London, United Kingdom,

²The Royal Marsden NHS Foundation Trust, Research and Development, London, United Kingdom,

³The Royal Marsden NHS Foundation Trust, Department of Physics, London, United Kingdom



P150

PROGNOSTIC VALUE OF SERUM THYROGLOBULIN DETERMINATIONS BEFORE RADIOIODINE ABLATION IN PATIENTS WITH DIFFERENTIATED THYROID CARCINOMA

Rodrigues FJ¹, Azevedo TC¹, Martinho MC¹, Martins TM¹, Cunha N², Cruz C³, Neves A³, Neto J⁴, Oliveira C⁴, Oliveira S⁴, Valido F², Campos B¹

¹Instituto Português de Oncologia de Coimbra, Serviço de Endocrinologia, Coimbra, Portugal, ²Instituto Português de Oncologia de Coimbra, Serviço de Patologia Clínica, Coimbra, Portugal, ³Instituto Português de Oncologia de Coimbra, Serviço de Cirurgia de Cabeça e Pescoço, Coimbra, Portugal, ⁴Instituto Português de Oncologia de Coimbra, Serviço de Medicina Nuclear, Coimbra, Portugal

P25 Thyroid Cancer 2

Discussion Leader: Christine Spitzweg (Munich, Germany)

P151

RETINOIC ACID TREATMENT FOR ADVANCED THYROID CARCINOMA- 6 YEARS OF FOLLOW-UP

Coelho SM^{1,2}, Vaisman F³, Buescu A², Corbo R^{4,5}, Carvalho DP¹, Vaisman M²

¹Universidade Federal do Rio de Janeiro, IBCCF, Rio de Janeiro, Brazil, ²Universidade Federal do Rio de Janeiro, Serviço de Endocrinologia/HUCCF, Rio de Janeiro, Brazil, ³Instituto Nacional de Cancer, Serviço de Cirurgia de Cabeça e Pescoço, Rio de Janeiro, Brazil, ⁴Universidade Federal do Rio de Janeiro, Serviço de Medicina Nuclear, HUCCF, Rio de Janeiro, Brazil, ⁵Instituto Nacional de Cancer, Rio de Janeiro, Brazil

P152

REVISITATION TO SOME ASPECTS OF LOW-IODINE DIETS (LID) FOR ¹³¹I ABLATION IN PATIENTS WITH THYROID CANCER: A) A SPOT URINARY IODINE SAMPLE IS EQUIVALENT TO A 24-HOUR URINE IODINE COLLECTION TO EVALUATE ITS ADEQUACY AND COMPLIANCE, AND B) THE USE OF L-T4 BY PATIENTS INCREASES THE IODINE POOL

Padovani RP¹, Kasamatsu TS¹, Camacho CP¹, Rio AL¹, Nakabashi CCD², Andreoni DM², Marone MMS³, Vieira JGH¹, Maciel RMB¹, Biscolla RPM¹

¹Federal University of São Paulo, Medicine/Endocrinology, Sao Paulo, Brazil, ²Federal University of São Paulo, Sao Paulo, Brazil, ³Santa Casa de Sao Paulo, Nuclear Medicine, Sao Paulo, Brazil

P153

MANAGEMENT OF PATIENTS WITH MILD HYPERCALCAITONINEMIA AND SPORADIC THYROID DISEASE

Cherenko MS¹, Sebag F², De Micco C³, Henry JF²

¹Ukrainian Scientific and Practical Center of Endocrine Surgery, Endocrinology Department, Kyiv, Ukraine, ²University Hospital La Timone, Department of Endocrine Surgery, Marseilles, France, ³University Hospital La Timone, Pathomorphology Department, Marseilles, France

P154

THE BENEFIT OF MEASURING BASAL SERUM CALCITONIN TO DETECT MEDULLARY THYROID CARCINOMA IN A DANISH POPULATION WITH A HIGH PREVALENCE OF THYROID NODULES

Hasselgren M¹, Hegedüs L¹, Godballe C², Bonnema S¹

¹Odense University Hospital, Endocrinology, Odense, Denmark, ²Odense University Hospital, Odense, Denmark

P155

SERUM CT MEASUREMENT IS THE MOST IMPORTANT DIAGNOSTIC TOOL FOR THE EARLY DIAGNOSIS AND THE CURE OF MEDULLARY THYROID CANCER

Renzini G¹, Bottici V¹, Passannanti P¹, Viola D¹, Romei C¹, Cosci B¹, Pacini F², Pinchera A¹, Elisei R¹

¹University of Pisa, Department of Endocrinology, Pisa, Italy, ²University of Siena, Departments of Internal Medicine, Endocrinology and Metabolism, and Biochemistry, Siena, Italy

Monday
7 September

P156

DIFFICULTIES IN THE PRE-SURGICAL DIAGNOSIS OF THE MEDULLARY CARCINOMA OF THE THYROID

Chiganer G¹, de Candia L¹, Quiroga S¹, Moloeznik L¹, Nebel E¹, Olguín MS¹, Brunás J¹, Novelli JL¹

¹Thyroid Centre "Dr. José Luis Novelli", Rosario, Argentina

P26 Thyroid Cancer 3

Discussion Leader: Ulla Feldt-Rasmussen (Copenhagen, Denmark)

P157

THE DIFFERENTIATED THYROID CARCINOMAS (DTC) DIAGNOSED IN THE LAST 15 YEARS SHOW DIFFERENT EPIDEMIOLOGICAL, CLINICAL AND PATHOLOGICAL FEATURES BUT THE SAME PROGNOSTIC FACTORS WHEN COMPARED WITH DTC DIAGNOSED BEFORE

Elisei R¹, Molinaro E¹, Agate L¹, Bottici V¹, Ceccarelli C¹, Lippi F¹, Grasso L¹, Masserini L², Basolo F³, Miccoli P³, Di Coscio G⁴, Vitti P⁴, Pacini F⁵, Pinchera A¹

¹University of Pisa, Department of Endocrinology, Pisa, Italy, ²University of Pisa, Department of Statistics and Applied Mathematics to Economy, Pisa, Italy, ³University of Pisa, Department of Surgery, Pisa, Italy,

⁴University of Pisa, Department of Oncology, Division of Pathology, Pisa, Italy, ⁵University of Siena, Departments of Internal Medicine, Endocrinology and Metabolism, and Biochemistry, Siena, Italy

P158

PAPILLARY THYROID CARCINOMA ASSOCIATED WITH THYROID AUTOIMMUNITY: CLINICAL AND MOLECULAR CHARACTERIZATION

Fugazzola L¹, Muzza M¹, Ravasi E², Colombo C¹, Degl'Innocenti D², Perrino M¹, Rossi S³, Cirello V¹, Borrello MG², Beck-Peccoz P¹

¹Endocrine Unit Fondazione Policlinico IRCCS, Dept. of Medical Sciences, University of Milan, Milan, Italy,

²Istituto Nazionale Tumori, Dept. of Experimental Oncology, Milan, Italy, ³Pathology Unit, Ospedale S. Paolo, Dept. of Medicine, Surgery and Dentistry, University of Milan, Milan, Italy

P159

DIFFUSE SCLEROSING VARIANT OF PAPILLARY THYROID CARCINOMA, A 30-YEAR RETROSPECTIVE STUDY AT A SINGLE INSTITUTION

Santos RJ¹, Martins A¹, Limbert E¹, Pereira C¹, Leite V¹

¹Portuguese Institute of Oncology, Endocrinology, Lisboa, Portugal

P160

RESULTS OF 10 YEARS FOLLOW UP OF MORE THAN 1500 SURGICALLY TREATED THYROID CANCER PATIENTS

Larin OS¹, Cherenko SM¹

¹Ukrainian Scientific and Practical Center for Endocrine Surgery, Kyiv, Ukraine

P161

THYROID CANCER RISK IN A COHORT IRRADIATED IN THE CHILDHOOD FOR TINEA CAPITIS TREATMENT

Boaventura P¹, Soares P^{1,2}, Sobrinho-Simoes M^{1,2}, Teixeira-Gomes J^{1,3}

¹IPATIMUP (Institute of Molecular Pathology and Immunology), Porto, Portugal, ²Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal, ³Department of Anatomy, ICBAS (Biomedical Sciences Institute Abel Salazar, University of Porto, Porto, Portugal



P162

PAPILLARY THYROID CARCINOMA AND THYROGLOSSAL DUCT CYSTS: A RETROSPECTIVE ANALYSIS

Martins AC¹, Carvalho HL², Cid O³, Ferreira TC², Santos RM¹, Bugalho MJ¹, Salgado LM², Leite V¹, Limbert E¹

¹Instituto Português de Oncologia de Lisboa Francisco Gentil, Endocrinology, Lisboa, Portugal,

²Instituto Português de Oncologia de Lisboa Francisco Gentil, Nuclear Medicine, Lisboa, Portugal,

³Instituto Português de Oncologia de Lisboa Francisco Gentil, Head and Neck Surgery, Lisboa, Portugal

P163

DIFFERENTIATED THYROID CANCER IN CHILDREN AND ADOLESCENTS: MANAGEMENT AND OUTCOME IN 70 PATIENTS

Palma Milla S¹, Gonzalez EN¹, Brocca MAM¹, Navarro IG¹, Pomares MA¹, Tous M¹, Oliva R¹, Villamil F¹

¹Hospital Universitario Virgen del Rocío, Endocrinology and Nutrition, Sevilla, Spain

P27 Thyroid Cancer 4

Discussion Leader: Patrice Rodien (Angers, France)

P164

CLINICAL AND HISTOLOGICAL FEATURES OF PTC DIAGNOSED DURING 15 YEARS (1990-2004)

Taccaliti A¹, Palmonella G¹, Silvetti F¹, Gesuita R², Scarpelli M³, Boscaro M¹

¹Division of Endocrinology University of Ancona, Department of Internal Medicine, Ancona, Italy, ²Epidemiology, Diagnostic and Informatic Center, Department of Internal Medicine, Ancona, Italy, ³Pathology Unit Institute, Ancona, Italy

P165

INCIDENTAL VERSUS NON INCIDENTAL PAPILLARY THYROID MICROCARCINOMA (PTMC) IN A SERIES OF 259 PATIENTS

Rodrigues E¹, Matos-Lima L², Sousa A³, Pimenta T⁴, Capela J⁴, Faria T⁵, Fonseca E⁶, Pereira J⁵, Pimenta A⁴, Medina JL¹

¹H. S. João, FMUP, Endocrinology, Porto, Portugal, ²H. S. João, Surgery, Porto, Portugal, ³H. S. João, Endocrinology, Porto, Portugal,

⁴H. S. João, FMUP, Surgery, Porto, Portugal, ⁵H. S. João, Nuclear Medicine, Porto, Portugal, ⁶H. S. João, FMUP, Pathology, Porto, Portugal

P166

JUVENILE DIFFERENTIATED THYROID CARCINOMA

Veloza FA¹, Bugalho MJ²

¹Hospital Garcia de Orta, Almada, Portugal, ²Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

P167

SECONDARY THYROID CARCINOMA FOLLOWING RADIOTHERAPY - THE MANCHESTER, UK EXPERIENCE

Hodgson CC¹, Yap BK¹, Menasce LP², Sikand KA²

¹The Christie NHS Foundation Trust, Clinical Oncology, Manchester, United Kingdom, ²The Christie NHS Foundation Trust, Pathology, Manchester, United Kingdom

P168

PAPILLARY THYROID MICROCARCINOMA: A STUDY OF 187 CASES

Azevedo T¹, Martinho M¹, Martins T¹, Rodrigues F¹, Campos B¹, Cruz C², Neves A², Oliveira C³, Oliveira S³, Neto J³, Figueiredo P⁴, Cunha N⁴, Valido F⁴

¹IPOFG Coimbra-EPE, Endocrinology, Coimbra, Portugal, ²IPOFG Coimbra-EPE, Surgery, Coimbra, Portugal,

³IPOFG Coimbra-EPE, Nuclear Medicine, Coimbra, Portugal, ⁴IPOFG Coimbra-EPE, Coimbra, Portugal

Monday
7 September

P169

TRENDS IN THE INCIDENCE OF DIFFERENTIATED THYROID CANCER OVER A PERIOD OF 13 YEARS IN A SINGLE INSTITUTION

Rodrigues E¹, Sousa A², Matos-Lima L³, Pimenta T⁴, Pimenta A⁴, Medina JL¹

¹H. S. João, FMUP, Endocrinology, Porto, Portugal, ²H. S. João, Endocrinology, Porto, Portugal,

³H. S. João, Surgery, Porto, Portugal, ⁴H. S. João, FMUP, Surgery, Porto, Portugal

P28 Radioiodine treatment of benign thyroid diseases 1

Discussion Leader: Steen Bonnema (Odense, Denmark)

P170

METHIMAZOLE AND POTASSIUM PERCHLORATE ARE NOT USEFUL IN TYPE 2 AMIODARONE-INDUCED THYROTOXICOSIS: A HISTORICAL PROSPECTIVE STUDY

Tomisti L¹, Urbani C¹, Lombardi M¹, Cosci C¹, Dell'Unto E¹, Martino E¹, Bogazzi F¹

¹University of Pisa, Department of Endocrinology and Metabolism, Pisa, Italy

P171

SERUM THYROXINE AND AGE - RATHER THAN THYROID VOLUME AND SERUM TSH - ARE DETERMINANTS OF THE THYROID RADIOIODINE UPTAKE IN PATIENTS WITH NODULAR NON-TOXIC GOITER SELECTED FOR RADIOIODINE THERAPY

Bonnema S¹, Fast S¹, Nielsen VE¹, Boel-Jørgensen H², Grupe P², Andersen PB², Hegedüs L¹

¹Odense University Hospital, Endocrinology, Odense, Denmark, ²Odense University Hospital, Odense, Denmark

P172

OUTCOME OF PATIENTS WITH AUTONOMOUS THYROID NODULES AFTER RADIOIODINE THERAPY: A COMPARISON BETWEEN PATIENTS WITH SUPPRESSED AND NON-SUPPRESSED EXTRANODULAR THYROID TISSUE

Correia JRL¹, Macedo R¹, Azevedo-Silva F¹, Costa G¹, Albuquerque A¹, Ribeiro C², Vieira A², Santos J², Carrilho F², Carneiro M², Pedroso de Lima J¹

¹Hospitais da Universidade de Coimbra, Serviço de Medicina Nuclear, Coimbra, Portugal, ²Hospitais da Universidade de Coimbra, Serviço de Endocrinologia, Coimbra, Portugal

P173

OPTIMIZED TREATMENT OF J -131 THERAPY IN THYROTOXICOSIS - ESTIMATED OR FIXED DOSE

Gjorgievski J¹, Petrovski Z²

¹Clinical Hospital - Bitola, Department of Endocrinology, Bitola, the Former Yugoslav Republic of Macedonia, ²Clinical Hospital - Bitola, Department of Nuclear Medicine, Bitola, the Former Yugoslav Republic of Macedonia

P174

THE BLOOD IN THYROTOXICOSIS BEFORE AND AFTER ACHIEVEMENT OF EUTHYROIDISM

Pontikides N¹, Kazepidis A², Bougoulia M¹, Krassas GE¹

¹Panagia General Hospital, Endocrinology, Diabetes and Metabolism, Thessaloniki, Greece,

²Agios Pavlos Hospital, Hematology, Thessaloniki, Greece



P29 Radioiodine treatment of benign thyroid diseases 2

Discussion Leader: Luca Persani (Milan, Italy)

P175

IMPEDANSOMETRICAL; ESTIMATION OF INTRAHEPATIC BLOOD CIRCULATION CHANGES IN PATIENTS WITH THYROTOXICOSIS

Stein K¹, Smirnova E¹, Popov A¹, Suhaya N¹, Ershova A¹, Zhukova E¹

¹Perm State Medical Academy, Perm, Russian Federation

P176

LOW TSH LEVELS AND BONE MINERAL DENSITY IN ELDERLY WOMEN AND MEN

Mascarenhas MR^{1,2,3}, Gonçalves A⁴, Carvalho MR⁴, Ferreira J¹, Dragomir M³, Cruzeiro S³, Santos Pinto D³, Bicho M¹, do Carmo P⁴

¹Lisbon's Faculty of Medicine, Metabolism and Endocrinology Centre (Genetics Lab), Lisboa, Portugal, ²Lisbon's Faculty of Medicine, Endocrinology, Lisboa, Portugal, ³Lisbon's Endocrinology, Diabetes and Metabolism Clinic, Osteoporosis Unit, Lisboa, Portugal, ⁴Santa Maria University Hospital, CHLN-EPE, Endocrinology, Diabetes and Metabolism Service, Lisboa, Portugal

P177

SEVERE ADVERSE ANTITHYROID DRUGS EFFECTS - EXPERIENCE OF GARCIA'S THE ORTA ENDOCRINOLOGY DEPARTMENT

Coelho C¹, Veloza A¹, Raimundo L¹, Passos D¹, Cordeiro MC¹, Portugal J¹

¹Hospital Garcia de Orta, Almada, Portugal

P178

EARLY OUTCOMES OF RADIOIODINE TREATMENT IN PATIENTS WITH AUTOIMMUNE AND NON-AUTOIMMUNE VARIANTS OF MULTINODULAR TOXIC GOITER

Kowalczyk A¹, Kamiński G¹

¹Military Institute of Health Services, Endocrinology and Radioisotope Therapy, Warsaw, Poland

P179

VARIATION OF THE HYPER-FUNCTIONAL THYROID MASS AFTER RADIOIODINE TREATMENT

Macedo R¹, Correia JR¹, Azevedo-Silva F¹, Costa G¹, Albuquerque A¹, Pedroso de Lima J¹

¹Hospitais da Universidade de Coimbra, Medicina Nuclear, Coimbra, Portugal

P30 Hypothyroidism 1

Discussion Leader: Junji Konishi (Fukui, Japan)

P180

HASHIMOTO'S THYROIDITIS: EPIDEMIOLOGICAL DATA AND DISEASE OUTCOME

Rentziou G¹, Athanasiadou A¹, Kyrtatzoglou E¹, Saltiki K¹, Zapanti E², Anastasiou E², Alevizaki M¹

¹Athens University School of Medicine, Endocrine Unit, Dept Medical Therapeutics, Alexandra Hospital, Athens, Greece,

²Alexandra Hospital, 1st Endocrine Section, Athens, Greece

P181

OPTIMIZATION OF THYROID HORMONE SUBSTITUTION AFTER ERADICATION OF HELICOBACTER PYLORI INFECTION

Rodrigues M¹, Knoll P¹, Mirzaei S¹

¹Wilhelminenspital, Institute of Nuclear Medicine with PET Center, Vienna, Austria

Monday
7 September

P182

THE SUCCESS RATE OF L-THYROXINE THERAPY IN ACHIEVING BIOCHEMICAL EUTHYROIDISM

Unluturk U¹, Dagdelen I¹, Kamel N¹, Gullu S¹

¹Ankara University School of Medicine, Department of Endocrinology and Metabolic Diseases, Ankara, Turkey

P183

SERUM NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN LEVELS IN MODERATE AND OVERT HYPOTHYROIDISM: PRELIMINARY RESULTS

Duntas LH¹, Loukari E¹, Papassotiriou P²

¹University of Athens Medical School, Endocrine Unit, Athens, Greece, ²Laikon Hospital, Biochemical Department, Athens, Greece

P184

ALTERATIONS OF CIRCULATING SELECTIN, INTERCELLULAR ADHESION MOLECULE-1, AND VASCULAR CELL ADHESION MOLECULE-1 IN PATIENTS WITH NON-IMMUNE THYROID DISEASE

Tretjakovs P¹, Ducena K¹, Jurka A¹, Bormane I¹, Pirags V²

¹University of Latvia, Riga, Latvia, ²Pauls Stradins Clinical University of Hospital, Riga, Latvia

P185

CLINICAL VALIDITY OF THE PATIENT-REPORTED OUTCOME THYPRO: A NEW MEASURE OF THYROID-SPECIFIC QUALITY OF LIFE IMPAIRMENT

Watt T^{1,2}, Hegedüs L³, Bonnema SJ³, Groenvold M², Bjorner JB⁴, Rasmussen AK¹, Feldt-Rasmussen U¹

¹Copenhagen University Hospital Rigshospitalet, Dpt. of Medical Endocrinology, Copenhagen, Denmark, ²University of Copenhagen, Health Service Research, Copenhagen, Denmark, ³Odense University Hospital, Medical Endocrinology and Metabolism, Odense, Denmark, ⁴National Research Centre for the Working Environment, Copenhagen, Denmark

P31 Hypothyroidism 2

Discussion Leader: Gerasimos Krassas (Thessaloniki, Greece)

P186

TIME ANALYSIS OF L-THYROXINE TREATMENT ON LIPID PARAMETERS IN PATIENTS WITH VARIOUS DEGREES OF HYPOTHYROIDISM

Kalarrytou M¹, Grammatikakis P², Pitsouni E³, Mantzou E⁴, Duntas LH⁵

¹University of Athens Medical School, Endocrine Unit, Evgenidion Hospital, Athens, Greece, ²University of Athens Medical School, Attikon Hospital, Department of Obstetrics and Gynecology, Athens, Greece, ³University of Athens, Biochemical Department, Evgenidion Hospital, Athens, Greece, ⁴University of Athens, Endocrine Unit, Evgenidion Hospital, Athens, Greece, ⁵University of Athens, Endocrine Unit, Evgenidion Hospital, Athens, Greece

P187

THYROID FUNCTION AND HOMOCYSTEINE LEVEL IN HEART ISCHEMIC DISEASE PATIENTS

Volkova A¹, Grineva E¹, Dora S¹

¹St. Petersburg State Medical University Named after I. P. Pavlov, St. Petersburg, Russian Federation

P188

ACQUIRED HYPOTHYROIDISM INDUCED BY THYROSINE KINASE INHIBITOR SUNITINIB

Barbosa AP¹, Couto J¹, Martins R¹, Santos AP¹, Savva-Bordalo J², Ferreira M², Pinto S², Torres I¹

¹Portuguese Institute of Oncology, Department of Endocrinology, Porto, Portugal, ²Portuguese Institute of Oncology, Department of Oncology, Porto, Portugal



Monday
7 September

P196

THE VALUE OF ^{18}F -FDG PET/CT, ^{111}In -OCTREOTIDE AND $^{99\text{mTc}}$ MIBI SC TO DETECT RECURRENCE AND METASTATIC FOCI IN DIFFERENTIATED THYROID CANCER (DTC) PTS WITH HIGH TG AND/OR ANTITG(ATG) AND NORMAL ^{131}I WBS

Tokmak E¹, Aras G¹, Küçük NÖ¹

¹Ankara University Faculty of Medicine, Nuclear Medicine, Ankara, Turkey

P33 Thyroid imaging 2

Discussion Leader: Enio Martino (Pisa, Italy)

P197

HISTOPATHOLOGIC AND CYTOLOGIC CORRELATION OF ULTRASOUND AND COLOR DOPPLER ULTRASOUND FINDINGS IN THYROID NODULAR DISEASE

Aslan A¹, Sancak S², Aslan M¹, Çimşit Ç¹, Ahıskalı R³, Güllüoğlu BM⁴, Akalın S², Arıbal E¹

¹Marmara University Medical School, Radiology, Istanbul, Turkey, ²Marmara University Medical School, Section of Endocrinology and Metabolism, Istanbul, Turkey, ³Marmara University Medical School, Pathology, Istanbul, Turkey, ⁴Marmara University Medical School, General Surgery, Istanbul, Turkey

P198

IMPORTANCE OF THYROID COLOR-DOPPLER ULTRASONOGRAPHY IN THE DIFFERENTIAL DIAGNOSIS OF AMIODARONE-ASSOCIATED HYPERTHYROIDISM

Anselmo JD¹, Sousa IM¹, Melo F², Teixeira R³, César RC¹

¹Hospital Divino Espírito Santo, Endocrinologia & Nutrição, Ponta Delgada, Portugal, ²Hospital Divino Espírito Santo, Serviço de Cardiologia, Ponta Delgada, Portugal, ³Hospital Divino Espírito Santo, Serviço de Radiologia, Ponta Delgada, Portugal

P199

THE ROLE OF TC-99M MIBI SCINTIGRAPHY FOR THE EVALUATION OF SOLITARY THYROID NODULES: WHICH ONES ARE BENIGN?

Caglar M¹, Kapulu C¹, Ersoz Gulcelik N², Usman A²

¹Hacettepe, Nuclear Medicine, Ankara, Turkey, ²Hacettepe, Endocrinology, Ankara, Turkey

P200

ENDOSCOPIC THYROID SURGERY FOR GRAVE'S DISEASE

Arima H¹, Nakajo A¹, Nakano S², Shirao K¹, Kaneko T³, Natsugoe S¹

¹Kagoshima University, Surgical Oncology, Kagoshima City, Japan, ²Nakano Clinic, Kagoshima City, Japan, ³Kaneko Clinic, Kagoshima City, Japan

P201

WONDERING ABOUT THE IDEAL TIME FOR THE POST-THERAPY ^{131}I WHOLE-BODY SCAN

Oliveira C¹, Neto J¹, Oliveira S¹, Barros C², Ferreira P¹, Almeida A¹, Martinho M³, Azevedo T³, Martins T³, Rodrigues F³, Cruz C⁴, Neves A⁴, Pereira H⁴

¹Portuguese Institute of Oncology of Coimbra, Nuclear Medicine, Coimbra, Portugal, ²Portuguese Institute of Oncology of Coimbra, Medical Physics, Nuclear Medicine, Coimbra, Portugal, ³Portuguese Institute of Oncology of Coimbra, Endocrinology, Coimbra, Portugal, ⁴Portuguese Institute of Oncology of Coimbra, Surgery, Coimbra, Portugal

P202

THE ROLE OF F-18FDG PET IN THYROID TUMOR

Mizoguchi T¹, Nakajo A¹, Arima H¹, Natsugoe S¹

¹Kagoshima University, Surgical Oncology, Kagoshima City, Japan



Poster Sessions **Monday**

75



Tuesday
8 September

Poster Exhibition Area

see plan on page 95

12.00-13.00

Lunch and Poster Discussions on site *Poster Sessions P34-P44*

P34 Thyroid cancer 5

Discussion Leader: Maria Alevizaki (Athens, Greece)

P203

EFFICACY OF LOW-DOSE I-131 FOR THE POSTOPERATIVE ABLATION OF LOW-RISK DIFFERENTIATED THYROID CANCER PATIENTS

Caglar M¹, Bozkurt F¹, Kapulu C¹, Ugur O¹, Bayraktar M¹

¹Hacettepe, Ankara, Turkey

P204

IMPORTANCE OF J-131 WHOLE BODY SCAN IN POST OPERATIVE FOLLOW-UP OF DIFFERENTIATED THYROID CARCINOMA

Petrovski Z¹, Trajkovska K¹

¹Clinical Hospital - Bitola, Department of Nuclear Medicine, Bitola, the Former Yugoslav Republic of Macedonia

P205

EFFICIENCY OF HIGH DOSE RAI TREATMENT IN DIFFERENTIATED THYROID CARCINOMA PATIENTS WITH POSITIVE SERUM TG AND/OR ANTI-TG LEVELS AND NEGATIVE I-131 WBS

Yağcı S¹, Laçın S¹, Küçük NÖ¹, Aras G¹

¹Ankara University Faculty of Medicine, Nuclear Medicine, Ankara, Turkey

P206

REPEATED RECOMBINANT HUMAN THYROTROPIN (RHTSH) ASSISTED RADIOIODINE TREATMENTS IN PATIENTS WITH ADVANCED THYROID CANCER

Handkiewicz-Junak D¹, Roskosz J¹, Hasse-Lazar K¹, Puch Z¹, Szpak-Ulczo S¹, Olczyk T¹, Paliczka E¹, Jarzab B¹

¹Maria Skłodowska Curie Memorial Cancer Center and Institute of Oncology, Nuclear Medicine and Endocrine Oncology Department, Gliwice, Poland

P207

THE USE OF RECOMBINANT HUMAN THYROTROPIN IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER

Lopes F¹, Alves M², Neves C², Queirós J², Tavares MR¹, Rodrigues E², Carvalho D², Medina JL²

¹Day Hospital of Endocrinology, São João Hospital, Endocrinology, Porto, Portugal, ²Day Hospital of Endocrinology, São João Hospital, Faculty of Medicine, University of Porto, Endocrinology, Porto, Portugal

P208

POSSIBILITY OF THYROID REMNANT ABLATION BY FRACTIONATED DOSING FOR THE OUTPATIENTS - THE PRESENT STATE IN JAPAN

Yoshimura M¹, Tsutsui H², Uchida K¹, Suzuki A², Kubota M², Yamada M², Hirayama K¹, Koizumi K¹, Tokue K¹, Kakizaki D¹

¹Tokyo Medical University, Radiology, Tokyo, Japan, ²Tokyo Medical University, Surgery, Tokyo, Japan



P35 Thyroid cancer 6

Discussion Leader: Bernard Corvilain (Brussels, Belgium)

P209

CLINICAL BEHAVIOR AND OUTCOME OF PAPILLARY THYROID CANCERS SMALLER THAN 1.5 CM IN DIAMETER

Marques AP¹, T Gomes J², Valente V², Oliveira MJ¹, Oliveira JM³, Santos F², Campos Costa D³, Mendes P¹

¹H. Pedro Hispano, Endocrinology, Matosinhos, Portugal, ²H. Pedro Hispano, Surgery, Matosinhos, Portugal,

³HPP MM, Nuclear Medicine, Porto, Portugal

P210

THYROID CANCER MULTIDISCIPLINARY TEAM OF HOSPITAL SÃO JOAO - AN EXPERIENCE OF 3 YEARS

Rodrigues E¹, Sousa A², Matos-Lima L³, Pimenta T⁴, Capela J⁴, Sá-Couto P³, Faria T⁵, Oliveira A⁵, Fonseca E⁶, Pereira J⁵, Pimenta A⁴, Medina JL¹

¹H. S. João, FMUP, Endocrinology, Porto, Portugal, ²H. S. João, Endocrinology, Porto, Portugal, ³H. S. João, Surgery, Porto, Portugal,

⁴H. S. João, FMUP, Surgery, Porto, Portugal, ⁵H. S. João, Nuclear Medicine, Porto, Portugal, ⁶H. S. João, FMUP, Pathology, Porto, Portugal

P211

POORLY DIFFERENTIATED AND ANAPLASTIC THYROID CARCINOMA OVER 3 YEARS IN A PORTUGUESE INSTITUTION

Sousa AM¹, Rodrigues E¹, Matos Lima L², Pimenta T², Capela J², Sá Couto P², Fonseca E³, Pimenta A², Medina JL¹

¹S. João Hospital, FMUP, Endocrinology, Oporto, Portugal, ²S. João Hospital, FMUP, Surgery, Oporto, Portugal,

³S. João Hospital, FMUP, Pathology, Oporto, Portugal

P212

THE CHARACTERISTICS AND PATTERN OF RECURRENCE FOLLOWING THYROIDECTOMY AND RADIOIODINE FOR WELL-DIFFERENTIATED THYROID CARCINOMA

Liew SC¹, Liong SY¹, Taylor B¹, Homer J², Loughran S³, Yap BK⁴

¹The Christie NHS Foundation Trust, Department of Radiology, Manchester, United Kingdom,

²Manchester Royal Infirmary, Department of Surgery, Manchester, United Kingdom, ³Manchester Royal Infirmary, Manchester,

United Kingdom, ⁴The Christie NHS Foundation Trust, Department of Clinical Oncology, Manchester, United Kingdom

P213

OCCURRENCE OF DISTANT METASTASES (DM) AS THE FIRST SIGN OF DISEASE IS A STRONG PROGNOSTIC FACTOR OF POOR OUTCOME IN PATIENTS WITH DIFFERENTIATED THYROID CANCER (DTC)

Malandrino P¹, Indrieri L², Spadaro A¹, Pellegriti G¹, Belfiore A²

¹University of Catania, Garibaldi-Nesima Hospital, Endocrinology, Department of Internal and Specialistic Medicine, Catania, Italy,

²University of Catanzaro, Endocrinology, Department of Experimental and Clinical Medicine, Catanzaro, Italy

P214

PRESENCE OF RET POLYMORPHISMS IN PATIENTS AFFECTED BY MEDULLARY THYROID CARCINOMA

Lupoli GA¹, Panico A¹, Del Prete M¹, Lupoli R¹, Afeltra A¹, Iacono D¹, Circelli L², Colantuoni V², Lupoli G¹

¹Università degli Studi "Federico II", Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Naples, Italy,

²Università degli Studi "Federico II", Dipartimento di Biochimica e Biotecnologie Mediche, Naples, Italy

Tuesday
8 September

P36 Thyroid cancer cases 1

Discussion Leader: Sevim Gullu (Ankara, Turkey)

P215

MOLECULAR ALTERATIONS IN A FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA IN STRUMA OVARI

Celestino R^{1,2,3}, Castro P¹, Triller M⁴, Soares P^{1,5}, Sobrinho-Simões M^{1,5,6}

¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal, ²Institute of Biomedical Sciences of University of Porto, Porto, Portugal, ³Medical Faculty, University of Porto, Porto, Portugal, ⁴CHU Cochin Port-Royal, Paris, France, ⁵Medical Faculty, University of Porto, Department of Pathology, Porto, Portugal, ⁶Hospital de São João, Porto, Portugal

P217

AGGRESSIVE PAPILLARY MICROCARCINOMA IN A PATIENT WITH THYROID HORMONE RESISTANCE SYNDROME

Borges F¹, Vinagre J², Castro R³, Costa AM⁴, Soares P^{2,5}

¹Hospital Geral de Santo António, CHP, Department of Endocrinology, Diabetes and Metabolism, Porto, Portugal, ²Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal, ³Hospital Geral de Santo António, CHP, Department of Nuclear Medicine, Porto, Portugal, ⁴Hospital Geral de Santo António, CHP, Department of Surgery, Porto, Portugal, ⁵Department of Pathology, Medical Faculty, University of Porto, Porto, Portugal

P217

MEDULLARY THYROID CARCINOMA AT YOUNG AGE - IMPORTANCE OF GENETIC TESTING

Santos AP¹, Martins RG¹, Couto J¹, Barbosa AP¹, Cunha D², Sanches C², Lobo C³, Amaro T³, Peixoto A⁴, Teixeira M⁴, Bastos L⁵, Torres I¹

¹Portuguese Institute of Oncology, Endocrinology, Oporto, Portugal, ²Portuguese Institute of Oncology, Surgery, Oporto, Portugal, ³Portuguese Institute of Oncology, Pathology, Oporto, Portugal, ⁴Portuguese Institute of Oncology, Genetics, Oporto, Portugal, ⁵Portuguese Institute of Oncology, Nuclear Medicine, Oporto, Portugal

P218

TG AFTER RHTSH VS TG IN THE NEEDLE WASHOUT AFTER FNA IN LYMPH NODES IN PATIENTS WITH DIFFERENTIATED THYROID CANCER

Ribeiro C¹, Paiva S¹, Martins T¹, Melo M¹, Martins MJ², Carrilho F², Carvalho M²

¹Coimbra's University Hospital, EPE, Endocrinology, Diabetes and Metabolism, Coimbra, Portugal, ²Coimbra's University Hospital, EPE, Coimbra, Portugal

P219

ANAPLASTIC TRANSFORMATION OF PAPILLARY THYROID CARCINOMA

Santos Sousa H¹, Sá Couto P¹, Guimarães M², Fonseca E², Matos Lima L¹

¹São João Hospital / Porto Medical Faculty, General Surgery Department, Unit of Endocrine and Breast Surgery, Porto, Portugal, ²São João Hospital / Porto Medical Faculty, Department of Pathology, Porto, Portugal

P220

¹⁸F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY SCANNING WITH PENTAGASTRIN-STIMULATION FOR THE IDENTIFICATION OF METASTASES OF MEDULLARY THYROID CARCINOMA

Erdoğan ME¹, Demir Ö¹, Küçük Ö², Ünlütürk U¹, Kamel N¹

¹Ankara University School of Medicine, Endocrinology and Metabolic Diseases, Ankara, Turkey, ²Ankara University School of Medicine, Nuclear Medicine, Ankara, Turkey



P221

A CASE OF THYROID MYOSARCOMA IN A 14 YEARS OLD GIRL

Allen M¹, Sapinho P², Lacerda A³, Lima MS⁴, Catarino AL⁵, Fonseca P⁵, Torrinha J¹, Limbert E⁶

¹Hospital Egas Moniz, General Surgery, Lisboa, Portugal, ²Hospital Fernando Fonseca, Endocrinology, Lisboa, Portugal, ³Instituto Português de Oncologia de Lisboa Francisco Gentil, Paediatrics, Lisboa, Portugal, ⁴Hospital Egas Moniz, Pathology, Lisboa, Portugal, ⁵Instituto Português de Oncologia de Lisboa Francisco Gentil, Pathology, Lisboa, Portugal, ⁶Instituto Português de Oncologia de Lisboa Francisco Gentil, Endocrinology, Lisboa, Portugal

P222

CINICAL AND PDS GENE ANALYSIS IN A FAMILY WITH PENDRED'S SYNDROME ASSOCIATED WITH THYROID PAPILLARY CANCER

Lacka K¹, Paradowska A², Korman E³, Lacki JK⁴

¹University of Medical Sciences, Department of Endocrinology, Poznan, Poland, ²Institute of Rheumatology, Biochemie, Poznan, Poland, ³University of Medical Sciences, Pediatrics Endocrinology, Poznan, Poland, ⁴Institute of Rheumatology, Department of Connective Tissue Disorders, Warsaw, Poland

P37 Thyroid cancer cases 2

Discussion Leader: Laura Fugazzola (Milan, Italy)

P223

ANAPLASTIC THYROID CARCINOMA ARISING IN A LYMPH NODE SEVEN YEARS AFTER TOTAL THYROIDECTOMY BECAUSE OF MODERATELY DIFFERENTIATED PAPILLARY CARCINOMA - A CASE REPORT

Besic N¹, Strazisar B¹

¹Institute of Oncology, Ljubljana, Slovenia

P224

METASTATIC BONE: FIRST PRESENTATION OF THYROID FOLLICULAR CARCINOMA (THREE CASES)

Baptista C¹, Ribeiro C¹, Santos J¹, Vieira A¹, Alves M¹, Costa G², Martins MJ³, Carrilho F¹, Carvalho M¹

¹Coimbra's University Hospital, EPE, Endocrinology, Diabetes and Metabolism, Coimbra, Portugal, ²Coimbra's University Hospital, EPE, Nuclear Medicine, Coimbra, Portugal, ³Coimbra's University Hospital, EPE, Anatomopathology, Coimbra, Portugal

P225

INTEGRATED ¹⁸F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY / COMPUTED TOMOGRAPHY THYROID INCIDENTALOMA: CASE REPORT AND LITERATURE REVIEW

Simões HF¹, Lalanda C¹, Raposo L¹, Rafael A², Saraiva M¹

¹Ocidental Lisbon Hospital Centre, Endocrinology, Lisbon, Portugal, ²Ocidental Lisbon Hospital Centre, General Surgery, Lisbon, Portugal

P226

PAPILLARY THYROID CARCINOMA METASTASIS TO THE PARAPHARYNGEAL SPACE

Perez Lopez G¹, Zurita P¹, Álvarez Santirso R¹

¹Ramon y Cajal Hospital, Endocrinology, Madrid, Spain

P227

INSULAR CARCINOMA OF THE THYROID GLAND: TWO CASES WITH UNUSUAL LONG SURVIVAL

Santos J¹, Paiva I¹, Martinho M¹, Vieira A¹, Ribeiro C¹, Martins T¹, Carrilho F¹, Carvalho M¹

¹Coimbra's University Hospital, EPE, Endocrinology, Diabetes and Metabolism, Coimbra, Portugal

Tuesday
8 September

P228

THYROID ANGIOSARCOMA

Gouveia P¹, Curado J¹, Silva C², Magalhães F³, Guerreiro E¹, Valente V¹, Santos F¹, Teixeira Gomes J¹

¹Hospital Pedro Hispano, Surgery, Matosinhos, Portugal, ²Hospital Pedro Hispano, Radiology, Matosinhos, Portugal, ³Hospital Pedro Hispano, Pathology, Matosinhos, Portugal

P229

FLOW CYTOMETRY COMBINED WITH FINE NEEDLE ASPIRATION BIOPSY IS ESSENTIAL FOR DIAGNOSIS OF A RAPIDLY GROWING THYROID GLAND

Evrano B¹, Ağbaht K², Atli T³, Yalcin B⁴, Erdoğan MF²

¹Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ²Ankara University Faculty of Medicine, Endocrinology and Metabolic Diseases Unit, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Geriatrics, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Medical Oncology, Ankara, Turkey

P38 Hyperthyroidism cases 1

Discussion Leader: Istvan Szabolcs (Budapest, Hungary)

P230

EFFICACY OF PLASMAPHERESIS IN THYROID STORM WITH PERSISTENT VENTRICULAR TACHYCARDIA

Marçal R¹, Sapinho I², Correia P³, Gil VM¹

¹Hospital Fernando Fonseca, EPE, UCIC - Serviço de Cardiologia, Amadora, Portugal, ²Hospital Fernando Fonseca, EPE, Endocrinologia (Consultora), Amadora, Portugal, ³Hospital Fernando Fonseca, EPE, Serviço de Nefrologia, Amadora, Portugal

P231

MOTHER'S TRAB'S AND BABY'S LAB'S - A CASE OF FETAL GOITER

Queirós J¹, Magalhães Â¹, Namora G², Ramalho C², Correia C³, Afonso C⁴, Montenegro N⁵, Medina JL¹

¹H. S. João, EPE, FMUP, Endocrinology, Porto, Portugal, ²H. S. João, EPE, Obstetrics and Gynecology, Porto, Portugal, ³H. S. João, EPE, Pediatrics, Porto, Portugal, ⁴H. S. João, EPE, FMUP, Pediatrics, Porto, Portugal, ⁵H. S. João, EPE, FMUP, Obstetrics and Gynecology, Porto, Portugal

P232

OCCURRENCE OF NEUTROPENIA IN A PATIENT WITH GRAVES' DISEASE AFTER MORE THAN 10-YEAR METHIMAZOLE THERAPY

Nakata Y¹, Miyoshi Y², Ohmura M³, Kou T⁴, Ozono K², Shimomura I⁵

¹Graduate School of Medicine, Osaka University, Department of Laboratory Medicine, Osaka, Japan, ²Graduate School of Medicine, Osaka University, Department of Pediatrics, Osaka, Japan, ³Ohmura ENT Clinic, Day Surgery Center, Osaka, Japan, ⁴Kou Clinic, Kyoto, Japan, ⁵Graduate School of Medicine, Osaka University, Department of Metabolic Medicine, Osaka, Japan

P233

SEVERE THYROTOXIC HYPERCALCEMIA - TWO CASE REPORTS

Ursu H¹, Musat M¹, Grigoras E¹, Voicu I¹, Giurcaneanu M², Neacsu E³

¹Institute of Endocrinology C.I. Parhon, Thyroid Unit, Bucharest, Romania, ²Institute of Endocrinology C.I. Parhon, Biochemistry, Bucharest, Romania, ³Institute of Endocrinology C.I. Parhon, Bone Markers Laboratory, Bucharest, Romania

P234

THYROTOXICOSIS FACTITIA, A FORM OF MUNCHAUSEN SYNDROME: AN UNUSUAL AND DIDACTIC CASE

Krassas G¹, Zeleva T¹, Spatsis S¹, Bougoulia M¹, Pontikides N¹, Markou K², Efthimiou I¹

¹Panagia General Hospital, Endocrinology, Diabetes and Metabolism, Thessaloniki, Greece, ²Rio Hospital, University of Patras, Endocrinology, Department of Internal Medicine, Patras, Greece



P235

PERSISTENT CHRONIC RETRO-OCULAR PAIN IN GRAVES' ORBITOPATHY (GO): A CASE REPORT

Daumerie C¹, Boschi A², Maiter D¹, Duprez T³

¹Université Catholique de Louvain, Endocrinology, Brussels, Belgium, ²Université Catholique de Louvain, Ophthalmology, Brussels, Belgium, ³Université Catholique de Louvain, Radiology, Brussels, Belgium

P39 Hyperthyroidism cases 2

Discussion Leader: Matthias Schott (Düsseldorf, Germany)

P236

APLASIA CUTIS ASSOCIATED WITH PROPYLTHIOURACIL TREATMENT FOR GRAVES' DISEASE

Hyer SL¹, Tran A¹, Shehata H²

¹Epsom & St Helier University Hospitals NHS Trust, Endocrinology, Carshalton, United Kingdom, ²Epsom & St Helier University Hospitals NHS Trust, Maternal Medicine, Carshalton, United Kingdom

P237

THYREOTOXICOSIS AND CONCOMITANT TAKO-TSUBO CARDIOMYOPATHY IN A PATIENT WITH CHRONIC HEPATITIS C: AN UNUSUAL CLINICAL ASSOCIATION

Martin CS¹, Fica S^{1,2}, Dimulescu D^{2,3}, Ionescu L³, Diculescu M^{2,4}, Lacau S⁵, Rotaru R⁶, Deleanu D⁷

¹Elias Emergency Hospital, Endocrinology, Bucharest, Romania, ²Carol Davila University of Medicine and Pharmacology, Bucharest, Romania, ³Elias Emergency Hospital, Cardiology, Bucharest, Romania, ⁴Elias Emergency Hospital, Gastroenterology, Bucharest, Romania, ⁵Elias Emergency Hospital, Radiology, Bucharest, Romania, ⁶Elias Emergency Hospital, Laboratory, Bucharest, Romania, ⁷CC Iliescu Institute of Cardiovascular Diseases, Bucharest, Romania

P238

SEVERE FLACCID QUADRIPLEGIA FOLLOWING THYROTOXIC CRISIS COMPLICATED BY GASTROINTESTINAL BLEEDING AND MULTIPLE ORGAN FAILURE

Mizokami T¹, Fukui T¹, Imoto H¹, Fujii H¹, Sato Y¹, Sumi A¹, Okamura K², Nunoi K¹

¹St. Mary's Hospital, Division of Endocrinology and Metabolism (Diabetes), Kurume, Japan, ²Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan

P239

THYROID HORMONE RESISTANCE AND PITUITARY TUMOUR: COINCIDENCE OR CONSEQUENCE?

Alves M¹, Bastos M¹, Santos J¹, Martinho M², Vieira A¹, Bugalho MJ³, Carrilho F¹, Carneiro M¹

¹Hospitais da Universidade de Coimbra, Endocrinologia, Diabetes e Metabolismo, Coimbra, Portugal, ²Instituto Português de Oncologia de Coimbra, Endocrinologia, Coimbra, Portugal, ³Instituto Português de Oncologia de Lisboa Francisco Gentil, Endocrinologia, Lisboa, Portugal

P240

REMISSION OF PERSISTENT INFLAMMATORY SYNDROME IN A PATIENT WITH GRAVES' DISEASE AND PAPILLARY CARCINOMA AFTER ANTITHYROID DRUG TREATMENT

Trifanescu RA^{1,2}, Ioachim D³, Stancu B^{1,4}, Corneci CM⁴, Coculescu M^{1,2}

¹Carol Davila' University of Medicine and Pharmacy, Endocrinology, Bucharest, Romania, ²C. I. Parhon' Institute of Endocrinology, Bucharest, Romania, ³C. I. Parhon' Institute of Endocrinology, Histology, Bucharest, Romania, ⁴C. I. Parhon' Institute of Endocrinology, Endocrine Surgery, Bucharest, Romania

P241

CHOLESTATIC JAUNDICE IN HYPERTHYROID PATIENT TREATED WITH METHIMAZOL

Ristic P¹, Kuzmic-Jankovic S¹, Brcrevic P², Andjelkovic Z¹, Hajdukovic Z¹, Karajovic J¹, Djuran Z¹, Kikovic S¹, Dragovic T¹, Cizmic M¹, Tavcar I¹

¹MMA, Endocrinology, Beograd, Serbia, ²MMA, Gastroenterology, Beograd, Serbia

Tuesday
8 September

P242

TSH SECRETING PITUITARY ADENOMA IN AN 24-YEAR-OLD-MAN

Mihajlovska S¹, Sekulovska M¹, Veljanovska J¹, Mihajlovska M¹

¹Clinical Hospital Bitola, Department of Nuclear Medicine, Bitola, the Former Yugoslav Republic of Macedonia

P40 Hypothyroidism and goiter cases 1

Discussion Leader: Claudio Marcocci (Pisa, Italy)

P243

CONGENITAL HYPOTHYROIDISM DUE TO A HOMOZYGOUS MUTATION IN THE THYROTROPIN β -SUBUNIT GENE MIMICKING ANTERIOR PITUITARY HORMONE DEFICIENCY

Ramos HE¹, Labedan P², Tron E¹, Carré A¹, Castanet M¹, Delacourt C², Polak M¹

¹University Paris-Descartes, INSERM U845, and Pediatric Endocrine Unit Hôpital Necker Enfants-Malades, Paris, France,

²Centre Hospitalier de Creteil, Service de Pédiatrie, Creteil, France

P244

FAILURE OF RENAL ALLOGRAFT ASSOCIATED WITH LEVOTHYROXINE WITHDRAWAL BEFORE RADIOIODINE EXPOSURE - A CASE REPORT

Alves M¹, Neves C¹, Rodrigues P¹, Castedo JL¹, Ferreira P², Bustorff M², Rodrigues E¹, Carvalho D¹, Medina JL¹

¹São João Hospital, Faculty of Medicine, University of Porto, Endocrinology, Porto, Portugal, ²São João Hospital, Nephrology, Renal Transplant Unit, Porto, Portugal

P245

HYPOTHYROIDISM PRESENTING WITH XANTHODERMA

Ghosh S¹, Collier A¹, Malik I¹, Davidson F², McClure J³, Williamson S³

¹The Ayr Hospital, Diabetes Day Centre, Ayr, United Kingdom, ²NHS Ayrshire & Arran, Department of Clinical Biochemistry, Ayrshire, United Kingdom, ³NHS Ayrshire & Arran, Department of Paediatrics, Ayrshire, United Kingdom

P246

OPHTHALMOPARESIA: A CLINICAL FEATURE OF HASHIMOTO'S THYROIDITIS?

Palavra FM¹, Marado DA², Gens H¹, Oliveira F¹, Freire S³

¹Centro Hospitalar de Coimbra, Neurology, Coimbra, Portugal, ²Centro Hospitalar de Coimbra, Medicine, Coimbra, Portugal,

³Centro Hospitalar de Coimbra, Ophthalmology, Coimbra, Portugal

P247

MYXEDEMA IN HANDS AND PRETIBIAL REGION OF PATIENTS WITH HYPOTHYROIDISM TREATED WITH AMIODARONE

Cavalcante T¹, Mezarila P¹, Knobel M¹, Lima N¹

¹University Sao Paulo-FMUSP, Endocrinology-thyroid Unit, Sao Paulo, Brazil

P248

SUBACUTE THYROIDITIS AND ETANERCEPT

Laboureaux-Soares S¹, Illouz F¹, Masson C², Rohmer V^{1,3}, Rodien P^{1,3}

¹University Hospital, Endocrinology, Angers, France, ²University Hospital, Rheumatology, Angers, France,

³University d'Angers, Angers, France



P249

PLUNGING GOITER WITH INTRATHYROIDAL PRIMARY HYPERPARATHYROIDISM

Leichsenring C¹, Sapinho P², Torrinha F³, Santos S⁴, Pinheiro N¹

¹Fernando Fonseca Hospital, Surgery C, Amadora, Portugal, ²Fernando Fonseca Hospital, Endocrinology, Amadora, Portugal, ³IMI, Lisboa, Portugal, ⁴Fernando Fonseca Hospital, Pathology, Amadora, Portugal

P41 Hypothyroidism and goiter cases 2

Discussion Leader: Nils Knudsen (Smorum, Denmark)

P250

A RARE CASE OF HYPOTHYROIDISM REFRACTORY TO HORMONE REPLACEMENT THERAPY

Lopes-Pereira MR¹, Matos AC¹, Mota F¹

¹Hospital São Marcos, Endocrinology Department, Braga, Portugal

P251

HYPOTHYROIDISM: A PITFALL IN THE MANAGEMENT OF EXTRAPYRAMIDAL DISORDERS

Marado DA¹, Palavra FM², Santos AL¹, Ribeiro PM¹

¹Centro Hospitalar de Coimbra, Medicine, Coimbra, Portugal, ²Centro Hospitalar de Coimbra, Neurology, Coimbra, Portugal

P252

A CASE OF RESISTANCE TO THYROID HORMONE (RTH)

Gonçalves A¹, Aragões JM¹, Batista F¹, Mascarenhas MR¹, Carvalho MR¹, do Carmo I¹

¹Santa Maria University Hospital, CHLN-EPE, Endocrinology, Diabetes and Metabolism Service, Lisbon, Portugal

P253

CONGENITAL HYPOTHYROIDISM WITH THYROID ECTOPY - CASE REPORT

Carvalho S¹, Paiva S², Ribeiro C², Martinho M², Carrilho F², Carvalheiro M²

¹Hospital de Vila Real, EPE, Internal Medicine Department, Vila Real, Portugal, ²Coimbra's University Hospital, EPE, Endocrinology, Diabetes and Metabolism Department, Coimbra, Portugal

P254

HYPERCAPNIC COMA: A LIFE-THREATENING PRESENTATION OF SUBSTERNAL GOITER

Amaral L¹, Silva E¹, Martins P¹, Mendes J¹, Quintanilha R¹, Medeiros A¹, Melo AS¹

¹Hospital Divino Espírito Santo, Ponta Delgada, Portugal

P255

THYROID DYSFUNCTION IN HEPATITIS C INDIVIDUALS: A CLINICAL CASE

Bagina RJ¹

¹HDJMG/ULNSA, EPE, Medicina Interna, Portalegre, Portugal

P256

LACK OF INCREASE OF SERUM TSH LEVELS AFTER RHTSH IN A MORBID OBESE WOMAN

Pitoia F¹, Fernandez Valoni V¹, Ase E¹, Abelleira E¹, Salvai ME¹, Haseitel M¹, Niepomnische H¹

¹Hospital de Clinicas - University of Buenos Aires, Buenos Aires, Argentina

Tuesday
8 September

P42 Iodine deficiency and goiter 1

Discussion Leader: Roland Gärtner (Munich, Germany)

P257

IODINE INTAKE AND PROXIMITY TO THE SEA

Smyth PP¹, Burns RA¹, Smith DF¹, O'Herlihy C^{1,2}

¹University College Dublin, Department of Medical and Medical Sciences, Dublin, Ireland, ²National Maternity Hospital, UCD Department of Obstetrics & Gynaecology, Dublin, Ireland

P258

DETRIMENTAL EFFECTS OF IODINE DEFICIENCY ON THE THYROID IN OLD AGE. A 10-YEAR FOLLOW-UP

Andersen S¹, Pedersen KM¹, Laurberg P¹

¹Århus University, Endocrinology, Aalborg Hospital, Aalborg, Denmark

P259

CORRECTION OF IODINE DEFICIENCY BY IODINE FORTIFIED SUNFLOWER OIL

De Benoist B¹, Simescu M², Podia-Igna CC³, Sava M⁴, Delange F⁵

¹WHO Consultant, Geneva, Switzerland, ²Institute of Endocrinology Bucharest, Thyroid, Bucharest, Romania, ³Astra Clinic, Sibiu, Romania, ⁴Institute of Endocrinology, Bucharest, Romania, ⁵University Hospital Saint Pierre, Brussels, Belgium

P260

IODINE DEFICIENCY STATUS IN GUINEA-BISSAU - A SENTINEL SURVEILLANCE STUDY IN BOLAMA

Carvalho AC¹, Savva-Bordalo J², Bordalo AA³

¹Sto. Antonio Hospital, Endocrinology, Porto, Portugal, ²Portuguese Oncology Institute of Porto, Oncology, Porto, Portugal, ³Institute of Biomedical Sciences - University of Porto, Laboratory of Hydrobiology, Porto, Portugal

P261

A NEW QUANTITATIVE METHOD FOR MEASURING URINARY IODINE

São-Pedro M¹, Prazeres S¹, Pereira T¹, Font P¹, Madureira D¹

¹Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal

P262

ENDEMIC GOITER ESTIMATION AND ROLES OF IRON DEFICIENCY AS THE GOITER FACTOR IN WEST-SIBERIAN REGION RUSSIA

Turovinina E¹, Suplotova L¹, Sharuh G¹

¹The Tyumen State Medical Academy, Tyumen, Russian Federation

P263

SERUM ZINC LEVELS AND THYROID VOLUME AND THYROID TESTS IN TURKISH POPULATION AFTER SUCCESSFUL IODINIZATION

Ertek S¹, Cicero AF², Caglar O³, Erdogan G¹

¹Ufuk University Medical Faculty, Department of Endocrinology and Metabolic Diseases, Ankara, Turkey, ²Bologna University, Atherosclerosis and Metabolic Diseases Research Center, Internal Medicine, Aging & Kidney Diseases Department, Bologna, Italy, ³Ufuk University Medical Faculty, Department of Radiology, Ankara, Turkey



P43 Iodine deficiency and goiter 2

Discussion Leader: Peter Smyth (Dublin, Ireland)

P264

PREDICTION OF HIGH URINARY IODINE EXCRETION BY URINARY IODINE EXCRETION FIVE YEARS AGO

Nautsch A¹, Ittermann T¹, Schmidt CO¹, Kramer A¹, Below H¹, Remer T², Gärtner R³, Wallaschofski H¹, Völzke H¹

¹University of Greifswald, Greifswald, Germany, ²Research Institute of Child Nutrition, Dortmund, Germany,

³University of Munich, Munich, Germany

P265

THYROID DISEASES IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM

Kalinin A¹, Kotova I¹, Britvin T¹, Proshin E¹

¹M. F. Vladimirsky Moscow Regional Clinical and Research Institute, Endocrine Surgery, Moscow, Russian Federation

P266

FEATURES OF TEN PATIENTS WITH THYROID HEMIAGENESIS

Ozuguz U¹, Berker D¹, Tutuncu Y¹, Isik S¹, Aydin Y², Akbaba G¹, Guler S¹

¹Ankara Numune Research and Training Hospital, Endocrinology and Metabolism Clinic, Ankara, Turkey,

²Duzce University Faculty of Medicine, Endocrinology and Metabolism, Duzce, Turkey

P267

THYROID NODULES MANAGEMENT IN AMBULATORY SURGERY: RETROSPECTIVE ANALYSIS OF 122 CONSECUTIVE CASES

Duarte L¹, Oliveira P², Lopes A-F¹, Silva-Nunes J¹, Malheiro F¹, Matos L¹, Tavares P²

¹Hospital de Curry Cabral, Endocrinology, Diabetes and Metabolism Department, Lisboa, Portugal,

²Hospital de Curry Cabral, Surgery Department, Lisboa, Portugal

P268

NODULAR GOITER AND THYROID CANCER

Kochergina II¹, Leonova SV¹, Doskina EV¹, Ametov AS¹

¹Russian Medical Academy for Advanced Medical Studies Ministry of Health Russia, Endocrinology and Diabetology, Moscow, Russian Federation

P269

ONCOMORBIDITY IN THE TREATMENT OF THE NODULAR GOITER

Kochergina I¹, Leonova SV¹, Doskina EV¹

¹Russian Medical Academy for Advanced Ministry of Health, Moscow, Russian Federation

Tuesday
8 September

P44 Fine-needle aspiration biopsy

Discussion Leader: Hans Graf (Curitiba, Brazil)

P270

COEXISTENT THYROID PATHOLOGY MAY IMPAIR PARATHYROID LOCALIZATION IN PRIMARY HYPERPARATHYROIDISM: USEFULNESS OF PTH ASSAY IN FNAB FLUID WASH-OUT

Boi F¹, Lombardo C¹, Cocco MC¹, Maurelli I¹, Piga M², Lai ML³, Nicolosi A⁴, Mariotti S¹

¹University of Cagliari, Dep. Medical Sciences 'M. Aresu' - Endocrinology, Monserrato - Cagliari, Italy, ²University of Cagliari, Dep. Medical Sciences 'M. Aresu' - Nuclear Medicine, Monserrato - Cagliari, Italy, ³University of Cagliari, Dept. of Cytomorphology, Cagliari, Italy, ⁴University of Cagliari, Dept. of Surgery, Cagliari, Italy

P271

FINE NEEDLE ASPIRATION REBIOPSY AND ULTRASOUND CHARACTERISTICS OF THYROID NODULES

Gasparyan EG¹, Goroshko OA¹, Vorobyov SL¹

¹Medical Centre "Professor", Medical Academy of Postgraduate Studies, St. Petersburg, Russian Federation

P272

COMPARISON OF THE ANALGESIC EFFICACY OF LIDOCAINE/PRILOCAINE (EMLA) CREAM AND NEEDLE-FREE DELIVERY OF LIDOCAINE DURING THE FINE-NEEDLE ASPIRATION BIOPSY OF THYROID NODULES

Gürsoy A¹, Anıl C¹, Başçıl Tütüncü N¹, Nar A¹, Aytürk S¹

¹Başkent University Faculty of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey

P273

CONTRIBUTION OF ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION CYTOLOGY TO DIAGNOSIS AND MANAGEMENT OF THYROID NODULES. RETROSPECTIVE ANALYSIS OF 617 CONSECUTIVE CASES

Godinho-Matos MDLM¹, Duarte L¹, Tavares P², Coutinho JM², Lázaro A³, Milheiro A³, Carvalho A³, Malheiro F¹

¹Hospital Curry Cabral, Endocrinology, Lisbon, Portugal, ²Hospital Curry Cabral, Surgery, Lisbon, Portugal,

³Hospital Curry Cabral, Histopathology, Lisbon, Portugal

P274

FOLLICULAR TUMOUR IN THE SETTING OF MULTINODULAR GOITRE (MNG) OR AS A SINGLE NODULE: THE SAME DISEASE ENTITY?

Paredes C¹, Capela J¹, Pimenta T¹, Sá Couto P¹, Matos Lima L¹, Pimenta A²

¹Hospital de São João, Serviço de Cirurgia Geral - Unidade de Cirurgia Endócrina e Mama, Porto, Portugal,

²Hospital de São João, Serviço de Cirurgia Geral, Porto, Portugal

P275

HISTOLOGICAL CORRELATION OF INDETERMINATE AND MALIGNANT THYROID FNA

Sapinho I¹, Leichsenring C², Gernano A³, Manso RT⁴, Pinheiro N²

¹Hospital Fernando Fonseca, Endocrinology, Lisboa, Portugal, ²Hospital Fernando Fonseca, General Surgery, Lisboa, Portugal,

³Hospital Fernando Fonseca, Radiology, Lisboa, Portugal, ⁴Hospital Fernando Fonseca, Pathology, Lisboa, Portugal

P276

SCREENING FOR THYROID ABNORMALITIES IN ADULT POPULATION OF VARNA REGION, BULGARIA

Siderova MV¹, Hristozov KH¹

¹University Hospital 'St. Marina', Endocrinology, Varna, Bulgaria



P277

CYTOLOGICAL AND HISTOLOGICAL FINDINGS OF NON-NEOPLASTIC NON-TOXIC RECURRENT NODULAR GOITER

Çinar Yavuz H¹, Berker D¹, Aydın Y², Topaloğlu O¹, Özüğüz U¹, Güler S¹

¹Ankara Numune Research and Training Hospital, Endocrinology and Metabolism, Ankara, Turkey,

²Düzce University Faculty of Medicine, Endocrinology and Metabolism, Düzce, Turkey

P278

FINE-NEEDLE ASPIRATION BIOPSY OF THE THYROID: 2008 EXPERIENCE OF A HOSPITAL CENTER

Santos A¹, Marado D¹, Pina R², Ribeiro P¹

¹Centro Hospitalar de Coimbra, Internal Medicine, Coimbra, Portugal, ²Centro Hospitalar de Coimbra, Clinical Pathology, Coimbra, Portugal

General Information

VENUE

Aula Magna, University of Lisbon
Alameda da Universidade
Cidade Universitária
1649 - 004 Lisboa

Smoking is strictly prohibited in the entire building

Oral Presentations

All conference rooms are fully equipped with up-to-date presentation systems. Powerpoint is the preferred format for presentations. Presenters must submit their presentations at least 1 hour prior to the beginning of their session at the MEDIA CHECK (see Floor Plan on page 94).

Poster Displays

Poster boards are 120cm high and 80cm wide.

Tape for posters will be provided. Posters can be mounted from 08.00hrs on Sunday September 6th, and should be removed no later than 14.00hrs on Wednesday September 9th. The organizers cannot be held responsible for any posters remaining after this time.

All posters have been allotted a number and should be positioned on the appropriate board.

Programme Changes

The organisers cannot assume liability for changes in the programme due to external or unforeseen circumstances.

Language

The official Congress language is English.

Name Badges

Entrance to the Congress area will be limited to badge holders only.

If the badge is lost, please contact the Congress registration desk. A fee of 5€ will be charged for each new badge.

Congress Material

The Congress participants who have pre-registered will receive the congress material, together with their name badge from the Pre-Registered desk of the Congress Secretariat.

CME

27 CME credits have been granted.

The 'European Thyroid Association, Portuguese Society of Endocrinology, Diabetes and Metabolism' is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The '34th Annual Meeting of the European Thyroid Association' is designated for a maximum of 27 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.





Visas

A visa may be required by citizens of some Non-European Union countries, please contact your travel agent or the Portuguese Consulate or Embassy in your country for further advice.

Visas are not required by citizens of the European Union.

Insurance

You are requested to arrange your own health and travel insurance. The Congress organisers take no responsibility for injuries or damages that may occur during the Congress.

Weather and Dress

In September the weather is usually hot, with day temperatures of around 20-25°C. At night the temperature can drop to 15°C and the air is humid due to the proximity of the ocean.

Voltage

Electricity in Portugal is 220 volt current.

Currency and Credit Cards

The currency in Portugal is the Euro. Major credit cards are accepted in hotels, restaurants and most shops.

Tipping

Service charges are always included. Extra gratuities are not necessary, but are welcomed.

Letter of Invitation

Available on request from euro-thyroid-assoc@endoscience.de

Special Requirements

Delegates and accompanying persons with disabilities are kindly requested to contact the secretariat of the Congress for any special requirements.

Transport

Lisbon Underground: there are 4 main Metro lines (blue, green, yellow and red). The Congress venue is right beside the Metro station CIDADE UNIVERSITARIA on the **Yellow Line**. (www.metrolisboa.pt)

Taxis: **Teletaxis:** (00351) 218111100 (www.teletaxis.pt)

Retalis: (00351) 218120077 (www.retalisis.pt)

Autocoope: (00351) 217932756

Parking: parking facilities on site (with pay meters)

34th Annual Meeting of the European Thyroid Association

Social Programme

Social programme registration will also be available on-site (registration desk) for each event according to availability.

Prices: Monday, Tour Parque das Nações: 40,00 € (on-site 45 €)

Tuesday, Gala Dinner: 70,00 € (on-site 75 €)

Welcome Cocktail

Centro Cultural de Belém

Set between “Jerónimos” and “Torre de Belém”, the Centro Cultural de Belém is a unique space that combines business with the excellence of intense cultural life. Originally created to accommodate the Portuguese Presidency of the European Union, that took place in 1992, it has a modern set of auditoriums and conference rooms, where scientific, cultural and social events take place.

The “Foundation of Modern and Contemporary Art – Berardo Collection” is installed in the Exhibition Centre of Centro Cultural de Belém since 2007. The Berardo Collection, internationally recognized, reunites the main artistic movements of the XX century. More than 70 artistic currents, represented through 862 pieces, constitute an important sample of contemporary art. Moreover, the collection is always in evolution, with the constant acquisition of new works.

The Welcome Cocktail will be held in the beautiful gardens of Museu Berardo on **Saturday, September 5th**, to mark the opening of the Congress for all delegates.

There will be transfers from the congress venue to the Welcome Cocktail (busses will take guests back to the following hotels: Hotel Villa Rica, Hotel Tivoli Lisbon, Hotel Radisson SAS, Hotel Marriott Lisbon).



Tour

Parque das Nações / Oceanário de Lisboa

EXPO' 98 was an unique opportunity to re-create a large area of Lisboa, in the oriental part of the city, by the river Tejo. It was a degraded area, occupied mainly by industrial structures. The project envisaged the construction of several pavilions to host the exhibition and previewed its future utilization as cultural and leisure centres. Simultaneously, the area was the stage of several architectural projects for housing, new hotels and social equipments, as well as important business centres. The theme of EXPO' 98 was "Oceans: a patrimony for the future". In that context, a large public aquarium (Oceanário) was built. This aquarium was to maintain and perpetuate the message of EXPO' 98, and is entirely dedicated to the oceans and their preservation. A representation of the 5 oceans with innumerable species of fish and sea mammals, Oceanário is a giant museum of marine biology.



On **Monday, September 7th**, the Parque das Nações and the Oceanário de Lisboa will be the scenario for the social programme of the Congress. A bus will pick up the delegates at Reitoria de Lisboa (Meeting Venue) and will take them to Parque das Nações. In Parque das Nações, the delegates can enjoy a trip in a cable car, with wonderful views over the west side of the city and the river Tejo, and a visit to the Oceanário de Lisboa. The dinner will be held in a nearby restaurant. The atmosphere will be relaxed and cheerful.



A pop-rock band will stimulate the participants to dance.

After the Tour, busses will take guests back to the following hotels: Hotel Villa Rica, Hotel Tivoli Lisbon, Hotel Radisson SAS, Hotel Marriott Lisbon.



Gala Dinner

Palácio Foz

A beautiful building of sober lines, according to the Italian "new taste", Palácio Foz was acquired by the Marquis of Foz in 1889. The building was originally the residence of the Marquis of Castelo Melhor, that ordered its construction by the Italian architect Francisco Xavier Fabri. The Marquis of Foz transformed the palace and refurnished it in a more sumptuous style, that was popular in Lisbon at the time. He acquired several works of art from important Portuguese

painters José Malhoa and Columbano.

With its magnificent epoch architecture, Palácio Foz offers a city center venue of refinement and atmosphere, and on **Tuesday, September 8th**, the noble Ballroom of Palácio Foz will be the scene of the Congress Gala Dinner. Musical entertainment after dinner will be Fado.

Optional Tours

Half Day Walking Tour to Lisbon:

Sunday Morning, September 6th

20,00 € / person (minimum of participants: 20 persons)



Departure from the congress venue at 09.00 towards the City Centre. Visit to Lisbon's historic centre, starting in the Fado Museum in the Alfama quarter where you can see Lisbon's Cathedral, St. Anthony Basilica and the Casa dos Bicos.

Continue discovering the Baixa Pombalina, walking along Rua Augusta, the main artery of this area, leading north from Terreiro do Paço, through the Elevador de Santa Justa, to end at the beautiful Praça do Rossio (Praça Dom Pedro V).

The Baixa is the city's traditional shopping district, where Rua do Carmo and Rua Garrett cannot be missed. These streets lead to Largo do Chiado and Praça de Camões, an area of iconic cafés including "A Brasileira", art schools, theatres and of living history. Next to

Chiado, The Bairro Alto is one of the most characterful and attractive neighbourhoods in the city, which boasts boutiques and bars and is a place where people meet in an eclectic and multicultural atmosphere. The tour finishes with a visit to Largo da Trindade e do Carmo, and the beautiful Railway Station in Rossio's Square. Return to the congress venue.

Half Day Tour of Lisbon:

Sunday Afternoon, September 6th

27,50 € / person (minimum of participants: 20 persons)

Departure from the Congress venue at 14.00 towards Belém quarter. Visit to the Jerónimos Monastery, the crown jewel of the Manueline architecture and an impressive memorial to Portuguese maritime discoveries. Stop at the "Padrão dos Descobrimentos", built in the shape of a caravel in 1940, as part of the Portuguese World Exhibition, and at the Torre de Belém, one of Lisbon's icons, built in the XVI century, to guard Lisbon's entrance. This area has numerous museums and cultural venues, where the Centro Cultural de Belém stands as a reference. Continuing to Praça do Comércio and Alfama, one of Lisbon's oldest quarters founded by the Arabs, for a little stroll along the narrow streets. Return to the Congress Venue.



Half Day Tour of Sintra, Cape Roca and Cascais:

Monday, September 7th

30,00 € / person (Minimum of participants: 20 persons)

Departure from the congress venue at 09.00

Sintra – The small village of Sintra, built right up against a mountain slope, was for six centuries the favourite summer residence of the Kings of Portugal, who were attracted by the cool climates and the beauty of the Town's setting. Sintra is made up of three different areas: the old town of Sintra which is grouped around the Royal Palace; the modern town Estefania, and the former village of São Pedro.

Cascais – is both a fishing port of long tradition and a bustling holiday resort. The town has everything in it's favour: a mild climate which combines sea air with the cool air from the Sintra Massif and fine sandy beaches lining a beautiful bay.

Return to the Congress Venue, passing by the Village of Estoril and along Lisbon's coast.



Visit to Óbidos/ Nazaré/ Fátima:

Tuesday, September 8th (Full day)

90,00 € / person (lunch included) (Minimum of participants: 20 persons)

Departure from the congress venue at 09.00

Óbidos – although 10 km inland, Óbidos stands like a watchtower in it's setting. The fortified city, flanked by small towers a massive square bastions, is considered UNESCO patrimony.

Alcobaça – located at the confluence of the Alcoa and Baça rivers, in an agricultural region, Alcobaça is an important fruit market and a production center for flavoured wine. The imponent Monastery is famous for its architectural splendour. Visit to the Monastery of St Mary of Alcobaça.

Batalha – Batalha Monastery is also considered one of the masterpieces of Portuguese gothic and Manueline art and architecture. Nearby, a stop will be made in Fátima, a center of world catholic pilgrimages.

Nazaré – the name Nazaré comes from a statue of the virgin brought by a monk in the 14th century. The town has three distinct quarters: the Praia which runs alongside the beach; the Sítio and Pederneira on the hills above. Nazaré is one of the most colourful fishing villages in Portugal. Return to the Congress Venue.




Registration details can be found under Registration / Social Programme page 2 at www.eta09.com


Floor Plan



Metro CIDADES UNIVERSITARIA




Poster Sessions Floor Plan



- | | |
|--|---|
| ● P01, P12
Thyroid Cell and Molecular Biology 1 - 2 | ● P18 - P19
Thyroid and Pregnancy 1 - 2 |
| ○ P02 - P03, P13
Genetics of Benign Thyroid Disease 1 - 2
Genetics of Thyroid Cancer | ● P20 - P21
Surgery of Benign Goiter 1 - 2 |
| ● P04 - P05 / P14 - P15
Molecular Biology of Thyroid Cancer 1-4 | ● P22 - P23 / P30 - P31 / P38 - P41
Thyroid hormone metabolism and action 1 - 2
Hypothyroidism 1 - 2
Hyperthyroidism cases 1 - 2
Hyperthyroidism and goiter cases 1 - 2 |
| ● P06 - P07
Thyroid Autoimmunity 1 - 2 | ● P28 - P29
Radioiodine treatment of benign thyroid diseases 1 - 2 |
| ● P08 - P09
Thyroid Function, Obesity and Heart 1 - 2 | ● P32 - P33
Thyroid imaging 1 - 2 |
| ● P10 - P11 / P24 - P27 / P34 - P37
Thyroid Cancer Surgery 1 - 6 | ● P42 - P43
Iodine deficiency and goiter 1 - 2 |
| ● P16 - P17
Graves Disease and Graves Orbitopathy 1 - 2 | ● P44
Fine-needle aspiration biopsy |

Exhibition area



Stand at time of print

Acknowledgements

The Local Organising Committee wishes to thank the below-mentioned companies for their generous support



Institutional Sponsors



Sociedade Portuguesa de Anatomia Patológica

Stand at time of print

Notes

Lined area for taking notes.

14th INTERNATIONAL THYROID CONGRESS

PARIS, PALAIS DES CONGRÈS

11 - 16 SEPTEMBER 2010

SAVE THE DATE!

www.itc2010.com



**Information,
Registration, Exhibition:**

ITC 2010 / MCI
24 rue Chauchat
75009 Paris, France
Tel: +33 (0)1 53 85 82 80
Fax: +33 (0)1 53 85 82 83
Email: itc2010@mci-group.com

A meeting co-organised by:



European
Thyroid
Association



American
Thyroid
Association



Asia & Oceania
Thyroid
Association



Latin American
Thyroid
Society

34th Annual Meeting of the European Thyroid Association

Programme at-a-glance

Saturday 5 September	Venue	Page
9.00 – 15.30	ETA-CRN	Room A – Salão Nobre 9
9.00 – 16.00	ICCIDD	Room C – Sala dos Doutoramentos 12
8.30 – 16.00	Ultrasonography Course	Room B – Salão das Conferências 14
16.30 – 17.45	Roche Satellite Symposium	Room A – Salão Nobre 16
20.00	Welcome Reception	Centro Cultural de Belém 90

Sunday 6 September	Venue	Page
8.00 – 10.00	Oral 1 Topic Highlights Orals OP1-OP6	Main Auditorium 18
10.00 – 10.10	Lissitzky Career Award	Main Auditorium 19
	Coffee Break	
10.30 – 12.00	Symposium 1 Educational Hybrid imaging in thyroid tumors	Main Auditorium 19
10.30 – 12.00	Symposium 2 Basic Molecular basis of thyroid hormone action in disease	Room A – Salão Nobre 20
12.00 – 13.00	Lunch & Poster Discussions 1 11 sessions Posters P01-P065	Poster Exhibition Area 20
13.00 – 14.00	Poster Discussions 2 10 sessions Posters P066-P131	Poster Exhibition Area 20
14.00 – 14.45	Genzyme Prize Lecture	Main Auditorium 20
	Coffee Break	
15.00 – 15.45	MTE 1 MicroRNAs in the thyroid	Room B – Salão das Conferências 21
15.00 – 15.45	MTE 2 Thyroid and obesity	Room C – Sala dos Doutoramentos 21
15.00 – 15.45	MTE 3 Thyroid hormones and mood disorders	Room A – Salão Nobre 21
15.00 – 15.45	MTE 4 Rare ultrasonographic findings: improve your visual skill	Main Auditorium 21
16.00 – 18.00	Oral 2 Clinical Thyroidology Orals OP7-OP14	Main Auditorium 21
16.00 – 18.00	Oral 3 Young Investigators Session Orals OP15-OP22	Room A – Salão Nobre 23
18.00 – 18.30	Thyroid Nodule Guidelines	Main Auditorium 24
18.45 – 20.30	Merck-Serono Satellite Symposium	Main Auditorium 25
20.30 – 21.30	Merck-Serono Buffet	

Monday 7 September	Venue	Page
8.00 – 10.00	Oral 4 Thyroid Cancer Basic Orals OP23-OP30	Room A – Salão Nobre 26
8.00 – 10.00	Oral 5 Thyroid Autoimmunity Orals OP31-OP38	Main Auditorium 27
	Coffee Break	
10.30 – 12.00	Symposium 3 Clinical Implications of long-term TSH suppression	Main Auditorium 29
10.30 – 12.00	Symposium 4 Basic Cell biology of the thyroid	Room A – Salão Nobre 29
12.00 – 13.00	Lunch & Poster Discussions 3 12 sessions Posters P132-P202	Poster Exhibition Area 30
13.00 – 14.30	Genzyme Lunch Symposium	Main Auditorium 30
14.30 – 15.15	Merck-Serono Prize Lecture	Main Auditorium 31
	Coffee Break	
15.30 – 16.15	MTE 5 The TSH receptor	Room A – Salão Nobre 31
15.30 – 16.15	Case Discussions Thyroid Nodules	Main Auditorium 31
16.30	Departure for Excursion	Oceanário de Lisboa 91

Tuesday 8 September	Venue	Page
8.00 – 10.00	Oral 6 Cell Biology Orals OP39-OP46	Room A – Salão Nobre 32
8.00 – 10.00	Oral 7 Hyperthyroidism Orals OP47-OP54	Main Auditorium 33
	Coffee Break	
10.30 – 12.00	Symposium 5 Genetics of thyroid disease	Room A – Salão Nobre 35
10.30 – 12.00	Symposium 6 Th. Kocher's Centennial Symposium: Thyroid Surgery	Main Auditorium 35
12.00 – 13.00	Lunch & Poster Discussions 4 11 sessions Posters P203-P278	Poster Exhibition Area 35
13.00 – 14.30	Exelixis Lunch Symposium	Main Auditorium 36
14.30 – 15.15	MTE 6 Studies design using transgenic mice	Room B – Salão das Conferências 36
14.30 – 15.15	MTE 7 Resistance to thyroid hormones	Room C – Sala dos Doutoramentos 36
14.30 – 15.15	MTE 8 Long-term side effects of low-activity radioiodine therapy	Main Auditorium 36
14.30 – 15.15	MTE 9 Thyroid problems in children born to mothers with Graves' disease	Room A – Salão Nobre 36
	Coffee Break	
15.30 – 17.30	Oral 8 Models of Thyroid Disease Orals OP55-OP62	Room A – Salão Nobre 37
15.30 – 17.30	Oral 9 Thyroid Cancer Clinical Orals OP63-OP70	Main Auditorium 38
17.30 – 19.00	General Assembly	Main Auditorium 39
20.30	Gala Dinner	Palácio Foz 91

Wednesday 9 September	Venue	Page
8.00 – 10.00	Oral 10 Genetics of Thyroid Disease Orals OP71-OP78	Room B – Salão das Conferências 40
8.00 – 10.00	Oral 11 Thyroid Hormone Metabolism & Action Orals OP79-OP86	Room A – Salão Nobre 41
	Coffee Break	
10.15 – 11.45	Symposium 7 TKI for differentiated thyroid carcinoma	Room A – Salão Nobre 43
10.15 – 11.45	Symposium 8 Environment, chemicals and the thyroid	Room B – Salão das Conferências 43
	Closing Ceremony	Room A – Salão Nobre 43

